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“PNA-Ligand Bioconjugates as Potential Building Blocks for Sequence-Specific, 
Metal-Mediated DNA-/RNA-Cleavage” 
 
Referees: Prof. Dr. Nils Metzler-Nolte 
  Prof. Dr. Andres Jäschke 
 
In this Thesis, the development of new nuclease mimics on the basis of PNA-metal bio-
conjugates is described. The design of artificial enzymes for sequence-specific DNA 
and RNA cleavage is one of the most challenging problems in modern biotechnology, 
since the commercially available biotools are restricted to a limited number of promoter 
sequences. Possible nuclease mimics consist of a recognition- and a cleavage domain, 
with the latter one in this case being chosen to be a metal complex. Complexes of sev-
eral chelating nitrogen ligands are proved to catalyze the phosphodiester cleavage of 
oligonucleotides. In the course of this Thesis, functionalized nitrogen ligands (terpyri-
dine, bis-picolylamine and phenanthroline) were synthesized, and their metal binding 
behaviour in unsubstituted form and as pseudoneurotensin conjugates were investigated, 
revealing different binding modes depending on the type of ligand and its substitution. 
As a recognition domain, PNA (peptide nucleic acid), a DNA mimic with a pseudopep-
tide backbone was chosen, and the synthesis of monomer building blocks was opti-
mized. PNA oligomers with terminal ligand substitution were developed, and their 
DNA hybridization behaviour was examined by UV melting experiments, revealing the 
intercalating effect of a terminal terpyridine ligand. A new criterion for the significance 
of PNA i DNA melting curves was introduced. The influence of the replacement of one 
internal PNA monomer with two unsubstituted amino acids on hybridization is de-
scribed. Presumably, a bulge structure is formed by the modified PNA, involving the 
insight that the substituted PNA nucleotide does not have to be omitted for optimum 
attraction. A new and versatile method for the internal derivatization of PNA oligomers 
was developed by the introduction of a p-nitro-phenylalanine residue which is reduced 
on resin and is accessible for peptide bond formation. A large variety of ligands, or-
ganometallic moieties or fluorescent markers can thus be coupled to PNA oligomers at 
any position. 

Zusammenfassung 
Kersebohm, Tim   Dipl.-Chem.   23. Februar 2005 
 
„PNA-Ligand-Biokonjugate als Potentielle Bausteine für die Sequenzspezifische, Me-
tallvermittelte DNA-/RNA-Spaltung“ 
 
Gutachter: Prof. Dr. Nils Metzler-Nolte 
  Prof. Dr. Andres Jäschke 
 
Im Rahmen der vorliegenden Arbeit wurde die Entwicklung neuer künstlicher Nuclea-
sen, basierend auf PNA-Metall-Biokonjugaten beschrieben. Das Design künstlicher 
Enzyme für die sequenzspezifische DNA- und RNA-Spaltung ist eine der größten Her-
ausforderungen der modernen Biotechnologie, da die kommerziell erhältlichen Werk-
zeuge auf einige wenige Promotersequenzen beschränkt sind. Mögliche Nucleasen be-
stehen aus einer Erkennungs- und einem Spaltungsdomäne, wobei die Letztere in die-
sem Fall ein Metallkomplex sein sollte. Komplexe vieler verschiedener stickstoffhalti-
ger Chelatliganden sind in der Lage, die Spaltung von Phosphodiesterbindungen in Oli-
gonucleotiden zu katalysieren. In dieser Arbeit wurden funktionalisierte Stickstoffligan-
den (Terpyridin, Bis-Picolylamin and Phenanthrolin) synthetisiert, und ihr Metallbin-
dungsverhalten in unsubstituiertem Zustand und in Form von Pseudoneurotensin-
Konjugaten wurde untersucht. Die Wahl einer Erkennungsdomäne fiel auf PNA (Pepti-
de Nucleic Acid), einem DNA-Analogon mit einem Pseudopeptid-Rückgrat, und die 
Synthese der Monomerbausteine wurde optimiert. PNA-Oligomere mit endständiger 
Ligandsubstitution wurden entwickelt, und ihr Hybridisierungsverhalten mit komple-
mentärer DNA wurde mittels UV-Schmelzexperimenten untersucht. Hierbei zeigte sich 
ein interkalierender Effekt des endständigen Terpyridin-Liganden. Ein neues Kriterium 
für die Signifikanz von PNA i DNA-Schmelzkurven wurde eingeführt. Der Einfluß einer 
internen Substitution eines PNA-Monomers durch ein Dipeptid auf die Hybridisierung 
wurde beschrieben und führte zu dem Ergebnis, daß die modifizierte PNA aller Wahr-
scheinlichkeit nach eine Schleifenstruktur ausbildet, so daß für eine optimale attraktive 
Wechselwirkung kein PNA-Monomer ersetzt, sondern das Dipeptid eingeschoben wer-
den sollte. Desweiteren wurde eine interne Derivatisierung von PNA-Oligomeren durch 
den Einbau eines p-Nitro-Phenylalanin-Bausteins erreicht, der am Harz reduziert wird 
und dadurch für eine Peptidbindung zur Verfügung steht. Mit Hilfe dieser Methode ist 
es möglich, eine vielfältige Anzahl von Liganden, Organometallverbingungen oder 
Fluoreszenzmarkern an jeder beliebigen Stelle des PNA-Oligomers einzuführen.
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Abbreviations 
Ǻ angström 
Ar aryl group 
B nucleobase 
br broad 
bp base pairs 
cm centimeter 
CT charge transfer 
d doublet 
dd double doublet 
ds double strand 
δ chemical shift, isomer shift 
EI electron impact 
ESI electro-spray interface 
Et ethyl 
ε molar extinction coefficient 
FAB fast atom bombardment 
h hour 
HPLC high performance liquid chromatography 
Hz hertz 
IR infrared 
J coupling constant 
K kelvin 
λ wavelength 
m multiplet, meter, milli-, medium (intensity) 
M molar, mega- 
MALDI-TOF matrix-assisted laser desorption/ionisation – time of flight 
max maximum 
Me methyl 
  
  
  
min minute, minimum 
m/z mass per charge ratio 
n.o. not observed 
n.m. not measured 
NMR nuclear magnetic resonance 
ν stretching vibration 
PG protection group 
ppb parts per billion 
ppm parts per million 
q quartet 
RT room temperature 
s singlet, second, strong (intensity) 
sm self-melting (of PNA) 
ss single strand 
σ standard deviation 
SPPS solid phase peptide synthesis 
SPS solid phase synthesis 
T tesla, temperature 
TM melting temperature 
t triplet 
tert tertiary 
UV ultra violet 
Vis visible 
vs. versus 
w weak (intensity) 
 
Abbreviations for chemicals and solvents 
 
A, Ad, a adenine 
AA amino acid 
Ac acetyl- 
Ada-OH adipic acid 
Aeg N-(2-aminoethyl)glycine 
Ahx-OH amino-hexanoic acid (deprotonated) 
BB PNA backbone (aminoethyl glycine) 
Bzl benzyl 
bpa N,N’-bis(2-picolyl)amine 
bpa*-OH bpa-Bzl 
bpa’ bpa*-Ahx- / bpa-Bzl-Ahx- 
Bhoc benzhydryloxycarbonyl 
Boc tert-butyloxycarbonyl 
C, Cy, c cytosine 
Cys cysteine 
DCC N,N’-dicylohexyl-carbodiimide 
DCM dichloromethane 
DIPEA di-isopropyl-ethylamine 
DMAc N,N’-dimethylacetamide 
DMF dimethylformamide 
DMSO dimethylsulfoxide 
EDC N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride 
EtOAc ethyl acetate 
EtOH ethanol 
Fmoc fluorenyl-9-methoxycarbonyl 
G, Gu, g guanine 
GF glycine-phenylalanine 
Gly glycine 
HATU 2-(1H-7-azabenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
  
  
HBTU 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
HOBt N-hydroxybenzotriazole 
Hex-OH hexanoic acid 
HOBt 1-hydroxy-1H-benzotriazole 
Ile isoleucine 
ivDde (N-α-Fmoc-N-ε-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl-L-lysine) 
K lysine 
Leu leucine 
Lys lysine 
MeCN acetonitrile 
MeOH methanol 
PG protecting group (in all cases: Bhoc) 
Phe phenylalanine 
phen 1,10-phenanthroline 
phen*-H 5-amino-1,10-phenanthroline 
PNA peptide nucleic acid 
pnt pseudo-neurotensin 
Pro proline 
T, Th, t thymine 
TBTU 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate 
tpy 2,2’:6’,2’’-terpyridine 
tpy*-OH 4-[4’-oxa-(2,2’:6’,2’’-terpyridinyl)]hexanoic acid 
TFA trifluoro-acetic acid 
THF tetrahydrofuran 
TIS tri-isopropylsilane 
Tyr tyrosine 
 
General Remarks 
Whenever terms like „standard SPPS chemistry” are used, it refers to the Fmoc-strategy 
described in the Experimental Part. 
 
Peptides in this Thesis are written according to the IUPAC Peptide Nomenclature 
(http://www.chem.qmul.ac.uk/iupac/AminoAcid), specifying the atoms at both sides of 
the amino acid which can be exchanged. For example, the free amino acid phenyla-
lanine is written “H-Phe-OH”; in a peptide chain, only “-Phe-“ is left. Protection and 
substitution is handled correspondingly (Fmoc-Phe-OH, H-Phe-OMe). Side chain sub-
stituents are written in brackets (Fmoc-Phe(NO2)-OMe). 
Exception: The term “Lys” stands for as Lys-NH2 except as indicated 
The synonym “tpy*-OH” refers to the carboxyl ligand 4-[4’-oxa-(2,2’:6’,2’’-
terpyridinyl)]hexanoic acid 3.5 in its free form, whereas “tpy*” refers to 3.5 as a sub-
stituent. Similarly, “bpa*” stands for “bpa-Bzl-”, and phen* for phen-NH-. 
 
DNA sequences are always displayed in capital letters, PNA sequences in lower case 
letters. PNA sequences are written with the N-terminus at the left side. 
 
For convenience, the numbering of compounds was conceived as follows: 
Each chapter was given a numbering of its own; the number is indicated “x.y” with x 
indicating the particular chapter. 
 
The melting curves displayed in this thesis only show the heating process; initial cool-
ing and final re-annealing data are left out. Whenever melting curves occur, representa-
tive examples are shown. The values written in tables are averages of four melting ex-
periments after cancelling mavericks. In literature, the melting temperature often is re-
ferred to as “Tm”, in this Thesis indicated “TM” – both are meaning the same. Because of 
their high quantity, some of the tables in Chapter 6 were not labelled, but embedded in 
the text. 
 
1 Introduction 
1.1 Bioinorganic Chemistry 
In former times, science and philosophy were seen as exactly the same topic.a 
With the increasing amount of knowledge earned by mankind during the ages and the 
human brain by nature being subject to various restrictions, the traditional sciences 
more and more started to divide. New specialized fields were built up such as organic 
chemistry, which did not represent an issue of its own until the important role of carbon 
became obvious. During the last two to three decades, the natural sciences started to 
develop into the opposite direction. Certain branches merged again, establishing new 
scientific (inter-)disciplines, one of which is bioinorganic chemistry, combining aspects 
both of biology and inorganic chemistry. Nearly 80% of the elements are metals, and 
their deposit in earth’s crust cannot be denied, so that a biological role of metal atoms is 
obvious. In fact, more than 2% of the human body consist of metals with alkaline and 
earth alkaline elements representing the main part; the rest is known as trace elements 
(0.1%).1 Recent investigations actually revealed that inorganic elements even played an 
essential role in the creation and evolution of living cells.2 
 
The broad range of studies on the synthesis and applications of metal conjugates with 
biomolecules (sugars, amino acids, nucleic acids, steroids etc.) has been widely re-
viewed.3, 4 Applications of bioinorganic chemistry extend over a wide scale including 
important medical breakthroughs such as labelling,5, 6 radiodiagnostics7 and cancer 
treatment.8, 9 In contrast to the relatively new field of bioorganometallic chemistry,10 
most of the bound metals in nature are not covalently attached to a biomoleculeb, but 
fixed by coordinative forces. 
                                                 
 
 
a gr. φίλος = friend; σοφία = wisdom 
b organometallic compounds: compounds with at least one metal-carbon bond 
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1.2 Metals in Biological Systems 
The important role of metal atoms in flora and fauna is not only restricted to the pres-
ence of alkaline and earth alkaline metals which are mainly responsible for buffer sys-
tems in blood and cells, charge carriers, osmotic and electrochemical gradients across 
cell membranes,11 signal transduction in neurons and structural constitution of bones 
and teeth.c When the investigation of biochemical systems became more detailed, scien-
tists learned that many biomolecules, such as enzymes,12, 13 transport proteins14 and 
structural cell molecules would not work without the presence of transition metal atoms. 
Vitamin B1215 and haemoglobin16 (binding dioxygen in its heme group)17 contain co-
balt18 and iron, respectively, coordinated by a porphyrinoid ring system. In most of the 
cases, the catalytic properties of the transition metal center are significantly involved. 
Metalloenzymes are biocatalysts bearing at least one metal atom or ion in their active 
site.19 They are involved in important biocatalytic processes such as fixation of nitro-
gen, methane biogenesis and oxidation, oxygen storage and utilization in higher organ-
isms, and oxidative or reductive degradation of metabolites or xenobiotics. Often sup-
ported by metal centers, enzymes are able to act in a highly specific way called lock-key 
principle, which was primarily expressed by Emil Fischer.20 
Well-known and important examples of metalloenzymes are superoxide dismutases 
(Cu, Zn), oxygenases (Fe, Cu) and hydrolases (Mg, Zn).d 
 
The most interesting metal-containing biomolecules are from the group of DNA-
binding proteins, which take over several different functions such as gene regulation 
and polymerase activity. Some of them contain the so-called zinc-finger domain,21 a 
protein loop motif with two histidines and two cysteines binding to a zinc ion,22 saturat-
ing the coordination sphere of the metal. 
                                                 
 
 
c Some earth alkaline metals such as Mg2+ and Ca2+ also act as enzyme activators, structure promoters and 
Lewis acids 
d Particular metalloenzymes will be described in the course of this Thesis 
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Thus, the role of zinc must be not catalytical but structural, maintaining the conforma-
tion of proteins that bind to DNA to activate and deactivate genes (Fig. 1.1). Zinc-finger 
proteins are found in nucleic acid polymerases and transcription factors.23 
Although the zinc atoms in zinc fingers do not participate in chemical reactions, there 
are metalloenzymes from the group of DNA cleaving molecules, called nucleases, 
where the zinc finger takes over the role of the binding domain, and also examples of 
non-structural, but catalytical zinc ions in nucleases are known. 
 
   
Fig. 1.1: left: Crystal Structure of Two Zinc Finger Proteins, Binding on the Major Groove of a DNA 
Double Helix24 (The Zinc Ions are Shown as Spheres); right: The Binding Domain of a Zinc 
Finger, Consisting of two Histidines and two Cysteines25, 26 
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1.3 Nucleases 
1.3.1 Natural Nucleases 
Natural nucleases are enzymes which are able to cleave phosphodiester bonds in oli-
gonucleotides (see Chapter 1.5.1) in a hydrolytic way. At physiological pH, the phos-
phate groups are negatively charged, complicating the attack of anionic nucleophiles.27 
Phosphodiester bonds are even more resistant to hydrolytic cleavage than amide or ester 
bonds.28 Out of this reason, a hydrolytic cleavage mechanism strongly affords the pres-
ence of electron acceptors. The cleavage mechanism in Ribonuclease A shows the in-
volvement of two histidines in the primary structure of this protein whose imidazoles 
act as Brønsted acids and bases, respectively (Fig. 1.2).29 
 
Nucleases can be divided into different groups: 
• Exonucleases (digest nucleic acids starting from one terminus) 
• Endonucleases (acting within the sequence and recognizing specific sites) 
• Ribonucleases (degrade RNA) 
• Deoxyribonucleases (degrade DNA) 
 
In contrast to most of the nucleases, restriction endonucleases30 are able to cleave DNA 
sequence-specifically. They were first discovered in bacteria31 which defend themselves 
against phages by digesting the alien DNA, protecting their own genetic material by 
methylation.32 Restriction endonucleases are able to recognize palindromic sequences of 
4-8bp. They consist of two independent proteins: The restriction enzyme and a methy-
lase, protecting hemimethylated DNA against degradation. 
 
Ribonucleases33 are often metalloenzymes containing Zn2+ or Mg2+ ions in their active 
sites.34, 35 The half-life of nonactivated phosphodiesters is approximately 2·1011a for 
DNA and 1·102a for RNA; metal cofactors are able to increase the rate of hydrolysis by 
the factor 1010-1015.36 Bleomycin, a product of streptomyces fermentation, cleaves DNA 
via an iron-oxo intermediate37 and therefore via a redox mechanism (the difference be-
tween a hydrolytic and an oxidative mechanism will be discussed in Chapter 1.3.3). 
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Fig. 1.2: Mechanism of Hydrolytic Phosphodiester Cleavage by RNase A 
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It is well established that phosphate ester hydrolysis (and phosphoryl transfer) are 
strongly metal-ion dependent and responsible for the observed rate-acceleration at neu-
tral pH when compared to metal-free conditions. The role of the metal ion or ions is to 
provide the nucleophile (coordinated hydroxide) for attack of the phosphorus atom, to 
act as a Lewis acid by polarizing P-O bonds and making the P more susceptible to at-
tack, and to stabilize the leaving group.38, 39 
The proposed mechanism is shown in Fig. 1.3.40 
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Fig. 1.3: Metal-Mediated Phosphodiester Cleavage Mechanism 
 
An example of a non-specific phosphomonoesterase with two catalytic metal centers is 
purple acid phosphatase (PAP), in mammals with a dinuclear Fe3+/Fe2+ active site 
(Fig. 1.4).41, 42 Their intense purple colour is caused by tyrosine-Fe(III) charge transfer. 
Other phosphatases contain Mn or Zn ions.43 
 
  
Fig. 1.4: left: Crystal Structure of a Purple Acid Phosphatase from rattus norvegicus with a 
µ-(Hydr)oxo Bridged Di-Iron Center.44 right: Active Center of PAP from Ipomoea batatas45 
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The sequence-specific hydrolysis of phosphodiester bonds in polymerase I is catalyzed 
by the Klenow fragment,46 one of three domains in this enzyme which is responsible for 
the removal of mismatched base pairs. The Klenow fragment is a 3’-5’-exonuclease 
with a binuclear active center bearing Mg2+ and Zn2+ (Fig. 1.5).47, 48 
 
  
Fig. 1.5: left: Crystal Structure of the Klenow Fragment from Escherichia Coli DNA Polymerase I 
right: Active Center of a 3’-5’-Exonuclease 
1.3.2 Nucleases in Biotechnology 
 
The most common use of nucleases in the context of genetic engineering is the frag-
mentation of DNA in order to isolate certain areas from the genome. Applications of 
this technique are sequencing, cloning, foot- and fingerprinting. 
 
Nucleases used in molecular biology are mostly isolated from bacteria in the form of 
restriction endonucleases and are quite specific. They are divided into three main cate-
gories: 
• Type I: specific sequence recognition, but random cleavage 
• Type II: specific sequence recognition, specific cleavage 
• Type III: specific sequence recognition, cleavage at a distance of 20-25bp 
 
2750 different enzymes of Type II nucleases are known up to date, and 211 different 
specifications have been isolated. The vast number of possible cleavage sites demanded 
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by the scientist reveals the limited use of these biotools. Type II nucleases are able to 
identify only some defined promoter sequences and only possess very short recognition 
sites which results in a huge number of different fragments after cleavage. Therefore, 
one of the major challenges for biotechnological and medical purposes is to develop 
artificial nucleases which are able to cleave nucleic acids at any favoured position 
within the sequence. 
 
1.3.3 Artificial Nucleases 
 
Biomimetic (hydrolytic or oxidative; see below) cleavage of oligonucleotides is of in-
creasing importance in biotechnology and medicine,49-52 because natural restriction en-
zymes are lacking selectivity.53, 54 A number of relevant enzymes have been studied 
extensively and model compounds for the same kind of chemistry have been devel-
oped.49, 55-58 
 
Natural restriction enzymes recognize the target cleavage site by a short sequence of 
four to eight nucleobases.59 This strongly limits the specificity of an enzyme, because 
the statistical frequency of such a recognition sequence leads to an uncontrollable frag-
mentation. For the uniqueness of a sequence in the human genome, a number of more 
than 12 nucleobases is statistically necessary.60 The development of artificial nucleases, 
being able to recognize longer and therefore rarer sequences is thus one of the major 
challenges in modern biotechnology. Such a tool should consist of a recognition domain 
(an antisense oligonucleotide) and a cleavage domain (the catalytic center). Further 
specifications comprise feasible cellular uptake properties61, 62 and resistance towards 
enzymatic degradation. The metabolism of natural nucleases limits their availability to 
cleave; artificial nuclease mimics therefore should be stable in biological environment. 
 
One major approach for the design of artificial nucleases are conjugates that are hybrid 
molecules between oligonucleotides and nucleases or nuclease fragments.63-65 
For example, attempts have been made to recruit the ubiquitous mammalian enzyme 
Topoisomerase I (TopoI) to cleave DNA by tethering a TopoI inhibitor, camptothecin, 
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to the third strand and “attracting” TopoI to cleave one strand of the double-stranded 
DNA, at the site determined by the oligonucleotide sequence.66 
Another concept of designing artificial nucleases is the covalent attachment of metal 
complexes to oligonucleotides.40, 67 Among the best investigated compounds are iron 
and copper complexes. In particular, single-stranded DNA67 but also RNA68-70 were 
cleaved by such conjugates at specific sites in a metal-dependent redox reaction. The 
metal ion generates oxygen or peroxide radicals which diffuse to the DNA target and 
initialize a radical-mediated hydrogen abstraction.53, 54 The disadvantage is that a core-
actant such as H2O2 is afforded to provide the cleaving species. Many artificial restric-
tion enzymes were designed executing oxidative scission.71, 72 
Another feasible mechanism is the hydrolytic cleavage, induced by redox-inactive metal 
complexes showing Lewis-acidity.49, 50 Polydentate ligands are strongly favoured for 
this, because they are chelating the metal atom, therefore increase the binding force and 
not reducing the Lewis acidity of the metal ions.50 
In contrast to the products of oxidative cleavage, the hydrolytic mechanism leads to 
fragments bearing hydroxyl groups both at the 3’ and 5’ ends which enables them to be 
recognized by religation enzymes.49, 50, 53, 54 The religation allows it to reinsert the nu-
cleic acid into a strand, whereas an oxidative cleavage causes an irreversible strand 
break.73 As a consequence, only the hydrolytic mode of operation makes artificial nu-
cleases usable as real restriction enzyme mimics. 
The question whether a hydrolytic or oxidative pathway is preferred led to several in-
vestigations concerning various metal complexes.53, 54, 57, 74, 75 
As a result, transition metal and lanthanide complexes were proven to most effectively 
degrade RNA27, 76-78 substrates, favouring non-redox active metal ions such as Zr(IV)79, 
Mg(II), Pb(II),80 Zn(II),81 Th(IV)82, Co(III)83, 84 and the lanthanides85, 86 for hydrolytic 
cleavage and redox active metal ions such as Fe(II)87, 88 and Mn57 for an oxidative 
mechanism. Ce(IV),79, 89-92 Rh(III)93 and Cu(II)94 ions turned out to behave depending 
on the reaction conditions. For the sequence-selective, hydrolytic95 and oxidative96 
cleavage of double-stranded DNA, only some examples are known up to the present. 
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Most of the artificial nucleases and also nucleases in nature cleave in the single-stranded 
region after their hybridization with the target strand. In the case of an internal position-
ing of the cleavage moiety within the recognition sequence, cleavage takes place in the 
double-stranded area, leading to a significant decrease of stability. The basic idea be-
hind this concept is the fact that a duplex of n base pairs will dehybridize again after 
cleavage because of the number of adjacent base pairs also being cut into halves. As a 
consequence, the artificial nuclease acts in a catalytic way (Fig. 1.6). This idea will be 
revisited in the course of this Thesis. 
 
 
Fig. 1.6: Sequence-Specific RNA Cleavage in Single (A) and Double Strand Region (B) 
 
Chemical nucleases 
“Chemical nucleases” are defined as redox-active coordination complexes that nick nu-
cleic acids under physiological conditions by oxidative attack on the ribose or deoxyri-
bose moiety.67, 97, 98 The 1,10-phenanthroline copper complex was the first synthetic 
coordination complex demonstrated to have an efficient nucleolytic activity.99, 100 
Other complexes showing oxidative nuclease activity are ferrous-EDTA,101, 102 
metalloporphyrins103, 104 and uranyl acetate.105 
 
Besides its known ability to hydrolytically cleave oligonucleotides, preliminary investi-
gations on our group suggested copper for its use in artificial nucleases.106 
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1.4 The Bioinorganic Chemistry of Copper 
1.4.1 Copper in Nature 
 
Apart from its questionable use in anti-aging cosmetics contain-
ing “Active Copper®” in the form of “peptide-copper com-
plexes”,107 Cu is an essential element in any living organism, 
forming a large number of metalloproteins bearing copper ions in 
their prosthetic group – the recommended dietary intake of cop-
per for adults is 1.0-1.5mg/d.108, 109 The importance of copper as 
a cofactor is proven by the fact that copper enzymatic defects cause various metabolic 
deficiency syndromes. For example, albinism is the direct after-effect of an underpro-
duction of tyrosinase110, 111 being responsible for the synthesis of pigments (Fig. 1.7, 
Fig. 1.8). A genetically caused lack of ceruloplasmin (Fig. 1.9), a copper transport pro-
tein,112 is the reason for Morbus Wilson, a lethal factor causing an increased accumula-
tion of copper compounds in brain, liver, eye and other tissues leading to death without 
treatment.113 In 2001, the essential role of another copper transporter, CTR1, in embry-
onic development was discovered.114, 115 
 
Among the functions of the copper proteins are: 
• Electron Transfer with either an outer-sphere mechanism, or functioning as an 
inner-sphere reductase, both involving the Cu(I)/Cu(II) couple 
• Superoxide Degradation to form dioxygen and peroxide 
• Dioxygen Transport 
• Oxygenases, which incorporate an oxygen atom into a substrate 
• Oxidases, which reduce primary alcohols to the corresponding aldehydes and 
thereby form either water or hydrogen peroxide from dioxygen 
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Fig. 1.7: X-Ray Structure of Catechol Oxidase, a Tyrosinase-Related Protein116 from Sweet Potatoes 
and an Enlarged Rendering of its Active Center (yellow: copper atoms, red: oxygen atoms). 
The amino acid sequence of tyrosinase was already revealed in the late seventies,117 and 
the structure of the binuclear copper active site has been studied intensively,118-120 whereas 
attempts to obtain diffraction quality crystals from tyrosinase have been failing up to the 
present.121 
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Fig. 1.8: A Tyrosinase Model Compound for Kinetic Study of Reversible Oxygenation.122 Pay atten-
tion to the binding pocket, allocated by two pyridines and one additional nitrogen atom 
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Fig. 1.9: Molecular Structure of Human Serum Ceruloplasmin, Containing 8 Cu Centers (green)123 
 
Examples of important copper enzymes are: 
• Cu/Zn Superoxide Dismutase (SOD) 
involved in antioxidant defense 
• Galactose Oxidase (see Chapter 3.5.2) 
catalyzing the oxidation of primary alcohols to aldehydes 
• Cytochrome C Oxidase (Fig. 1.10) 
terminal enzyme in the electron transport chain 
 
 
Fig. 1.10: Crystal Structures of the Heme a3-CuB Site of Fully Reduced (left) and Fully Oxidized 
(right) (FeII···CuI) Bovine Cytochrome C Oxidase124 
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From a structural and spectroscopic point of view, the three main types of biologically 
active copper centres in copper proteins may be distinguished according to a generally 
accepted convention deriving mainly from their electron paramagnetic resonance (EPR) 
spectra.125 
Type 1, (T1), have 'blue' copper centers, with the copper normally coordinated to two 
nitrogen and two sulphur atoms 
Type 2, (T2), have 'non-blue' copper centers, with the copper coordinated to two or 
three nitrogen and oxygen atoms 
Type 3, (T3), have copper dimers. The nitrogen atoms come from histidine groups, the 
sulphur atoms from methionine and cysteine, the oxygen atoms from a carboxylic acid 
in the protein. Water, hydroxide and alkoxide oxygen atoms are also used. 
 
In most of the copper enzymes found in nature, the metal center is bound to the imida-
zole of histidines. Those structural motifs of copper enzymes directly result in the idea 
of mimicking their active centers by the use of nitrogen ligands. In consideration of the 
design of artificial nucleases, copper is predestined because its offers both possibilities 
to either cleave in an oxidative or a hydrolytic way.  
 
1.4.2 Cleavage of Nucleotides by Copper 
 
In nature, no nucleases are known which work with the help of copper ions in their ac-
tive site. Nevertheless, the redox activity and therefore cleavage ability of mono-,126 
di-127 and trinuclear128 copper(II) complexes have been extensively studied.129 
Many of these compounds have similar structures to the dinuclear active site of tyrosi-
nase shown in Fig. 1.8. For example, Karlin et al. isolated a copper-dioxygen complex 
with two tmpa ligands (Fig. 1.11). 
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Meunier et al. developed a ligand system comprising two phenanthroline ligands in one 
molecule (Fig. 1.12),130 retaining an advantageous copper-ligand ratio of 1:2. Up to the 
present, no sequence-selective cleavage with this oxidative system could be achieved 
except the conjugation of 3-Clip-Phen with a DNA minor groove binder (a distamycin 
analogue) which decreased its ability to perform C1′ oxidation as well as the initial rate 
of the reaction.131 
 
Cu(II) complexes containing N,N-donor ligands and dipeptides132 and copper-histidine 
systems133 were shown to act as hydrolytic DNA-cleavage agents, as well. 
 
However, an all-purpose site-specific cleavage of oligonucleotide targets is still far from 
being commercially exploited and a fortiori far from working at satisfactory rates. 
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Fig. 1.11: [{(tmpy)Cu}2(O2)]2+ 
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Fig. 1.12: 2-Clip-Phen (left) and 3-Clip-Phen (right) 
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1.5 DNA and PNA 
As shown before, many compounds are able to cleave phosphodiester bonds in oligonu-
cleotides, but in order to do this in a sequence specific way, a recognition domain has to 
be implemented into the artificial nuclease, which was chosen to be, in this case, PNA, 
whose features and those of DNA will be described in the following. 
1.5.1 Desoxyribonucleic Acid (DNA) 
In every living organism, the genetic information is retained in the DNA, determined by 
the sequence of nucleobases serving as a template. The human genome consists of more 
than 3·109 nucleobases. During the transcription of this template, ribonucleic acid 
(RNA) is formed which is transported out of the nucleus. Ribosomes translate this in-
formation into the amino acid sequence of a protein (Fig. 1.13). 
 
 
Fig. 1.13: A Ribosome Translating  the Genetic Code into a Protein Sequence134 
 
DNA consists of two antiparallel strands forming a right-handed double helix.135 
Each single strand is made up of single nucleotides being composed of a 
2’-desoxyribose, a phosphate group, a purine base (adenine A or guanine G) and a 
pyrimidine base (thymine T or cytosine C), respectively. The nucleotides are connected 
via phosphodiester bonds between the 5’-hydroxy and 3’-hydroxy groups of the 
2’-desoxyribose units (Fig. 1.14). The sugar phosphates serve as structural factors, rep-
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resenting the backbone of the DNA, whereas the nucleobases are pointing towards the 
center of the helix, bearing the genetic information in their sequence. 
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Fig. 1.14: Structure of a DNA Single Strand 
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Fig. 1.15: The Watson-Crick Base Pairing between Nucleobases Leads to a Double Helical Structure 
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The DNA is self-complementary, so that every single strand contains the information of 
its counterpart. Within the helix, each adenine is linked to a corresponding thymine by 
two hydrogen bonds, whereas each guanine is related to a cytosine by three hydrogen 
bonds (Fig. 1.15). In RNA, the desoxyribose is replaced by a ribose, containing a 
2’-hydroxy group. Besides that, in RNA uracil is used instead of thymine. 
 
The idea to regulate gene expression by the use of deoxyoligonucleotides as chemo-
therapeutic agents136 lead to a number of related concepts – antisense strategy (prevent-
ing translation by hybridizing single-strand oligonucleotides with an mRNA 
target),60, 137, 138 antigene approach (preventing transcription by the inhibiting formation 
of a DNA triplex),139 ribozyme targeting140 or aptamer binding to proteins141 – presently 
being investigated and in clinical testing. The principle of antisense- and antigene oli-
gonucleotides is displayed in Fig. 1.16. 
 
It is generally assumed that an oligonucleotide containing 12-15 nucleobases is suffi-
cient to target a unique sequence of an mRNA, because the number of unique sequences 
being a combination of the four bases (412=1.7·107) exceeds the number of bases repre-
senting potential targets. 
 
 
   
Fig. 1.16: Antisense and Antigene Technology134 
 
1.5  DNA and PNA 19 
 
The use of DNA as gene suppressors underlying several constraints resulted in various 
attempts to develop DNA analogues142 in order to overcome those restrictions 
(Tab. 1.1), one of those being PNA. 
Tab. 1.1: DNA Modifications 
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1.5.2 Peptide Nucleic Acid (PNA) 
In 1991, Nielsen et al. developed a DNA analogue with the phosphate-sugar backbone 
being replaced by an uncharged N-(2-aminoethyl)glycine peptide backbone 
(Fig. 1.17).143-146 
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Fig. 1.17: DNA and PNA 
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This invention turned out to be one of the most revolutionary discoveries in chemistry 
in the last decade, providing a versatile tool for mimicking DNA including many advan-
tages: In comparison to DNA, PNA is stable in biological environment147 because of its 
resistance to enzymatic degradation148, 149 and shows a high binding specificity and in-
creased thermal stability to a complementary DNA strand.150 Duplexes of PNA and 
DNA (Fig. 1.18) show a higher melting temperature than the corresponding DNA-DNA 
duplexes due to the lack of charge repulsion of the uncharged PNA backbone.149 This 
has the effect that triplex formation and strand displacement can be observed.151-153 The 
binding affinity is independent on salt concentration,154-157 and even the presence of 
Mg2+ does not have any inhibiting influence. 
Unfortunately, these facts lead to the disadvantage that PNAs show a reduced water 
solubility and tend to aggregate which can be compensated by including one ore more 
lysine units into the PNA sequence.158 
The pseudopeptide backbone of PNA is resistant even towards strong acids, so that 
well-established synthetic strategies such as solid phase peptide synthesis (SPPS; see 
Chapter 1.6) can be applied. Furthermore, many possibilities of functionalizing PNA in 
order to attach reactive centers, proteins or functional groups are established by the use 
of SPPS which made PNA the right choice for our idea of sequence-specific targeting of 
metal complexes. 
 
 
Fig. 1.18: Solution Structure of a PNA-DNA Duplex150 
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The therapeutic use of PNA is limited by insufficient cell delivery148 leading to attempts 
to enhance cellular uptake by chemical modifications (see also Chapter 5.5). 
Biotinylated PNA was successfully delivered into human mitochondria in vitro,159 and 
connecting PNA to a lactose moiety enables it to be taken up by liver cells.160 
However, unmodified PNA is able to enter neuronal cells in vivo161 and to cross the 
blood-brain barrier, which has been shown by targeting it to the neurotensin receptor.162 
 
Other important applications of PNA are 
• activation of transcription163 
• antigene164 and antisense165-167 applications 
• restriction enzyme blocking168 
• screening for genetic mutations169 
• nucleic acid capture enhancement of the selectivity of PCR170 
• probes in molecular biotechnology, diagnostics and mutation research 
• gene therapy and microbiology 
 
PNA-like molecules have been proposed as candidates for a prebiotic genetic material 
preceding RNA and DNA, which was recently shown by Miller,171 who was the first 
one to demonstrate how easily nucleobases and amino acids are obtained under condi-
tions thought to imitate the primitive earth.172, 173 
 
In addition to the fact that PNA cannot be digested by nucleases itself, its hybridization 
properties suggest its use for targeting DNA and RNA in order to cleave oligonucleo-
tides in a sequence-specific way. 
In 1993, Nielsen et al. targeted a DNA double strand with a PNA sequence, and single 
strand specific nuclease S1 was shown to digest the target at the occupied PNA strand 
displacement binding site.153 
The lack of specificity of oligonucleotide cleaving agents leads to the development of 
recognition domains, connected to a metal-ligand moiety. 
In our group, PNA thymine monomers were labelled with organometallic moieties,174 
and transition metal derivatives of PNA were shown to bind to complementary DNA 
oligomers.175, 176 
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PNA-metal conjugates already have been used for the sequence-specific cleavage of 
RNA81, 177 and for oxidative cleavage of DNA.178 
 
A PNA-metal conjugate which was able to cleave dsDNA in a hydrolytic way was de-
veloped by Krämer et al.179 (Fig. 1.19). This conjugate cleaves DNA in its single strand 
region, hybridizing with the full length of the PNA sequence. 
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Fig. 1.19: A Proposed Model for Hydrolytic DNA Scission by a PNA-Zr(IV) Conjugate 
 
One of the major advantages of PNA is its facile assembly by solid phase peptide syn-
thesis. 
 
1.6 Solid Phase Synthesis 
The use of bifunctional precursors in chemistry (in this case PNA monomers; see Chap-
ters 4 and 5) faces one major problem. Since each molecule is bearing two reactive 
sites, every possible combination of building blocks can be thought of forming prod-
ucts. The most common example of this is the use of amino acids for the synthesis of 
oligopeptides. Peptides are poly-amino acids linked via amide (peptide) bonds 
(Fig. 1.20). 
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Fig. 1.20: Condensation of two Amino Acids Forming a Dipeptide 
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The problem can be schematized as follows. 
Presuming two different amino acids forming only dimers, one can imagine four differ-
ent products: 
 
 
 
If trimers are allowed, the number of products raises up to eight: 
 
 
 
In general: If m different amino acids react with each other, mn different n-mer species 
are possible (22=4, 23=8 etc.). In an uncontrolled solution-phase reaction, this increases 
the number of unintentional side-products over the limits. With only two different 
amino acids forming oligomers up to n=10, 2046 different species will be potentially 
present in the reaction mixture. With 10 different amino acids, this number will go up to 
1011, and with 100 amino acids forming 100mers, this number (10202) will exceed by far 
the number of atoms in our universe (1078). 
R.B. Merrifield (Nobel Price 1984) developed a technique which allows to overcome 
those limitations180 and became known as solid phase peptide synthesis (SPPS). 
In contrast to the peptide synthesis carried out by nature,181 Merrifield’s concept builds 
up the chain from the C-terminus to the N-terminus. 
The amino acids are protected at one function (usually N-protection, Fig. 1.22, 
Fig. 1.23) and immobilized on a solid support, namely a polymer resin (Fig. 1.21). The 
carboxyl function of the second protected amino acid is activated (Fig. 1.24, Fig. 1.25), 
and after deprotection of the resin-bound amino group, coupling is performed. The 
polymer chain is built up step by step, thus avoiding by-products (Tab. 1.2). 
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Tab. 1.2: Solid Phase Synthesis – Schematic Course of Action 
1) Deprotection 
2) Activation  
3) Coupling 
4) Chain Elongation 
(repeat steps 1-3) 
5) Cleavage from Resin & Depro-
tection of Side Chains; Workup 
Ac OH  
 
CH2Cl  
Fig. 1.21: Merrifield Resin, Consisting of Cross-Linked Polystyrene Chains and a Linker for 
“Semi-Permanent” Binding 
 
For the two major strategies of modern, N-terminal protected SPPS, the most common 
protecting groups are Fmoc and Boc (Fig. 1.22). During SPPS, Boc is removed by 
TFA/DCM or HBr/HOAc, and the resin linker is chosen to be base or HF labile. The 
deprotection of Fmoc is carried out with 20% piperidine in DMF, shown in Fig. 1.23, 
and the resin is cleaved with TFA. 
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Fig. 1.22: Boc and Fmoc Protecting Groups 
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Fig. 1.23: Removal of an N-terminal Fmoc Protecting Group 
 
If amino acids with reactive side chains are incorporated (Lys, Cys, Tyr etc.), they also 
have to be prevented from coupling (“orthogonal protection”). Usually, protecting 
groups are chosen which are resistant to N-terminal deprotection and are removed in the 
context of the final cleavage from the resin. 
 
The assembly of amino acids is performed by preceding activation of their carboxyl 
group, because harsh reaction conditions could have an effect on the protection groups. 
This activation can be achieved by various coupling reagents, forming a more reactive 
acid derivative, for example an acid halide (using SOCl2), O-acylisourea (using car-
bodiimides such as DCC and EDC; Fig. 1.24) or activated esters (using benzotriazoles 
like HOBt, HBTU, TBTU and HATU; Fig. 1.25). 
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Fig. 1.24: DCC (left) and EDC (right) Act as Coupling Reagents 
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Fig. 1.25: HATU in its Commercially Available Form (left) and as an Activated Amino Acid (right) 
 
 
The innovative advantages of SPPS are: 
• Easy Removal of Byproducts by Washing 
• Quick Work Steps 
• High Yields by Use of Excess and Repeated Coupling (>99%) 
? longer chains are possible 
• Good Reproducibility 
• Automation Possible 
 
 
For PNA synthesis, the strategy in Fig. 1.26 turned out to be optimum. Fig. 1.27 shows 
the coupling of an adenine monomer to a PNA chain and the final cleavage of the oli-
gomer from the solid support. As an amine side chain protection, the acid labile Bhoc 
protecting group (written as “PG”) was chosen. 
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Fig. 1.26: PNA SPS Cycle – Acid Labile Strategy (B=A, T, G, C) 
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Fig. 1.27: Coupling of a Final Adenine PNA Monomer to a Growing Chain and Final Deprotection 
 

2 Objectives and Outline of This Thesis 
The cleavage of oligonucleotide phosphodiester bonds in biological systems is often 
catalyzed by metalloenzymes the mimicking of which is the aim of this project. A ver-
satile artificial nuclease should be able to perform its action at any desired sequence 
within a genome. 
 
Based on the known abilities of copper complexes with chelating nitrogen ligands such 
as terpyridine, phenanthroline and bis-picolylamine to catalyze the backbone cleavage 
of RNA and DNA, this work aims at combining both the cleavage activity of metal 
complexes and the selectivity / specificity of PNA (peptide nucleic acid). In addition to 
that, PNA comprises several advantages in contrast to DNA/RNA, predominantly the 
resistance towards enzymatic degradation preventing self-cleavage of the artificial nu-
clease as well as a higher affinity to a complementary oligonucleotide strand. 
 
In the first part of this thesis, nitrogen ligands will be functionalized in order to enable 
them to be incorporated into standard solid phase peptide synthesis (SPPS). Those 
ligands and their copper complexes will be characterized by mass spectrometry and by 
UV-Vis titration in their free form and as peptide bioconjugates in order to illustrate 
their ability to bind metal ions and fix them at the desired position. 
Furthermore, the synthesis of PNA monomers with base labile protecting groups is as-
pired. Terminal PNA-ligand conjugates are to be assembled by SPPS and characterized, 
including the investigation of their hybridization behaviour with complementary DNA 
strands in comparison to non-substituted sequences. 
The most important challenge is the introduction of ligands into the center of a PNA 
sequence in order to obtain a bioconjugate being able to cleave oligonucleotides in a 
catalytic way and thus being a nuclease mimic. 
 
 

3 Ligands 
3.1 Introduction 
As mentioned above, the most versatile nuclease mimic should consist of a recognition 
domain (PNA) and a cleavage domain, namely a metal complex. The feasibility of ni-
trogen-containing, pyridine-derived ligands for oligonucleotide cleavage has been 
shown by numerous investigations.182 
 
1,10-phenanthroline (phen) is a well-known motif to prepare a large range of strong 
chelating ligands for various metal ions.183 
In 1977, Sigman et al. investigated the DNA binding properties of the phenanthroline 
copper complex Cu+(phen)2184, 185 which was able to cleave DNA instead of just interca-
lating.100 The cleavage turned out to be oxygen-dependent and was thoroughly investi-
gated in the aftermath.67, 186 This complex was the first reagent oxidatively attacking 
ribose moieties in the presence of hydrogen peroxide. DNA conjugates of phenan-
throline were obtained by linking 5-glycylamido-1,10-phenanthroline to a 
5’-phosphorimidazolide of DNA (Fig. 3.1a).187 
In order to turn DNA binding proteins into site specific scission reagents, Sigman con-
verted amino acid residues adjacent to the DNA to cysteines which were then alkylated 
by 5-iodoacetamido-1,10-phenanthroline (Fig. 3.1b).188 The involvement of cysteine 
may cause complications; therefore, the ligand conjugates in this project were designed 
based on peptide bonds. 
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Fig. 3.1: DNA- and Peptide Conjugates of Phenanthroline 
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2,2’:6’,2’’-terpyridine (tpy) 
In contrast to the oxidative Cu+(phen)2, requiring the presence of H2O2, another copper 
complex was developed by Bashkin et al., comprising tpy as a ligand and cleaving in a 
hydrolytic way.189 
Bashkin managed to successfully synthesize tpy-DNA conjugates (by connecting the 
ligand to a thymine monomer; Fig. 3.2)190 which were shown to sequence-specifically 
cleave HIV mRNA.191 Another tpy-oligonucleotide with nuclease activity was pre-
sented by Ohtsuka et al.192-194 However, PNA conjugates of terpyridine are not known 
yet. 
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Fig. 3.2: A Terpyridine Unit as Part of a Ribozyme Mimic 
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N,N-bis(2-picolyl)amine (bpa) 
The cleavage abilities of several bpa complexes already were extensively studied in our 
group,106 so that an incorporation of bpa (Fig. 3.3) into a PNA sequence appeared to be 
reasonable. 
N
H NN  
Fig. 3.3: N,N-bis(2-picolyl)amine 
 
 
 
The basic concept behind the choice, functionalization and coupling of ligands was to 
build up the ligand coupling via amide bonds, exclusively in order to make them com-
patible with standard solid phase synthesis. 
Because of peptide chains in the majority of cases being assembled from the C-terminus 
to the N-terminus, a carboxylic acid functionalization of ligands was aimed at. 
 
In the following Chapter, synthesis and characterization of the three ligands tpy*-OH 
3.5, bpa*-OH 3.6 and phen*-H 3.8 are described. 
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3.2 Synthesis of Ligands 
3.2.1 Terpyridine 
 
Carboxylic acid derivatives of 2,2’:6’,2’’-terpyridine with various chain lengths were 
obtained from 4’-chloro-2,2’:6’,2’’-terpyridine and the corresponding lactones via a 
base catalyzed nucleophilic substitution (Fig. 3.4). 
The lactones were suspended with an excess of KOH in dry DMSO, and equimolar 
amounts of 4’-chloro-2,2’:6’,2’’-terpyridine and H2O were added, followed by refluxing 
the mixture for 7-10d at 60°C. Aqueous workup and precipitation at neutral pH yielded 
the ligand derivates as white solids (Tab. 3.1). 
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Fig. 3.4: Synthesis of Carboxylic Acid Derivatives of 2,2’:6’,2’’-Terpyridine 
 
Tab. 3.1: Carboxylic Acid Derivatives of 2,2’:6’,2’’-Terpyridine – Overview 
 n reactant Yield 
3.2 1 glycolic acid 50% 
3.3 3 γ-Butyrolactone 57% 
3.4 4 δ-Valerolactone 69% 
3.5 5 ε-Caprolactone 78% 
 
The progress of the reaction could be easily monitored by 1H-NMR spectroscopy, ex-
amining the chemical shift of the 3’- and 5’-protons (Fig. 3.7) which is exemplified by 
the hexanoic acid derivative 3.5 (n=5; also referred to as “tpy*-OH”). The side reaction 
of 4-chloro-2,2’:6’,2’’-terpyridine (“tpy-Cl”) with water giving 4-hydroxy-2,2’:6’,2’’-
terpyridine 3.1 (“tpy-OH”) also was observed in single cases. 
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Tab. 3.2: 1H-NMR Chemical Shift of the Protons Adjacent to Substitution 
δ (ppm) tpy-Cl tpy-OH 3.1 tpy*-OH 3.5 
H3’tpy & H5’tpy 8.42 7.88 7.95 
 
The concurring side reaction to the hydroxyl derivative obviously is slower the longer 
the chain is and hence negligible for the synthesis of 3.5. 
Therefore, the use of the hexanoic acid derivative 3.5 (n=5; “tpy*-OH”) for all further 
investigations turned out to be the most feasible in terms of yield and handling. Fur-
thermore, the enhanced flexibility of its extended alkyl chain is presumably advanta-
geous for catalytic attack of the oligonucleotide phosphate ester.81 
 
In addition to 1H-NMR, 13C-NMR, HPLC and ESI-MS showed pure products in all 
cases. The [tpy-OH]+ peak in Fig. 3.6 must be a product fragment and not tpy-OH 3.1, 
because the corresponding 1H-NMR spectrum of 3.5 (Fig. 3.7c) does not show this im-
purity. 
 
 
Fig. 3.5: HPLC Chromatogram of 
tpy*-OH 3.5 at 254nm 
 
Fig. 3.6: ESI-MS Spectrum of tpy*-OH 3.5 
(Mcalc=363.16) 
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Fig. 3.7: 1H-NMR Spectra of Terpyridine Derivatives 
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3.2.2 Bis-Picolylamine 
 
The aromatically substituted ligand N-(4-carboxymethyl)benzyl-N,N-bis(2-
picolyl)amine 3.6 was synthesized by refluxing N,N-bis(2-picolyl)amine and methyl-p-
(bromomethyl)benzoate in THF together with DIPEA as a base.195 After column chro-
matography, the methyl ester of 3.6 was obtained in 81% yield. It was saponified with 
1M NaOH and, and 3.6 was crystallized in 71% yield. 1H-NMR, 13C-NMR, HPLC and 
ESI-MS showed a pure product. 3.6 will be referred to as “bpa*-OH” in the following. 
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Fig. 3.8: Synthesis of bpa* 3.6 
 
38 Ligands 
 
3.2.3 Phenanthroline 
 
The functionalization of 1,10-phenanthroline was carried out by nitrating the ligand in 
5-position, followed by reduction of the nitro group with ammonium sulphide (Fig. 3.9). 
Each reaction step could easily verified by 1H-NMR (Fig. 3.11). 
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Fig. 3.9: Synthesis of phen*-H 3.8 
 
Attempts to turn aminophenthroline (phen*-H) 3.8 into carboxylic acid derivatives ap-
plicable for SPPS were carried out by reaction with bromo-toluic acid bromide, cyclic 
anhydrides, bromoacetic acid methylester, dicarboxylic acid monoesters and its acid 
halides (Fig. 3.10). Those reactions either failed or the products were hard to purify, so 
that the main attention of further research was concentrated on the ligands tpy*-OH 3.5 
and bpa*-OH 3.6. 
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Fig. 3.10: Attempts to Convert 3.8 into a Carboxylic Acid 
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Fig. 3.11: 1H-NMR Spectra of Phenanthroline Derivatives 
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3.3 Phenylalanine Conjugates 
 
In order to prove the usability of 3.5 and 3.6 for SPPS, the ligands were coupled to 
phenylalanine methyl ester (Fig. 3.12, Fig. 3.13). 
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Fig. 3.12: Synthesis of tpy*-Phe-OMe 3.9 
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Fig. 3.13: Synthesis of bpa*-Phe-OMe 3.10 
 
3.5 and H-Phe-OMe were condensated with EDC in DMF. After reaction of the mixture 
overnight at ambient temperature and evaporation of the solvent, a pink oil was ob-
tained and coevaporated with MeOH. The residue was stirred with water overnight 
yielding a white solid which was separated from the pink supernatant by filtration and 
dried in vacuo. For the synthesis of 3.9, bpa*-OH 3.6 was activated using 
TBTU/DIPEA in acetonitrile.195 After removal of the volatiles, the residue was tritu-
rated with DCM, which was after filtration dried over Na2SO4 and evaporated. The re-
sulting white product was purified by column chromatography. 
1H-NMR, 13C-NMR and EI-MS revealed the ligands 3.5 and 3.6 being suitable for pep-
tide coupling in good yield. 
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3.4 Pseudoneurotensin Conjugates 
 
Neurotensin is a biologically active tridecapeptide isolated from the hypothalamus:196 
pGlu1-Leu2-Tyr3-Gly4-Asn5-Lys6-Pro7-Arg8-Arg9-Pro10-Tyr11-Ile12-Leu13-OH 
It has been shown to induce hypotension and hypothermia in the rat brain,197 to stimu-
late contraction of guinea pig ileum and rat uterus, and to cause relaxation of rat duode-
num. There is also evidence that it acts as both a peripheral and a central nervous sys-
tem neurotransmitter.198 
Actual findings suggest that in brains of Alzheimer's disease patients there are deficits 
in this peptide in certain regions involved with memory function.199 Neurotensin may 
also be implicated in the pathophysiology of Parkinson's disease200 and schizophre-
nia.201 Therefore, metal-neurotensin conjugates could represent important markers for 
the localization of those receptors and potential novel therapeutic agents for these neu-
ropsychiatric diseases, stimulating neurotensin receptors in the brain. 
Recently, Bläuenstein et al. presented a 99mTc-labelled neurotensin analogue showing 
enhanced tumor uptake (Fig. 3.14).202, 203 
 
Fig. 3.14: Model structure of [99mTc(CO)3](NαHis)Ac-Lys-(ψCH2-NH)-Arg-Pro-Tyr-Tle-Leu-OH 
 
Copper complexes of tpy-neurotensin conjugates could be promising anti-tumor agents 
by accumulating in tumor cells and cutting DNA. 
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The peptide model compounds were also synthesized in order to examine the copper 
binding behaviour of the ligands and their bioconjugates in solution and to show that 
side chains like amine groups within the sequence do not influence coordination chem-
istry. Peptides are known to be able to bind several metal ions. Metalloenzymes are 
based on a metal center, surrounded by amino acid ligands as mentioned in the Intro-
duction. 
 
Richelson et al. have clearly shown that the last six amino acids of this peptide are all 
that is needed to activate potently neurotensin receptors.204, 205 Therefore, in this work 
the neuropeptide pseudoneurotensin H-Lys-Lys-Pro-Tyr-Ile-Leu-OH (pnt) was chosen 
to be part of metal-ligand bioconjugates. 
Pnt also can be written as [Lys8, Lys9]-neurotensin(8-13), indicating the modifications 
and the section related to the original peptide. 
 
For all pnt conjugates in this Thesis, standard SPPS chemistry with Fmoc protection 
(Fig. 3.15; for details and procedures, see Experimental Part) was performed, using 
Lys(Boc), Tyr(tBu) and a preloaded Fmoc-Leu-Wang resin (0.68mmol/g) which leads 
to the free acid after cleavage with TFA. Capping with hexanoic acid as a comparison 
and N-terminal derivatization of pnt with tpy*-OH 3.5 and bpa*-OH 3.6 was carried out 
by this means, as well (Fig. 3.15). Each substance was purified by HPLC and character-
ized with ESI mass spectrometry. 
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Fig. 3.15: Synthesis of Pseudoneurotensin Conjugates – Overview and Synthesis Scheme 
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For comparison, pseudoneurotensin was synthesized without ligand, but with a hexa-
noic acid capping group (Hex-Lys-Lys-Pro-Tyr-Ile-Leu-OH 3.11). After HPLC-
purification, ESI-MS showed a very pure product ( Fig. 3.16). 
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 Fig. 3.16: ESI spectrum of Hex-Lys-Lys-Pro-Tyr-Ile-Leu-OH 3.11 
after HPLC purification (Mcalc=858.7) 
 
With the help of HH-correlation, all 1H-NMR signals could be identified. The HH-
COSY spectrum of 3.11 is shown in Fig. 3.17. 
 
Fig. 3.17: HH-COSY 2D NMR Spectrum of Hex-pnt 3.11, measured in DMSO-d6 at 300.16MHz 
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The crude product of the tpy*-substituted pnt derivative (tpy*-Lys-Lys-Pro-Tyr-Ile-
Leu-OH 3.12) was of conspicuous pink colour. It was purified by HPLC, and besides 
the obtainment of the pure and colourless bioconjugate, the pink coloured peak could be 
separated (Fig. 3.19, Fig. 3.20). ESI-MS of this peak revealed that the observed colour 
comes from the iron complex of 3.12. It was supposed that the iron originates from the 
TFA which is used for the cleavage from the resin. In fact, the addition of Fe(II) salts to 
any compound containing tpy leads to a pink solution, and 3.5, dissolved in Millipore® 
water, turns pink if TFA (purchased from Acros) is added (Fig. 3.18). This observation 
will be taken a rain check on in the course of this Thesis. An overview of UV-Vis spec-
tra of these compounds with and without iron is given in Fig. 3.25. 
 
 
Fig. 3.18: Aqueous Solutions (Millipore®) of 
left: 3.12 and FeCl2; middle: 3.12 alone; right: 3.12 and TFA 
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Fig. 3.19: HPLC Purification of tpy*-pnt 3.12 
The pictures and chromatograms show (from top to bottom): the dry crude product, 
a) the lyophilized, purified product, b) and c) the two HPLC fractions of the particular by-
products. Note the intense colour in comparison to the low iron compound peak height in 
the crude product. 
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Fig. 3.20: Three-Dimensional HPLC Spectrum of the Crude Product of 3.12,  
Showing the Iron Peak at 555nm. 
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Fig. 3.21: ESI-MS Spectra of 3.12 before (top) and after (bottom) HPLC Purification (Mcalc=1106.6) 
 
In the case of bpa-substitution of pnt (bpa*-Lys-Lys-Pro-Tyr-Ile-Leu-OH 3.13), no iron 
peak was observed, and the product could be obtained in high purity after HPLC-
purification, which was again proved by ESI-MS (Mcalc= 1075.6; Mfound=1075.8). 
 
An overview of all mass spectra will be given in the next Chapter. 
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3.5 Copper Complexes 
3.5.1 Synthesis and Characterization 
 
For the in situ preparation of Cu complexes, equimolar amounts of ligand / bioconjugate 
and copper solution as well as 2:1 ratios were mixed to obtain a 10mM dilution which 
was subjected to MS. The intense blue colour indicated the formation of the complex 
(Fig. 3.22; see Fig. 3.25 for UV-Vis spectra). 
 
 
Fig. 3.22: Equimolar Aqueous Solutions (Millipore®) of 
left: 3.12 alone; middle: 3.12 and Cu(NO3)2·3H2O; right: Cu(NO3)2·3H2O alone 
 
 
In the case of bpa*, the complexes were crystallized and collected by filtration. 
 
 
Mass spectra of the samples were taken in order to verify the complex formation 
(Tab. 3.3). 
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Tab. 3.3: Overview of MS Data from tpy- and bpa-Derivatives and their Copper Complexes 
 MS Mcalc (ML, ML2) Mfound (ML, ML2) 
Hex-pnt 3.11 ESI+ 858.6 859.8 
tpy*-OH 3.5 ESI 363.2 362.0 (-) 364.3 (+) 
(tpy*-OH)Cu 3.5Cu ESI+ 426.1, 789.3 426.2, 788.3 
tpy*-Phe-OMe 3.9 EI 524.2 524.9 
(tpy*-Phe-OMe)Cu 3.9Cu FAB+ 587.2, 1111.4 587.2, 1111.6 
tpy*-pnt 3.12 ESI+ 1105.6 1106.9 
(tpy*-pnt)Cu 3.12Cu ESI- 1168.6, 2274.2 1167.6, /// 
bpa*-OH 3.6 EI 333.2 333.1 
(bpa*-OH)Cu 3.6Cu ESI+ 396.1, 729.2 396.1 
 FAB+ 396.1, 729.2 396.4 
bpa*-Phe-OMe 3.10 EI 494.2 494.2 
(bpa*-Phe-OMe)Cu 3.10Cu ESI+ 557.2, 1051.4 557.0 
 FAB+ 557.2, 1051.4 557.0 
bpa*-pnt 3.13 ESI+ 1075.6 1075.8 
(bpa*-pnt)Cu 3.13Cu ESI- 1138.6, 2214.2 1137.6 
 FAB+ 1138.6, 2214.2 1138.7 
 
 
As one can clearly see from the MS data displayed in Tab. 3.3, the formation of bivalent 
complexes is observed for tpy-derivatives with shorter chain length. For tpy*-pnt 3.12, 
no peak was found at all in that area. This might be due to the length of the peptide 
chain, sterically preventing a second equivalent from binding to the copper center. In 
the case of most of the bpa derivatives, the measuring range was not extended to the 
masses of the ML2 complexes, so that their existence is neither proved nor disproved. 
 
Exemplarily, the ESI spectra of (tpy*-OH)Cu 3.5Cu, (tpy*-OH)2Cu (3.5)2Cu and 
(tpy*-pnt)Cu 3.12Cu are displayed in Fig. 3.23. 
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Fig. 3.23: ESI Spectra and Isotopic Patterns of 3.5Cu, (3.5)2Cu and 3.12Cu (from top to bottom) 
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3.5.2 UV-Vis Titration 
 
In order to examine the copper complexation behaviour of the ligands and their biocon-
jugates and to verify the applicability of the conjugates for ligand-specific metal bind-
ing, UV-Vis titration was performed, showing the increase of absorbance (hyperchro-
mic shift) at certain wavelengths depending on the metal/ligand ratio when preparing 
the complexes in situ. Advantage was taken of the fact that complexes of transition met-
als are usually coloured. This can be observed on the basis of the metal-to-ligand-
charge-transfer band (MLCT) in UV-Vis spectra which is a result of the electronic con-
stitution of aromatic π-electrons. The hypso- or bathochromic shift of the MLCT is a 
consequence of the change of ligand field energy caused by ligand exchange. 
 
For all measurements, Cu(NO3)2·3H2O was used as the copper salt, being stable on air 
and non-hygroscopic, so that exact concentrations could be ensured. 400µl of a 10mM 
solution of the particular analyte were titrated in 5µl steps with a 50mM solution of ti-
trant, recording a spectrum from 900 to 500nm after each addition. All absorbance val-
ues were corrected according to the dilution effect by adding solvent during the titra-
tion. For the general procedure and practical details of UV-Vis titration, see Experimen-
tal Part. 
 
In contrast to its pnt-conjugate 3.12, the free terpyridine ligand 3.5 turned out to be 
completely insoluble in water and methanol, but readily dissolved in DMF, so that the 
experiments had to be carried out in that solvent. The solution of Cu(NO3)2·3H2O in 
DMF turned from blue to green some minutes after preparation because of the ligand 
substitution by the solvent (Fig. 3.24). Nevertheless, this solution was used for the ex-
periments, and this fact did not influence the measurements as long as equilibration time 
was maintained after each titration step. In the case of the free bpa ligand 3.6, MeOH 
was used as a solvent for both the titrant and the analyte out of the same reason. All 
other compounds were dissolved in water. An overview of important UV-Vis spectra is 
displayed in Fig. 3.25. 
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Fig. 3.24: Solution of Cu(NO3)2·3H2O in Water (left) and DMF (right) 
 
 
 
Fig. 3.25: UV-Vis Spectra of Miscellaneous Compounds  
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For comparison, hexanoic acid capped pseudo-neurotensin 3.11 was titrated with cop-
per(II) in order to rule out coordinating influence of the peptide chain. This was impor-
tant, because there are several examples for copper-binding proteins where the side 
chains of tyrosine or lysine are involved in metal binding. For example, galactose oxi-
dase, a copper containing enzyme that catalyzes the oxidation of primary alcohols to the 
corresponding aldehydes, is bearing tyrosine in its active site206, 207 (Fig. 3.26), and lysyl 
oxidase has been shown to oxidize lysyl side chains in structural proteins by binding 
them to its copper center.208-210 
 
 
Fig. 3.26: Crystal Structure of Galactose Oxidase with two Tyrosine Side Chains 
bound to the Copper Center211 
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3.5.2.1 Experiments and Results 
 
 
Titration of Hex-pnt 3.11 with Cu(II) 
 
 
Fig. 3.27: Absorbance Curves during the in 
situ-preparation of 3.11Cu 
 
Fig. 3.28: Plot of the Absorbance at 806nm 
against the Ratio Cu2+:3.11 
 
Each curve shows a maximum at 806nm with a linear increase of absorbance. The curve 
progression is similar to that of free copper salt at different concentrations, so that it can 
be concluded that the presence of the neuropeptide does not influence the absorbance 
and no reaction takes place at all. 
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Titration of tpy*-OH 3.5 with Cu(II) 
 
 
Fig. 3.29: Absorbance Curves during the in 
situ-preparation of 3.5Cu 
 
 
At the beginning of the experiment, the maxima of the curves have values of 694nm; 
after addition of 35µl of Cu(II) solution, they are hypsochromically shifted to 675nm, 
just to rise again for τ > 1. For this reason, the particular values of absorbance were plot-
ted against τ (Fig. 3.30) and compared with the plot of Amax against τ (Fig. 3.31). 
 
 
Fig. 3.30: Plot of A at Misc. Wavelengths 
against the Ratio Cu2+:3.5 
 
Fig. 3.31: Plot of the Absorbance at Maximum 
against the Ratio Cu2+:3.5 
 
The two plots, not revealing a significant difference in shape, both show an increase of 
slope at τ = 0.47 and stagnate after τ = 0.98. In the accordant areas of the λmax plot, the 
values change significantly. 
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This leads to the assumption that between a Cu/tpy ratio of 0.0 and 0.5, the bivalent 
complex Cu(tpy)22+ is formed with a lower extinction coefficient and a different absorb-
ance maximum than the monovalent complex. After exceeding this point, the Cu(tpy)2+ 
complex starts to form at the expense of the Cu(tpy)22+ compound. Further addition of 
Cu(II) does not have an effect on the absorbance, because there are no more free ligand 
molecules present in the solution. 
 
Titration of Cu(II) with tpy*-OH 3.5  
 
In order to confirm this, the titration was repeated by adding equivalents of 3.5 to 
Cu(II). Minimization of inherent bias was done by the dividing the titration into two 
different experiments with the second one starting from τ = 1. 
For clarity, the two parts of this experiment are displayed separately. 
 
The first part of the titration indicates an isosbestic point at 824nm, alluding to a proper 
direct reaction with no detectable intermediates (Fig. 3.32). 
 
Fig. 3.32: Absorbance Curves during the re-
verse in situ-preparation of 3.5Cu 
 
Fig. 3.33: Plot of the Absorbance at 679nm 
against the Ratio Cu2+:3.5 
 
The maxima of the curves show a hypsochromic shift from λmax = 803nm (τ = 0) to 
λmax = 679nm (τ = 1) due to the fact that the broadness of the absorbance curve of the 
free copper and the curve of the complex overlap and therefore pass into each other. 
Thus, A679 was plotted against τ, showing a linear increase of absorption up to τ = 1. 
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The second part of the titration shows decreasing absorbance values as supposed: 
 
Fig. 3.34: Absorbance Curves during the re-
verse in situ-preparation of 3.5Cu 
 
Fig. 3.35: Plot of the Absorbance at Maximum 
against the Ratio 3.5:Cu2+ 
 
A bathochromic shift of the maxima was observed reaching from 676 to 692nm. Never-
theless, Amax was plotted indicating a point of equivalence at Cu:L = 1:1.92. 
 
 
As it can be concluded from this experi-
ment, the formation of the bivalent com-
plex CuL2 is very likely. This is confirmed 
by the observation that after the addition of 
one equivalent of ligand to the copper solu-
tion, the isosbestic point vanishes, which is 
a hint for a multi-component system 
(Fig. 3.37). 
 
Fig. 3.36: Absorbance Curves of the Whole 
Range of Titration 
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Titration of tpy*-pnt 3.12 with Cu(II) 
 
The fact that CuL2 complexes are observed raises a problem concerning a possible oli-
gonucleotide cleavage mechanism, because the formation of mononuclear PNA dimers 
would definitely affect the activity of the artificial nuclease. 
In order to obtain knowledge about the influence of biomolecular moieties on the com-
plexation behaviour, the tpy*-pnt conjugate 3.12 was titrated with copper as well and 
vice versa. 
 
Fig. 3.37: Absorbance Curves during the in 
situ-preparation of 3.12Cu 
 
Fig. 3.38: Plot of the Absorbance at Maximum 
against the Ratio 3.12:Cu2+ 
 
The spectra show a slight shoulder at ~550-560nm, originating from iron contamination 
of the bioconjugate (already mentioned in Chapter 3.4). This observation corresponds to 
the occurrence of an [M+54]+ peak in all ESI and MALDI-TOF spectra measured of 
solid-phase made tpy* conjugates being worked up with TFA. These iron traces must 
originate from a different source than TFA, because the conjugate was HPLC purified. 
The iron is diluted with the proceeding experiment, so that the shoulder disappears. The 
resulting unavailability of some ligand molecules was neglected. The maxima demon-
strate a hypsochromic shift from 685 to 667nm, which was ignored for the evaluation. 
Plotting A685 or A667 versus τ does not have a significant effect on the curve / the point 
of equivalence, so that for clarity, Amax was chosen to be plotted against τ. The curve 
shows a linear increase of absorbance without any change in slope until equal amounts 
of ligand and metal are present. Further addition of copper does not have any influence. 
As a comparison, the converse experiment was carried out as well. 
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Titration of Cu(II) with tpy*-pnt 3.12 
 
As expected on the basis of the previous results, the absorbance maximum of the solu-
tion did not decrease significantly again after one equivalent of ligand being added. 
 
Fig. 3.39: Absorbance Curves during the re-
verse in situ-preparation of 3.12Cu 
 
Fig. 3.40: Plot of the Absorbance at 670nm 
against the Ratio Cu2+:3.12 
 
The maximum absorbance of the curves shifts from 803nm (pure copper) to 667nm at 
τ = 0.44 till the end (670nm). For this reason, A670 was plotted against ratio. The ap-
pearance of an isosbestic point at 842nm proves the reaction being consistent. Again, a 
Fe(tpy)2+ peak can be observed, but emerges because this time, the contaminated ligand 
is being added to the copper solution, thus accumulating iron in the cuvette. This con-
tamination was hard to avoid because of the syringe used for titration consisting of steel 
and the very high complexation constant of iron and terpyridine. 
 
The absorbance linearly increases during the progress of complex formation and re-
mains nearly constant after equimolarity is reached. 
 
The results indicate that the influence of the peptide chain attached to the ligand com-
pletely prevents the formation of a bivalent complex. As a result, the effect mentioned 
above should have no influence on the copper binding behaviour of PNA conjugates. 
This strongly favours the tpy*-OH ligand 3.5 for its incorporation into PNA oligomers. 
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Titration of bpa*-OH 3.6 with Cu(II) 
 
 
Fig. 3.41: Absorbance Curves during the in 
situ-preparation of 3.6Cu 
 
Fig. 3.42: Plot of the Absorbance at Maximum 
against the Ratio Cu2+:3.6 
 
The curves show a bathochromic shift from 632nm at the beginning to 656nm at the 
point of equivalence (final maximum of the complex). Plotting Amax or A656 against τ 
does not make any difference. The absorbance linearly increases up to τ = 1 and remains 
constant after that. Adding more equivalents of titrant to the solution (tested up to τ = 2) 
did not reveal any changes. The formation of a bivalent complex (3.6)2Cu seems to be 
obvious. 
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Titration of bpa*-pnt 3.13 with Cu(II) 
 
 
Fig. 3.43: Absorbance Curves during the in 
situ-preparation of 3.13Cu 
 
Fig. 3.44: Plot of the Absorbance at Maximum 
against the Ratio Cu2+:3.13 
 
The maxima of the curves were determined to be at nearly the same wavelength; no 
significant shift was observed (average maximum: 651nm). As a consequence, Amax was 
plotted against τ (Fig. 3.44). Similar to the case of 3.6, the increase of absorbance stops 
at a Cu2+:3.13 ratio of 0.5. Adding more equivalents of titrant to the solution (tested up 
to τ = 2) did not reveal any changes. Apparently, the peptide chain of the bioconjugate 
3.13 does not prevent a second equivalent of ligand from binding to the metal center. 
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3.5.2.2 Discussion 
 
The titration of the free ligands tpy*-OH 3.5 and bpa*-OH 3.6 exposed a dominant dif-
ference in their metal binding behaviour. An overview of the data obtained from the 
experiments is given in Tab. 1.1. 
Tab. 3.4: Points of Equivalence – Overview (Absorbance Maxima in Brackets) 
 Ratio Cu2+/L (λmax/nm) Ratio L/Cu2+ (λmax/nm) 
Hex-pnt 3.11 not observed not observed 
tpy*-OH 3.5e 0.47 (694) / 0.98 (680) 0.96 (679) / 1.92 (692) 
tpy*-pnt 3.12 1.02 (667) 0.99 (670) 
bpa*-OH 3.6f 0.58 (656) / 
bpa*-pnt 3.13 0.47 (651) / 
 
The free terpyridine ligand 3.5 was suspected to form a 2:1 complex with copper which 
was broken up again with addition of further metal indicating reversible complexation 
equilibria. In the converse experiment (titration of Cu with added ligand), the Cu(tpy)22+ 
complex did not start to build until every copper was bound monovalently. 
The presence of two different species can be observed by a hypsochromic shift in the 
first case (694nm?680nm/-14nm) and a bathochromic shift in the second case 
(679nm?692nm/+13nm). 
In the following, general insights into structural details of terpyridine will be presented 
and pulled together with the results obtained in this Chapter. 
Terpyridine is typically depicted in the cis/cis conformation with regard to the dihedral 
angle of the N-C-C-N bonds in order to emphasize its ability to act as a chelating ligand 
(Fig. 3.45). However, it has to be kept in mind that the solid state conformation of the 
uncomplexed and unprotonated form is trans/trans, which is explained by the steric 
repulsion of the ortho-hydrogen atoms (3/3’ and 5’/3’’) in combination with an electro-
                                                 
 
 
e Solvent: DMF 
f Solvent: MeOH 
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static repulsion of the three nitrogen lone pairs. The steric effect can be seen in the 
space-filling model in Fig. 3.45. 
 
N
N N
N
N N
H
H H
H
 
   
Fig. 3.45: Scheme and Molecular Model of the tpy Ligand in the cis/cis (left) and the trans/trans 
(right) Conformation. Note the proximity of the 3/3’ and 5’/5’’ hydrogen atoms in the 
space-filled model of the cis/cis conformation 
 
Theoretical calculations212 of different conformations also gave support for the 
trans/trans conformation as the energetically favoured one, and showed that the cis/cis 
conformation should be twisted with a dihedral angle of ca. 48°. The conformation of 
tpy in solution follows the same trend but is dependent on the hydrogen bonding proper-
ties of the solvent. In acidic media, stabilization of the cis/cis conformation can be 
achieved by protonation of one pyridine unit, which leads to a favourable hydrogen 
bonding between the proton and the lone pairs of the remaining free nitrogen atoms. 
The lowest energy structure is one with the central nitrogen protonated and the lateral 
pyridine units forming hydrogen bonds, which leads to the cis/cis conformation being 
energetically favoured (Fig. 3.46).213 
 
N
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H  
Fig. 3.46: 2,2’:6’,2’’-Terpyridine in its Free and its Protonated Form 
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In the decades after its discovery,214, 215 tpy complexes with a large number of metal 
ions were studied.216-219 Crystal structures revealed that there are two predominant com-
plex types to be found, depending on the metal ion and on the stoichiometry applied in 
the crystallization process: a 2:1 complex showing a slightly distorted octahedral coor-
dination with the two tpy units arranged perpendicular to each other, and a 1:1 complex 
with the metal ion coordinated in a distorted trigonal pyramidal way, the tpy coordinat-
ing the axial sites and one site in the trigonal plane, and the counter ions situated in the 
two residual planar positions. Fig. 3.47 shows both the 1:1 and the 2:1 complex. The 
distortion of the complex from its ideal structure can be seen clearly by the deviation of 
the axial N-M-Ng bond from an ideal 180° angle. 
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Fig. 3.47: Schemes and Molecular Models of 1:1 (left) and 2:1 (right) tpy Complexes. The 1:1 
complex is modelled with two acetonitrile molecules. X represents any counter ion or 
coordinating solvent molecule 
 
DMF, MeOH and H2O were chosen as solvents for the titrations since they act as com-
petitive ligands for the complexation which should lead to a decreased binding constant 
and additionally facilitate ligand exchange. 
                                                 
 
 
g Not to be mixed up with certain acronyms ! Characters, places and incidents in this thesis are fictitious. 
Any resemblance to actual events, locales or persons, living or dead, is entirely coincidental 
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The characteristic feature of the Cu(tpy)22+ complex (Fig. 3.47) is the metal-ligand 
charge transfer (MLCT) band with a maximum at 694 nm, which is responsible for its 
blue to green colour, whereas the monovalent terpyridine complex shows an absorbance 
maximum at 680nm. 
The plots of λmax against τ show significant changes indicating the presence of these two 
different species. Due to the different ε values of the particular complexes, the absorb-
ance of the solution changes during the progress of the titration, as well, signifying the 
re-detachment of the second ligand (τ > 0.5; titration of 3.5 with Cu2+) and its additional 
binding (τ > 1.0; titration of Cu2+ with 3.5), respectively. Possible mechanisms for this 
observation are shown in Fig. 3.48 and Fig. 3.49. 
In the first case, the slope of the A vs. τ curve rapidly changes when the second half-
equivalent of Cu is started to be added. This second process stops immediately when 1:1 
stoichiometry is reached, indicating the smooth formation of a 1:1 complex. 
M(tpy)2+ and M(tpy)22+ cannot be distinguished but based on the change of slope at a 
ratio of 0.5 it can be concluded that from that point on, all added metal ions and 1:2 
complexes are directly converted to M(tpy)2+ up to a ratio of 1.0. 
 
During the titration of Cu(II) with 3.5, the absorbance rises straight proportionally with 
the amount of added ligand 3.5. All titrations show very clear isosbestic points suggest-
ing that only two species (the uncomplexed 3.5 and 3.5Cu) are present during the titra-
tion process. After equimolarity is reached, the absorbance decreases again with a con-
comitant bathochromic shift, indicating the formation of the bivalent complex. 
 
The fact that the spectra of Cu(tpy)22+ and Cu(tpy)2+ are not identical suggests two dif-
ferent terpyridine coordination modes in the two species. In the case of a similar binding 
of the second ligand, the absorbance maximum should remain constant without any 
hypso- or bathochromic shift, whereas the extinction coefficient would be expected to 
change because of the doubled number of chromophores per metal center. 
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It can be concluded that the second ligand does not bind to copper as firmly as the first 
one, which might be explainable by the Jahn-Teller distortion caused by the first ligand 
which prevents the second one from binding as a tridentate. This leads to a cis/trans 
conformation for the second tpy, making it act as a bidentate ligand like 2,2’-bipyridine. 
In fact, Merbach et al.220 substantiated this suggestion by kinetic measurements, which 
was confirmed by ∆H0 determinations carried out by Würthner et al.221 Furthermore, it 
is common knowledge since the early eighties (but only for coordination chemists) that 
especially Cu2+ can strike an unusual five-coordination caused by a second-order Jahn-
Teller effect.222, 223 
As a consequence, the complexation constant of the second tpy is significantly lower 
than that of the 1:1 complex which enables Cu(tpy)22+ to break up again (Fig. 3.48) in 
favour of the formation of Cu(tpy)2+. In the case of a reverse titration, a second ligand is 
able to bind additionally, causing a spectral change at higher ligand/metal ratios than 
1:1 (Fig. 3.49). 
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Fig. 3.48: Supposed Mechanism for the Titration of 3.5 with Cu2+  
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Fig. 3.49: Supposed Mechanism for the Titration of Cu2+ with 3.5 
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These results were not observed with the tpy*-pnt conjugate 3.12, indicating a proper 
1:1 complexation during the progress of the titration which did not show any species 
present except a monovalent complex. The presence of an isosbestic point even after 
exceeding equimolarity substantiates this observation, so it can be concluded that the 
peptide chain is bulky enough to prevent a second ligand from binding to the metal cen-
ter. In the case of a PNA-conjugate, it can be expected that the similar effect will take 
place, so that no dimer formation during hybridization has to be worried about. 
In contrast to that, bpa*-OH 3.6 as a free ligand as well as a bioconjugate formed a 2:1 
complex with copper which was not able to break up again. 
All curves showed the formation of a stable complex at a metal/ligand ratio of 0.5. 
Those results were shown to be reproducible by repeating the experiments with fresh 
stock solutions and disagree with X-ray structures obtained in our group from the free 
ligand copper complexes.106 In the solid state, Cu is obviously complexed by only one 
ligand molecule, maybe due to the coordinating assistance of nitrates or solvent mole-
cules. Mass spectra, as mentioned in the previous chapter, show the monovalent com-
plex, but the existence of ML2 species was not investigated for bpa. The formation of 
dimers also can be taken into consideration. 
A valid explanation for the different behaviour of bpa could be its flexibility in contrast 
to tpy which allows it to adapt to the distorted ligand field caused by a primarily bound 
ligand. Thus, the second binding constant is high enough to prevent further copper ions 
from displacing the second ligand (Fig. 3.50) and even high enough to rule out the steri-
cal influence of the peptide chain. In fact, the octahedral conformation of bivalent 
Cu(bpa)22+ complexes is known from literature.224, 225 
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Fig. 3.50: The Complexation of Cu2+ with bpa*-OH 3.6 Stops at a Ratio of 1:2 
3.6  Summary 69 
 
3.6 Summary 
In this Chapter, several functionalized ligands were synthesized and characterized. 
The hexanoic acid derivative of terpyridine 3.5 and the bpa ligand 3.6 were successfully 
coupled to phenylalanine methyl ester and therefore shown to be suitable for SPPS. All 
ligands and their phenylalanine conjugates were obtained in good yield and high purity, 
which was confirmed by NMR and MS methods. Aminophenanthroline turned out to 
defy functionalization and therefore was decided not to be useful for a peptide-based 
artificial nuclease design. Nevertheless, an attempt to couple aminophenanthroline 3.8 
to a PNA chain will be described in Chapter 5.5.3. 
 
Conjugates of the ligands with the peptide pseudoneurotensin (pnt) were synthesized 
and characterized. 
 
In order to examine the copper binding ability of the synthesized ligands and their con-
jugates, the particular complexes were either prepared in solution or isolated by crystal-
lization. The complexes were characterized by ESI and FAB mass spectra  
 
UV-Vis-titration with Cu(II) was performed on the free ligands and on the correspond-
ing conjugates. The experiment with a ligand-free pnt derivative revealed that the side 
chains of the neuropeptide are not involved into metal binding, and the copper ion is 
expected to be bound by the chelating ligands, exclusively. In the case of tpy*-OH 3.5, 
the formation of a bivalent complex, comprising two ligand molecules and one copper 
center, was observed. The attachment of this ligand to pnt prevented the binding of a 
second ligand because of the bulky peptide chain. bpa ligands turned out to form biva-
lent complexes, exclusively, in their free form as well as in the form of peptide conju-
gates. 
 
The results presented in this chapter lead to the conclusion that terpyridine is the most 
favoured ligand to be incorporated into a PNA SPS. 
 

4 Peptide Nucleic Acids – Monomer Synthesis 
4.1 Introduction 
 
The assembly of PNA oligomers by solid phase synthesis, as explained in the Introduc-
tion, normally is conceived with acid labile side chain protecting groups. In the context 
of the final deprotection from the solid support with TFA, this orthogonal protection is 
abolished. Fmoc deprotection during the synthesis is performed with piperidine. 
The major motivation for designing a base labile side chain protection concept was the 
challenge of attaching acid labile moieties to PNA, such as ferrocene, which are not 
resistant to TFA. Only PNA monomers with acid labile side chain protection are com-
mercially available, so that the monomers for this purpose have to be synthesized. 
 
Another difference between the basic cleavage strategy in contrast to the TFA method is 
that the hydrazide of the oligomer is obtained, whereas the acidic cleavage results in 
formation of the amide. 
 
The first synthesis of PNA was described by Nielsen et al. using the Merrifield solid 
phase synthesis protocols and therefore a Boc/Z protection group scheme.226, 227 Since 
then many different protection strategies have been introduced, basically to circumvent 
the harsh Merrifield conditions and to make the PNA synthesis compatible to oligonu-
cleotide synthesis.228-232 The improved monomer synthesis described here is based on 
the work of Kovacs et al.,233 who uses an Fmoc/acyl protection scheme. For this reason, 
the particular steps will not be discussed in detail in this Chapter; details are to be found 
in the Experimental Part. 
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4.2 Synthesis of PNA Backbone 
 
The synthesis of the PNA backbone 4.2 was carried out in two steps: ethylenediamine 
was substituted with t-butyl-bromo acetate, followed by N-terminal protection with 
Fmoc succinimide (Fig. 4.1). The resulting white and crystalline product was obtained 
as its hydrochloride salt and had to be deprotonated before the coupling of the particular 
nucleobases. 
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Fig. 4.1: Synthesis of PNA Backbone 4.2 
 
 
4.3 Synthesis of Thymine Monomer 
 
Because of thymine lacking reactive side chains, no orthogonal protection had to be 
performed, so that the acetic acid linker could be directly attached to the nucleobase, 
followed by coupling to the backbone 4.2 and cleavage of the t-butyl ester (Fig. 4.2). 
Dissolving in THF and precipitation from hexane:toluene yielded a very pure product. 
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Fig. 4.2: Synthesis of Thymine Monomer 4.5 
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4.4 Synthesis of Cytosine Monomer 
 
First attempts to protect the amino side chain of cytosine made use of anisoyl chloride 
(Fig. 4.3). The free acid 4.8 could be obtained in good yield and purity, but turned out to 
be very poorly soluble in DMF and therefore not suitable for its coupling to the back-
bone. 
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Fig. 4.3: Synthesis of Cytosine Acetic Acid 4.8 
 
For that reason, a different protection strategy had to be established, comprising the 4-t-
butylbenzoyl group as an amino substituent (Fig. 4.4). 
After protection of the side chain, acetic acid methylester was attached to the aromatic 
amine, followed by saponification to yield the free acetic acid derivative 4.11. Coupling 
to the backbone was carried out in DMF with TBTU/HOBt and DIPEA as a base, and 
the t-butylester of 4.12 was cleaved with TFA. 
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Fig. 4.4: Synthesis of Cytosine Monomer 4.13 
 
 
4.5 Synthesis of Adenine Monomer 
 
Early experiments for the synthesis of adenine PNA monomers comprised the protec-
tion of its side chain with anisoyl chloride and the coupling of acetic acid methylester 
(Fig. 4.5). The two emerging isomers 4.15a and 4.15b were separated by column chro-
matography, but resisted from being purified by recrystallization which is indispensable 
for providing satisfactory quantities. 
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Fig. 4.5: Synthesis of Adenine-Acetic Acid Methyl Ester 4.15a 
 
Because of that, the strategy was changed in favour of the use of acetic acid t-butyl ester 
instead of its methyl ester (Fig. 4.6). The resulting isomers 4.16a and 4.16b were sepa-
rated by column chromatography, and dissolution experiments revealed that 4.16a could 
be easily separated by recrystallization from ethyl acetate. 
The t-butyl ester of 4.16a was cleaved with TFA, followed by coupling to the backbone 
and saponification, yielding the adenine monomer 4.19 in quantitative yield. 
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Fig. 4.6: Synthesis of Adenine Monomer 4.19 
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4.6 Synthesis of Guanine Monomer 
 
The synthesis of guanine PNA turned out to be the most difficult one, because guanine 
possesses two reactive side chains. The exocyclic amino function of guanine was pro-
tected by an acetyl group. The diphenylcarbamoylation of the O6 position ensures the 
regioselective coupling234 of methyl bromoacetate in the next step. Both protection 
groups are readily removed under the basic conditions of the final oligomer cleavage 
from the resin. Acetylation with methyl bromoacetate, followed by the removal of the 
methyl ester, coupling to the backbone and t-Bu-ester cleavage yielded two products. 
This was revealed by FAB-MS, showing that the majority of the carbamoyl protecting 
groups must have been lost. This fact should not influence the oligomer synthesis, so 
that the monomer was used as it was without worry. 
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Fig. 4.7: Synthesis of Guanine Monomer 4.25 
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4.7 Synthesis of PNA Oligomers with Base Labile Protecting 
Groups 
 
In order to prove the feasibility of the monomers for oligomer synthesis, the random 
sequence 4.26 was prepared by SPPS according to the standard procedure (see succeed-
ing Chapter and Experimental Part), using TentaGel® S HMB-Lys(ivDde)Fmoc resin 
with a base labile resin linker (Fig. 4.8).h Cleavage was performed with 5% hydrazine in 
DMF for 1h, followed by filtration and removal of the volatiles. The workup was simi-
lar to the standard procedure. 
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Fig. 4.8: TentaGel® S HMB-Lys(ivDde)Fmoc 
 
 
HN
N
O
O
N
O
O
HN
N
O
O
N
O
O
N
H
N
H
H
N
O
NH2
N
H
N
N N
N
OH
H2N
N
O
O
N
H
N
N N
N
NH2
N
O
O
N
NO
NH2
N
O
O
N
H
N
H
O
NH2
 
Fig. 4.9: Ac-agctt-Lys-NHNH2 4.26 
                                                 
 
 
h ivDde (N-α-Fmoc-N-ε-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl-L-lysine) is more 
stable to piperidine than Dde and less prone to migrate from protected to unprotected lysine side chains 
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HPLC purification afforded the PNA oligomer as a white solid, and MALDI-TOF mass 
spectrometry showed a single product peak at m/z = 1553.2 (calc: 1552.7). 
 
 
Fig. 4.10: MALDI Spectrum of 4.26 
 
4.8 Summary 
The synthesis of PNA monomers with base labile side-chain protecting groups was of 
importance in terms of establishing a system which allows the attachment of acid-
sensitive moieties to PNA oligomers. Otherwise, those would be degraded during TFA 
cleavage from the resin. In this project, PNA monomers with all four nucleobases could 
be synthesized and fully characterized in high purity. The resistance of the side chain 
protecting groups towards Fmoc-deprotection with piperidine and their removal with 
hydrazine showed the usability of this system. An unfunctionalized PNA oligomer was 
assembled and characterized by MALDI-TOF spectrometry. 
One major application of PNA monomers with base labile protecting groups was devel-
oped in our group by Maurer et al.,235 who attached an acid labile ferrocene moiety to 
the N-terminus of a PNA chain consisting of the monomers described in this Chapter. 
 
5 Peptide Nucleic Acids – Oligomer Synthesis 
5.1 Introduction 
 
In contrast to the base labile protected monomers presented in the previous Chapter, 
oligomer synthesis in this project was chosen to be based on commercially available 
PNA monomers with acid labile Bhoc side chain protection (Fig. 5.1). The thymine 
monomer was self-made and synthesized as described before, since it has no reactive 
side chains and therefore is suitable for both the base and the acid labile strategy. 
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Fig. 5.1: PNA Monomers with Acid Labile Side Chain Protecting Groups 
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Solid Phase Synthesis was carried out in DMF, comprising HATU / DIPEA as coupling 
reagents. This procedure is described in detail in the Experimental Part. 
The resin of choice was a TentaGel® R RAM-Lys(Boc)Fmoc resin provided by Rapp 
Polymers, Inc., preloaded with a Boc-protected lysine residue (0.17mmol/g), finalizing 
each PNA oligomer at the C-terminus for enhanced solubility. TentaGel® R is a resin 
designed for difficult sequences and long peptides showing an increased swelling vol-
ume. The RAM linker requires acidic cleavage with 95% TFA yielding the oligomer as 
its C-terminal amide. Fig. 5.3 shows the RAM linker immobilized on a resin bead, pre-
loaded with orthogonally (Boc-/Fmoc-) protected lysine. 
 
 
Fig. 5.2: Chemical Architecture of TentaGel® Resins (PS=Polystyrene; POE=Poly(ortho)ester)236 
 
O
O
H
N
O
OO
N
H
HN
O
O
O
O
 
Fig. 5.3: TentaGel® R RAM-Lys(Boc)Fmoc Resin (The “X” from Fig. 5.2 is shown here) 
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The synthesis cycle performed in this Chapter is illustrated in Fig. 5.4. 
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Fig. 5.4: Elongation of a PNA chain (B = A, C, G, T) 
 
After N-terminal deprotection and acetylation (capping), the oligomers were both depro-
tected and freed from the solid support by treatment with TFA containing 2.5% water 
and 2.5% TIS. The use of TIS is required because the removal of the Bhoc protection 
produces benzhydryl cations (Ph2CH+), which are scavenged and otherwise would alky-
late the electron rich aromatic rings of the nucleobases. All PNA oligomers were puri-
fied by reverse phase HPLC237 and characterized by MALDI-TOF spectrometry.238 
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5.2 Choice of Sequences 
 
As a model sequence for the investigation of the duplex binding of modified and un-
modified PNAs, an 18bp sequence was chosen that is originally recognized by the site-
specific homing endonuclease I-Sce I, encoded by a mitochondrial intron of Saccharo-
myces cerevisiae.239, 240 Homing endonucleases allow the introduction of a single or 
several double-strand breaks into complex genomes.241-243 They recognize long, 14-
40bp sequences and are, therefore, extremely rare-cutting restriction enzymes.244, 245 
Statistically, an 18bp recognition site will occur once in 6.9·1010bp, or once in every 
20th human genome.246 The investigation of this sequence originally was derived from a 
project of our group together with C. Happel and C. Klein, Hannover. This sequence is 
applicable for PNA synthesis, because no self-complementarity with more than 2 bases 
in a row and no hairpin formation are expected. 
In order to mimic the sequence-specific cleavage carried out by I-Sce I, PNA oligomers 
with the same sequence recognized by this endonuclease were synthesized in the con-
text of this Thesis. 
 
I-Sce I recognition sequence: 
5’- T A G G G A T A A C A G G G T A A T -3’ 
3’- A T C C C T A T T G T C C C A T T A -5’ 
 
For both the terminal and the central strategy of ligand attachment (Fig. 1.6), the cleav-
age moiety of the particular PNA scissors was intended to cleave at the same position. 
For that reason, different sections of the original sequence were chosen for synthesis 
(DNA sequences are always displayed in capital letters, PNA sequences in lower case 
letters; the cleavage / modification site is red-coloured): 
 
5’- T A G G G A T A A C A G G G T A A T -3’ 
5’- T A G G G A T A A C A G G G T A A T -3’ 
C/3’- a t c c c t a t t g t c c c a t t a -N/5’ 
C/3’- a t c c c t a t t g t c c c a t t a -N/5’ 
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As a convention, all PNA sequences in this thesis from now on will be written from the 
N- to the C-terminus, according to their peptide character. Because of the C-terminus 
for the PNA being equivalent to the 3’-terminus of the DNA (anti-parallel hybridisation 
can be observed, but is not favoured),149 the corresponding complementary PNA oli-
gomers will all be part of the following sequence: 
 
N/5’- a t t a c c c t g t t a t c c c t a -C/3’ 
 
In order to compare the influence of different chain lengths on the melting behaviour 
(i.e. hybridisation properties), each main type of sequence was prepared in three varia-
tions of length containing an acetyl capping group at the N-terminus and a lysine resi-
due at the C-terminus in order to enhance solubility.247 
The acidic cleavage from the TentaGel R RAM Lys resin yields the PNA oligomer as 
its C-terminal amide. For clarity, “Lys” is written in this chapter, actually standing for 
“Lys-NH2” (i.e. lysine carboxamide) in correct notation. 
 
terminal: 
N/5’- a t t a c c c t g t t a t c c c t a -C/3’  
      x- t g t t a t c c -Lys x8K 
      x- t g t t a t c c c -Lys x9K 
      x- t g t t a t c c c t -Lys x10K 
 
central: 
N/5’- a t t a c c c t g t t a t c c c t a -C/3’  
Ac- t a c c x t g t t -Lys Ac4-x-4K
Ac- t t a c c x t g t t a -Lys Ac5-x-5K
Ac- a t t a c c x t g t t a t -Lys Ac6-x-6K
 
Another series of sequences was synthesized in order to obtain evidence about the influ-
ence of omitted monomers within the sequence on its melting behaviour compared to 
non-match, mismatch and amino acid-replaced sequences: 
N/5’- a t t a c c – t g t t a t c c c t a -C/3’  
Ac- t a c c – t g t t -Lys Ac4-4K 
Ac- t t a c c – t g t t a -Lys Ac5-5K 
Ac- a t t a c c – t g t t a t -Lys Ac6-6K 
All other sequences and special modifications will be explained in the particular 
chapters. 
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5.3 Nomenclature 
 
The naming of PNA oligomers is normally based on the standard peptide nomenclature. 
In this Thesis, abbreviations had to be found in order to obtain short oligomer names. 
The disadvantage of a mere numbering of compounds is the complete lack of informa-
tion which would have to be looked up each time in order to know which sequence is 
talked about. This could be cinfusing especially for the discussion of melting curve data 
(Chapter 6). 
 
In order to provide a short and definite naming of the compounds in this Chapter, the 
following conventions were made: 
 
• Every sequence or part of a sequence contains will be represented by the number 
of nucleobases it consists of. Because of the use of only two main sequence 
types in this Thesis (see preceding Chapter), the numbers will be unambiguous. 
 
• N- and C-termini of the sequences will be indexed by their substituent, so that 
confusion and mixing up with compounds in other Chapters can be excluded. 
 
• Besides that, the substituents are written similar to peptide nomenclature, ignor-
ing their special functionalization which is clear from the context. bpa’ is written 
for bpa*-Ahx. 
 
• Lysine residues at the C-terminus of the PNA oligomer are obtained as amides 
after cleavage. Nevertheless, “Lys” or simply “K” is written for that. 
 
The DNA nomenclature (introduced in Chapter 6.3) will be analogous. 
 
See Appendix for a complete list of sequences. 
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5.4 PNA Oligomers without Ligand 
 
Unsubstituted PNA oligomers were synthesized in order to be able to compare their 
hybridisation behaviour with that of the PNA-ligand conjugates. 
 
All sequences were prepared following the standard procedure described in the Experi-
mental Part and finally acetylated at the N-terminus. The final cycle of SPPS is dis-
played in Fig. 5.5. 
 
O
O H
O
OFmoc-BPG-OH
HATU/DIPEAPNA1
PG PNA1PG PNA2PG
20% Piperidine
DMF
O
PNA2PG
Deprotection
Capping
Ac8K:   PNA2 = N'tgttatcc-LysC'
Ac9K:   PNA2 = N'tgttatccc-LysC'
Ac10K: PNA2 = N'tgttatccct-LysC'
Ac4-c-4K: PNA2 = N'taccctgtt-LysC'
Ac5-c-5K: PNA2 = N'ttaccctgtta-LysC'
Ac6-c-6K: PNA2 = N'attaccctgttat-LysC'
Ac4-4K: PNA2 = N'tacctgtt-LysC'
Ac4-4K: PNA2 = N'ttacctgtta-LysC'
Ac4-4K: PNA2 = N'attacctgttat-LysC'  
Fig. 5.5: Elongation of a PNA Chain – Final Cycle 
 
The consecutive steps of the solid phase synthesis were monitored by MALDI-TOF 
spectrometry, which is shown exemplarily, considering spectra of the last two steps in 
the synthesis of compound Ac8K (Fig. 5.6, Fig. 5.7). The MALDI spectrum of the Fmoc-
protected oligomer Fmoc8K shows many impurities. In most of the cases, this are capping 
products of intermediate steps, which was ignored when only monitoring was aimed at, 
as long as the final product was successfully purified by HPLC (Fig. 5.8). 
 
An overview of all sequences is given at the end of this subchapter. 
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Fig. 5.6: MALDI Spectrum of Fmoc8K (Mcalc=2501.0) 
 
 
 
Fig. 5.7: MALDI Spectrum of Ac8K after HPLC Purification 
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Fig. 5.8: HPLC Chromatograms of Ac8K, the Crude Product Showing Capping Residues 
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Tab. 5.1: Sequences for Terminal Attachment of Ligands 
terminal  Mcalc Mfound 
Ac-tgttatcc-Lys Ac8K 2321.0 2323.0 
Ac-tgttatccc-Lys Ac9K 2572.1 2573.2 
Ac-tgttatccct-Lys Ac10K 2838.2 2839.7 
 
 
Tab. 5.2: Sequences for Central Attachment of Ligands 
central  Mcalc Mfound 
   Ac-taccctgtt-Lys Ac4-c-4K 2572.1 2573.1 
  Ac-ttaccctgtta-Lys Ac5-c-5K 3113.3 3115.1 
Ac-attaccctgttat-Lys Ac6-c-6K 3655.5 3654.9 
 
 
Tab. 5.3: Central Sequences with Cytosine Omitted 
central  Mcalc Mfound 
   Ac-tacctgtt-Lys Ac4-4K 2321.0 3221.7 
  Ac-ttacctgtta-Lys Ac5-5K 2862.2 2863.1 
Ac-attacctgttat-Lys Ac6-6K 3404.4 3404.5 
 
 
All oligomers were purified by semi-preparative reverse-phase HPLC and characterized 
by MALDI-TOF mass spectrometry. 
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5.5 PNA Oligomers with Terminal Ligand 
 
The metal labelling of PNA is a very promising goal for the development of sequence-
specific markers and biomolecular tools in general. 
In our group, a transition metal complex was successfully coupled to the N-terminus of 
a thymine monomer (Fig. 5.9).174, 248 
HN
N
O
O
N
O
OO
N
H
O
N
N
(bpy)2Ru  
Fig. 5.9: Ruthenium-Labelled Thymine PNA Monomer 
 
In this subchapter, the coupling of the ligands synthesized in Chapter 3 is described. 
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5.5.1 Terpyridine 
 
The terpyridine ligand 3.5 was attached to the N-terminus of PNA oligomers by stan-
dard HATU/DIPEA coupling, but under slightly modified conditions (see Experimental 
Part). Fig. 5.10 illustrates this last step. 
 
O
O H Otpy*-OH 3.5
HATU/DIPEAPNA
PG PNAPG PNAPG
20% Piperidine
DMF
5
O
tpy8K:   PNA = N'tgttatcc-LysC'
tpy9K:   PNA = N'tgttatccc-LysC'
tpy10K: PNA = N'tgttatccct-LysC'
N
N
N
 
Fig. 5.10: Final Attachment of 3.5 to the PNA Chain 
 
 
The coupling of 3.5 turned out to be quantitative under the optimized procedure. As an 
example, the MALDI spectrum of tpy8K is shown in Fig. 5.11. 
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Fig. 5.11: MALDI Spectrum of tpy8K 
 
Similar to all other tpy-conjugates mentioned in this Thesis, iron peaks could be ob-
served in every single case, but the contamination was completely removed after HPLC 
purification. Three different chain lengths with N-terminal terpyridine were prepared, as 
shown in Tab. 5.4. 
 
Tab. 5.4: Sequences for Terminal Attachment of tpy* 3.5 
terminal  Mcalc Mfound 
tpy*-tgttatcc-Lys tpy8K 2624.1 2626.2 
tpy*-tgttatccc-Lys tpy9K 2875.2 2876.3 
tpy*-tgttatccct-Lys tpy10K 3141.3 3143.5 
 
92 Peptide Nucleic Acids – Oligomer Synthesis 
 
5.5.2 Bis-Picolylamine 
 
For a better comparison of the terminal bpa oligomer to the tpy derivative, an amino-
hexanoic acid linker (Ahx) was introduced in order to adjust the chain length between 
PNA and ligand to that of the terpyridine compounds (Fig. 5.12). 
 
O
O H OFmoc-Ahx-OH
HATU/DIPEAPNA
PG PNAPG PNAPG
20% Piperidine
DMF
5
NH
O
PNAPG
5
H2N
O
PNAPG
5
HN
Fmoc
20% Piperidine
DMF
bpa*-OH 3.6
HATU/DIPEA
bpa'8K:   PNA = N'tgttatcc-LysC'
O
NN
N
 
Fig. 5.12: Attachment of the bpa-Ligand 3.6 to PNA via an Aminohexanoic Acid Linker (Ahx) 
 
 
Tab. 5.5: Sequence for Terminal Attachment of bpa* 3.6 
terminal  Mcalc Mfound 
bpa*-Ahx-tgttatcc-Lys bpa’8K 2707.2 2709.0 
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5.5.3 Phenanthroline 
 
In order to be able to attach amino-phenanthroline 3.8 to the N-terminus of the PNA 
chain, the latter one had to be converted into a C-terminus. 
This was achieved by coupling adipic acid monomethylester (MeO-Ada-OH) to the 
amino end and subsequent saponification with 0.5% LiOH in DMF/dioxane. As a con-
sequence, the activation had to occur on resin instead of in solution (Fig. 5.13). 
 
O
O H OMeO-Ada-OH
HATU/DIPEAPNA
PG PNAPG PNAPG
20% Piperidine
DMF
4
O
O
0.5% LiOH
DMF/dioxane
O
PNAPG
4
OH
O
O
PNAPG
4
NH
O
1) HATU/DIPEA
2) phen*-H 3.8phen8K:   PNA = N'tgttatcc-LysC'
 
Fig. 5.13: Attachment of phen*-H 3.8 to PNA via an Adipic Acid Linker (Ada) 
 
Both the linker coupling and its saponification were shown to be quantitative by 
MALDI spectroscopy (Fig. 5.14, Fig. 5.15). 
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Fig. 5.14: MALDI Spectrum of MeO-Ada-tgttatcc-Lys MeOAda8K 
 
 
Fig. 5.15: MALDI Spectrum of HO-Ada-tgttatcc-Lys HOAda8K 
 
5.5  PNA Oligomers with Terminal Ligand 95 
 
 
The succeeding on-resin activation with HATU/DIPEA and the ligand coupling both 
were carried out overnight. 
 
The MALDI spectrum of the expected phen*-conjugate only showed unreacted 
HOAda8K. 
 
Tab. 5.6: Overview of Intermediates of the PNA Synthesis with Terminal phen*-Attachment 
terminal  Mcalc Mfound 
  MeO-Ada-tgttatcc-Lys MeOAda8K 2421.0 2422.4 
    HO-Ada-tgttatcc-Lys HOAda8K 2407.0 2408.1 
phen*-Ada-tgttatcc-Lys phen’8K 2485.1 / 
 
 
These results lead to the conclusion that an on-resin activation of carboxyl residues on 
PNA is more difficult than expected. A change of activation / coupling time and/or the 
use of a different coupling reagent could remedy those deficiencies. 
 
Nevertheless, a versatile method for converting the PNA amino terminus into a free 
carboxyl group was established, disclosing various possibilities for further derivatiza-
tion. 
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5.6 PNA Oligomers with Central Ligand 
 
As already mentioned in the Introduction, the development of artificial ribonucleases 
with their cleavage site being located in the center of the recognition sequence is very 
promising due to their assumed catalytic functionality. After cleavage, the PNA iOli-
gonucleotide duplex should reopen again, being ready for further turnovers (Fig. 
5.16).249 
 
 
Fig. 5.16: Catalytic Operation of an Artificial Nuclease with Central Cleaving Moiety 
 
Double-stranded RNA is considerably more resistant to metal ion promoted transesteri-
fication than its single-stranded counterpart.250 
Häner et al. developed modified DNA oligonucleotides with a central europium com-
plex (Fig. 5.17) which were able to cleave in the double strand region formed by the 
artificial nuclease and the RNA target.251 Those catalysts were shown to cleave RNA 
only within a bulgei in the target strand.252 
 
                                                 
 
 
i A bulge is defined as a region of unpaired nucleobases within a double strand region forming a loop 
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Fig. 5.17: A Modified T-DNA Monomer with an RNA Cleaving Moiety 
 
According to the PNA sequences synthesized in the preceding chapters, central func-
tionalization in this project was planned to be achieved by replacing the central cytosine 
with a cleaving moiety (Tab. 5.7). 
 
Tab. 5.7: Sequences for Central Replacement of a Cytosine by a Cleaving Unit x 
central  
   Ac-taccxtgtt-Lys Ac4-x-4K 
  Ac-ttaccxtgtta-Lys Ac5-x-5K 
Ac-attaccxtgttat-Lys Ac6-x-6K 
 
The most self-evident way of doing so is the development of an additional PNA mono-
mer consisting of an Aeg-backbone derivative connected to a ligand instead of a nu-
cleobase. 
An example of a ligand-substituted PNA backbone was published by Achim et al.253 and 
represents a further development of the metal-labelled PNA monomers synthesized in 
our group174 (see Chapter 5.5). Substitution of bipyridine for a nucleobase leads to 
modified PNA single strands that are bridged in the presence of Ni2+ into a duplex con-
taining a combination of hydrogen and coordinative bonds (Tab. 5.12). 
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Fig. 5.18: Cartoon Representation of a PNA Duplex Containing one Ni2+ Site253 
 
 
Balasubramanian et al. developed a cleavage monomer with a neocuproine ligand suit-
able to be incorporated into PNA SPS (Fig. 5.19).81 PNA oligomers with this unit at the 
N-terminus and at an internal site were hybridized with complementary RNA se-
quences, and cleavage experiments in the presence of Zn(II) provided the first demon-
stration of a PNA-based ribonuclease mimic utilizing a metal-cleaving system. The 
melting temperatures (74°C and 70°C) turned out to be quasi similar, so it can be as-
sumed that only one half of the internally modified oligomer actually binds to the RNA 
strand, whereas the other half sticks out which is not mentioned by the authors.  
This observation makes the compound unusable in a catalytic sense. 
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1) 4.2, EDC
2) TFA / DCM
 
Fig. 5.19: Coupling of Neocuproine to the PNA Backbone 
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Maiorana et al. labelled thymine monomers by attaching a Fischer-type chromium car-
bene complex to the α-carbon of the glycine part of the backbone254 and by condensat-
ing a benzaldehyde chromium complex via an Ugi reaction,255 retaining the Watson-
Crick base pairing properties of the nucleobase (Fig. 5.20). 
 
HN
N
O
O
N
O
O
Fmoc-NH O
NN
(CO)4Cr
O 8
SiMe3
 
HN
N
O
O
N
O
O
Cbz-NH N
H
(CO)3Cr
NO2
O
 
Fig. 5.20: Backbone Labelling of PNA Thymine Monomers 
 
Another mentionable α-derivatization of the PNA backbone, not involving metal atoms, 
but modulating the pharmacokinetic properties of PNA was developed by Hamzavi et 
al.256 by replacing the glycine part of a thymine PNA monomer by miscellaneous amino 
acids with derivatizable side chains and subsequent glycosylation. 
 
A different possibility of synthesizing a metal-labelled PNA monomer is the connection 
of metal complexes or organometallic moieties to a PNA nucleobase instead of the 
backbone.257, 258 For example, 5-iodo-derivatized uracil PNA monomers are accessible 
for Sonogashira coupling of alkyne residues (R=Fc-CONH) which was shown by Hud-
son et al. (Fig. 5.21).259 
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2) NaOH/THF
 
Fig. 5.21: Sonogashira Coupling of 5-Iodo-Uracil PNA 
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In contrast to the examples of N-derivatized PNA backbone mentioned above, in these 
two cases the base-pairing properties of the monomer are at least partially maintained. 
For a universal application (meaning arbitrary choice of sequences), four monomers 
would have to be provided, which does not favour this concept for an all-round use. 
 
Unfortunately, all mentioned methods of introducing a ligand-PNA monomer require a 
solution phase synthesis of their own including workup and analysis which makes these 
methods time-consuming, circumstantial and constricted. An all-purpose concept should 
facilitate the implementation of various substituents into the chain and thus be more 
universal. 
Early efforts to couple the ligand 3.5 to the PNA backbone failed, but were not pursued 
in favour of developing a new strategy based on the fact that the PNA backbone has 
exactly the length of two amino acids (repeating unit of six atoms) which suggests the 
replacement of one PNA monomer unit by an isostructural dipeptide, consisting of one 
functionalized phenylalanine and one glycine and being amenable to preparation by 
SPPS (Fig. 5.22). 
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Fig. 5.22: Standard PNA and PNA with a GlyPhe-Dipeptide Spacer 
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In order to be able to attach carboxyl ligands to the abasic site, nitro-phenylalanine was 
chosen to be incorporated into the sequence. An on-resin reduction of the aromatic nitro 
group of Phe does not require additional orthogonal side-chain protection and therefore 
simplifies the synthesis planning (Fig. 5.23). 
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Fig. 5.23: Strategy for the Central Attachment of Carboxylic Acid Derivatives 
 
The strategy of introducing functionalizable amino acids into the PNA sequence is very 
promising in terms of the mentioned versatility; any moiety bearing a carboxyl group 
should be able to be attached. This equals the N-terminal functionalization to the inter-
nal one, because most of the known terminal PNA bioconjugates are connected via pep-
tide bonds, as well. 
In addition to that, this method offers the possibility of synthesizing the entire oligomer 
on solid support which facilitates the whole process. 
Finally, the chain length variability of the used amino acids (e.g. use of β-alanine or γ-
amino butyric acid instead of glycine etc.) gives the opportunity to easily modify the 
disturbing impact of the internal building block (see melting experiments below) by 
simply incorporating another component into the SPPS. Thus, hybridization on both 
sides of the cleavage moiety should be achieved at the same time. 
 
In this subchapter, the replacement of the PNA backbone with two amino acids, their 
functionalization and the attachment of ligands will be described. 
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5.6.1 Replacement of a PNA Monomer with a Dipeptide 
 
The fact that the PNA backbone consists of a poly-aminoethylglycine chain and is syn-
thesized by SPPS suggests the incorporation of other amino acids or peptides into the 
PNA synthesis. Several PNA-peptide chimera have been synthesized in order to en-
hance cellular uptake to eukaryotic cells,260-262 bacteria263 and tumors.264 
In all those examples, the peptide residue is connected to the N-terminus of the PNA 
strand – either on resin or in solution. This can be achieved by finalizing the PNA se-
quence with an N-terminal cysteine265 (a method originally developed for DNA266) 
which is thus accessible for peptide attachment.267 For example, van Boom et al. re-
ported the convergent synthesis of a PNA-peptide conjugate by chemical ligation of a 
thioester peptide fragment containing a nuclear localization signal (NLS) sequence with 
an N-terminal cysteine PNA derivative.268 
Interest in the development of peptide analogues of DNA (besides and before PNA with 
its beneficial properties) lead to building blocks incorporating dipeptidic subunits like 
Ser(CH2B)-Gly269 and Ala(B)-Pro270 (B = A, C; G, T). 
 
Up to now, only little information about the influence of the replacement of PNA 
monomers with amino acids within a sequence is known except investigations concern-
ing backbone modifications in order to modify PNA properties in general.271 
Zuckermann et al. moved the amide carbonyl of the acetic acid linker of PNA away 
from the nucleobase to the backbone and replaced it with a methylene group, the result-
ing molecule lacking the stabilizing hydrogen bond.272 Those modifications emerged to 
completely prevent oligomer interaction with DNA. 
Vilaivan et al. developed backbone-modified PNA monomers which, in fact, consist of 
the dipeptide GlyPro(B) (B = A, C, G, T) in order to obtain a configurationally and con-
formationally constrained PNA.273-275 
Trifilieff et al. presented a PNA derivative with a real polypeptide backbone instead of 
aminoethylglycine.276 Melting experiments suggested self-aggregation, caused by the 
semi-rigid structure of this chiral molecule making it difficult to adopt the double heli-
cal structure in solution. 
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Fig. 5.24: PNA Modifications 
 
Seitz et al. connected amino acids to PNA and used a complementary oligonucleotide-
template to accelerate a peptide ligation (Fig. 5.25).277 
The resulting PNA oligomers with an internal abasic site (dipeptide spacer) were identi-
fied by MALDI-TOF spectrometry,278 but their hybridization properties were not inves-
tigated. In a recent paper,279 Seitz et al. reported melting experiments with the unligated 
PNA-AA precursors, but assumed a dehybridization after the ligation having taken 
place (Fig. 5.25) and therefore did not study the duplex formation of the products. In 
their case, the dissociation of the resulting double strand was intended, whereas for a 
cleavage purpose, the duplex should reopen not until cleavage has occured. 
 
AA-AA
AA AA
AA AA+
target template
 
Fig. 5.25: PNA Ligation Mediated by a DNA Template 
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5.6.2 Synthesis of PNA Oligomers with a Central Dipeptide Unit 
 
In order to investigate the properties and melting behaviour of PNA oligomers with two 
internal amino acids in general, the central cytosine of the I-Sce I sequence fragment 
was replaced by the unfunctionalized dipeptide GlyPhe. All oligomers were synthesized 
pursuing the SPPS standard protocol, incorporating the Fmoc-protected amino acids 
into the procedure (Fig. 5.26). 
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Fmoc
PNA1PG
Ac4-GF-4K:  PNA1 = N'tgtt-LysC'
        PNA2 = N'taccC' 
Ac5-GF-5K:  PNA1 = N'tgtta-LysC'
        PNA2 = N'ttaccC'
Ac6-GF-6K:  PNA1 = N'tgttat-LysC'
        PNA2 = N'attaccC'  
Fig. 5.26: Incorporation of Amino Acids into the PNA Sequence 
 
 
Purification was performed by reverse-phase HPLC, and the oligomers were character-
ized by MALDI-TOF mass spectrometry. 
 
Tab. 5.8: PNA Sequences with a Central Dipeptide Unit 
central  Mcalc Mfound 
   Ac-tacc-GlyPhe-tgtt-Lys Ac4-GF-4K 2525.0 2526.7 
  Ac-ttacc-GlyPhe-tgtta-Lys Ac5-GF-5K 3066.3 3067.6 
Ac-attacc-GlyPhe-tgttat-Lys Ac6-GF-6K 3608.5 3608.5 
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G-rich Oligomers 
 
Guanine and cytosine rich oligonucleotides show an increased binding affinity to com-
plementary strands because of the formation of three hydrogen bonds in the duplex in 
contrast to two hydrogen bonds in the case of adenine and thymine. 
In order to test the increase of melting temperature by raising the G/C content of the 
oligomer, two G-rich sequences with a central dipeptide were synthesized (Fig. 5.27) 
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PNA1PG
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Acg1-GF-g2K:  PNA1 = N'aaggg-LysC'
             PNA2 = N'gggttC' 
Acg3-GF-g4K:  PNA1 = N'ggtgg-LysC'
             PNA2 = N'ggaggC'  
Fig. 5.27: Synthesis of G-rich Sequences with Central Dipeptide Unit 
 
 
Purification was performed by reverse-phase HPLC, and the oligomers were character-
ized by MALDI-TOF mass spectrometry. 
 
Tab. 5.9: G-Rich PNA Sequences with a Central Dipeptide Unit 
central  Mcalc Mfound 
  Ac-gggtt-GlyPhe-aaggg-Lys Acg1-GF-g2K 3221.3 3221.3 
Ac-ggagg-GlyPhe-ggtgg-Lys Acg3-GF-g4K 3262.3 3263.0 
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5.6.3 Synthesis of Fmoc-Phe(NO2)-OH 
 
The incorporation of ligands into a PNA sequence containing phenylalanine requires its 
preceding functionalization which was, in this case, achieved by the nitration of the 
phenyl side chain, followed by Fmoc-protection and subsequent reduction (see next 
subchapter). 
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H2N
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NO2 NO2
Fmoc-ONSu
NEt3
HNO3
H2SO4
5.1 5.25.0
 
Fig. 5.28: Synthesis Scheme for Fmoc-Phe(NO2)-OH 5.2 
 
In the first step, phenylalanine was nitrated with HNO3/H2SO4, and the product was 
precipitated with aqueous NaOH at pH7. Fmoc-protection was carried out in a mixture 
of H2O and MeCN with triethylamine as a base. After removal of the volatiles, the re-
sulting red oil was dissolved in water and at neutral pH, the crude product precipitated. 
Recrystallization from EtOAc yielded 53% of pure 5.2. 
 
The synthesis steps were easy to be observed by 1H-NMR spectroscopy (see Fig. 5.32), 
and the compounds were characterized by 13C-NMR, MS and IR, as well. HPLC analy-
sis revealed them to be of satisfactory purity. 
 
Nitro-phenylalanine is stable under SPPS conditions and is therefore suitable for its 
integration into a PNA sequence. 
Avoiding orthogonal protection of the Phe side chain, the nitro group was planned to be 
reduced on resin, followed by attachment of the carboxyl ligand. 
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5.6.4 Synthesis of Fmoc-Phe(NH2)-OH 
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Fig. 5.29: Reduction of Fmoc-Phe(NO2)-OH 5.2 
 
In order to show that the aromatic nitro group of Fmoc-protected phenylalanine can be 
reduced without affecting the rest of the molecule, the compound was subjected to a 
catalytic reduction with Pd/C and H2 in dioxane/MeOH (4:1). 
 
The reaction progress was monitored by HPLC, impressively showing the decrease of 
Fmoc-Phe(NO2)-OH 5.2 in favour of the amino compound 5.3 (Fig. 5.30). 
 
During the first three hours of reaction, the percentages of the two major components 
changed significantly, just to change into a linear transformation (Fig. 5.31). Interest-
ingly, the composition of the samples changed upon standing even when the catalyst 
was filtered of (maybe due to Pd residues), so that HPLC was performed immediately 
after sampling to assure reproducibility. 
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Fig. 5.30: HPLC-Monitored Reduction of Fmoc-Phe(NO2)-OH 5.2 with Supposed 
Nitroso-Intermediate at 8.5min 
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Fig. 5.31: Percentage of HPLC Fractions During the Progress of the Reduction of 5.2 
 
The selective reduction of Fmoc-protected nitro-phenylalanine was thus shown to be 
straightforward even under harsh conditions by converting the compound with Pd/C 
catalyst and hydrogen. 
 
110 Peptide Nucleic Acids – Oligomer Synthesis 
 
 
H2N
OH
O
2
3
4
5
6
5.0
H2N
OH
O
NO22
3
5
6
5.1
O N
H
OH
O
O
NO22
3
5
6
1
23
4
5
6
7 8
5.2
O N
H
OH
O
O
NH22
3
5
6
1
23
4
5
6
7 8
5.3
Fig. 5.32: 1H-NMR Spectra of Phe-Derivatives 5.0-5.3 
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The successful reduction of Fmoc-Phe(NO2)-OH 5.2 to the amine 5.3 showed the suit-
ability of the compound to be incorporated into solid phase synthesis. 
 
Attempts to couple the activated terpyridine ligand 3.5 to Fmoc-Phe(NH2)-OH 5.3 in 
solution (Fig. 5.33) failed and supported the plan of performing the whole synthesis 
based on SPPS. 
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Fig. 5.33: Attempting to Couple Ligand 3.5 to Fmoc-Phe(NH2)-OH 5.3 in Solution 
 
Further experiments with modified conditions and coupling reagents are expected to 
afford the desired cleavage monomer, but were not pursued because of the undoubted 
advantages of the SPPS pathway. 
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5.6.5 Synthesis of PNA Oligomers with Central Ligand 
 
The advantages of SPPS lead to the concept of performing the entire synthesis of inter-
nally functionalized PNA oligomers on resin (Fig. 5.23). 
As a preliminary investigation, the oligomer Ac-tacc-GlyPhe(NO2)-tgtt-Lys 
(Ac4-GFO-4K) was synthesized. After assembly of the PNA-peptide chain, incorporating 
nitro-phenylalanine into the sequence, a test cleavage was performed with some resin 
beads, and the MALDI spectrum confirmed the formation of the intermediate 
(Fig. 5.34). 
 
Fig. 5.34: MALDI Spectrum of Ac4-GFO-4K 
 
Subsequent reduction was carried out by converting the resin-bound oligomer nitro 
group with 0.9M SnCl2 in DMF overnight, followed by ligand coupling with 
HATU/DIPEA in DMF (Fig. 5.35). 
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Fig. 5.35: Strategy of Attaching the Ligand 3.5 to a Central Phenylalanine 
 
A MALDI spectrum of the supposed products (Fig. 5.36) revealed that neither the re-
duction nor the ligand coupling had been quantitative which may be explainable with 
the sterical shielding by the PNA chain. 
 
 
Fig. 5.36: MALDI Spectrum after the Futile Synthesis of Ac4-GFtpy-4K 
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Tab. 5.10: Overview of Intermediates of Ac4-GFtpy-4K 
 Mcalc Mfound 
Ac-ttacc-GlyPhe(NO2)-tgtta-Lys Ac4-GFO-4K 2569.0 2570.6 
Ac-ttacc-GlyPhe(NH2)-tgtta-Lys Ac4-GFH-4K 2539.1 2541.7 
Ac-ttacc-GlyPhe(tpy*)-tgtta-Lys Ac4-GFtpy-4K 2885.2 (2886.8) 
 
Instead of optimizing or modifying this pathway, a change of strategy seemed to me 
more promising. In order to prevent the PNA chain from hindering the subsequent steps, 
the oligomer assembly was interrupted after glycine, and continued after reducing the 
nitro group and coupling of the ligand (Fig. 5.37). 
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Fig. 5.37: Improved Strategy of Internal Ligand Coupling 
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The whole process was monitored by performing MALDI spectrometry after each sin-
gle step, and the particular intermediates revealed an unobstructed progression. Exem-
plarily, the MALDI spectra of the intermediates shown in Fig. 5.37 are presented for 
Ac6-GFtpy-6K (Fig. 5.38, Fig. 5.39) 
 
 
Fig. 5.38: MALDI Spectrum of FmocGFO-6K 
 
 
Fig. 5.39: MALDI Spectrum of FmocGFH-6K 
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A test spectrum of Fmoc-GlyPhe(tpy*)-tgttat-Lys (FmocGFtpy-6K) showed unreacted 
Fmoc-GlyPhe(NH2)-tgttat-Lys (FmocGFH-6K). This may be due to the reduced reactivity 
of aromatic amino groups towards the formation of peptide bonds. As a consequence, 
the ligand coupling was prolonged and performed twice. In addition, the standard cou-
pling conditions were optimized for this special purpose (see Experimental Part). 
 
The MALDI spectrum of HGFtpy-6Kafter the successful coupling of 3.5 to the Phe(NH2) 
side chain and terminal deprotection (Fig. 5.40) shows some capping products of inter-
mediate steps, and an iron peak which is observed in all cases, but was easy to remove 
by performing HPLC on the final crude product (the effect of iron contamination of 
tpy* conjugates already has been mentioned in Chapter 3). 
Impurities in intermediate spectra were ignored, as long as only some beads were 
cleaved for monitoring and thus the spectrum not being representative. Furthermore, 
HPLC-purification was performed on the final product. 
 
 
Fig. 5.40: MALDI Spectrum of HGFtpy-6K 
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The amino terminus was deprotected, and the chain extension was continued till the end 
(Fig. 5.37). After cleavage from the resin, the final crude product was purified by 
HPLC, and the MALDI spectrum showed the success of the reaction (Fig. 5.41). 
 
 
 
Fig. 5.41: MALDI Spectrum of Ac6-GFtpy-6K without Iron Contamination (m/z=4022.3) 
 
 
Tab. 5.11: Overview of Intermediates of Ac6-GFtpy-6K 
 Mcalc Mfound 
    Fmoc-GlyPhe(NO2)-tgttat-Lys FmocGFO-6K 2247.9 2248.3 
    Fmoc-GlyPhe(NH2)-tgttat-Lys FmocGFH-6K 2217.9 2218.2 
   H-GlyPhe(tpy*)-tgttat-Lys HGFtpy-6 2341.0 2341.2 
Ac-attacc-GlyPhe(tpy*)-tgttat-Lys Ac6-GFtpy-6K 3967.6 3968.2 
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The same strategy was applied on two other PNA oligomers, completing the three vary-
ing chain lengths (Tab. 5.12). All compounds were purified by HPLC and characterized 
by MALDI spectrometry. 
 
Tab. 5.12: Overview of PNA Oligomers with Central tpy* Attachment 
central  Mcalc Mfound 
   Ac-tacc-GlyPhe(tpy*)-tgtt-Lys Ac4-GFtpy-4K 2885.2 2886.2 
  Ac-ttacc-GlyPhe(tpy*)-tgtta-Lys Ac5-GFtpy-5K 3426.4 3428.6 
Ac-attacc-GlyPhe(tpy*)-tgttat-Lys Ac6-GFtpy-6K 3967.6 3968.8 
 
 
 
 
 
 
bpa 
 
The same synthesis strategy (as shown in Fig. 5.37) could be applied on the bpa ligand 
3.6, and MALDI spectra of the HPLC purified products proved a successful reaction. 
 
Tab. 5.13: Overview of PNA Oligomers with Central bpa* Attachment 
central  Mcalc Mfound 
   Ac-tacc-GlyPhe(bpa*)-tgtt-Lys Ac4-GFbpa-4K 2855.2 2855.1 
  Ac-ttacc-GlyPhe(bpa*)-tgtta-Lys Ac5-GFbpa-5K 3396.4 3397.8 
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5.7 Summary 
 
In the preceding Chapter, several unmodified PNA oligomers were synthesized, corre-
sponding both to terminally and centrally substituted sequences. An overview of the 
synthesized sequences in this Chapter is given in the Appendix. All oligomers were 
purified by HPLC, and MALDI-TOF spectrometry showed pure products in all cases.  
 
The ligands 3.5 and 3.6 could be successfully coupled to the N-terminus of PNA. At-
tempts to attach the amino ligand phen*-H 3.8 to the N-terminus which was success-
fully converted into a C-terminus prior to coupling, exposed the difficulty of on-resin 
carboxyl activation by the use of HATU. 
 
A versatile method for an internal attachment of carboxyl ligands to a PNA chain was 
developed, consisting of the incorporation of Fmoc-protected p-nitro-phenylalanine and 
a glycine spacer. The chain assembly was interrupted after that, the nitro group was 
successfully reduced on resin, and after coupling of the particular ligand, the oligomer 
synthesis was continued to the end. 
 
As a comparison, the corresponding PNA oligomers bearing an unfunctionalized inter-
nal dipeptide spacer and guanine rich oligomers with a central GlyPhe unit were synthe-
sized, as well. 
 
 

6 Hybridization Experiments 
6.1 Introduction 
 
The so-called melting of oligonucleotide double strands describes the thermal denatura-
tion of a duplex, caused by the breaking of Watson-Crick base pairings with increasing 
temperature (Fig. 6.1). 
 
 
Fig. 6.1: Denaturation and Renaturation of DNA 
 
This process can be observed by measuring at certain wavelengths (260nm) the absorb-
ance of a solution of two more or less complementary single strands versus the tempera-
ture.280 The change of absorbance with increasing temperature is caused by the hyper-
chromicity due to the loss of π-stacking present in oligonucleotide helices. The absorp-
tion coefficient of nucleobases is higher in single strand oligonucleotides than in the 
duplex which leads to an increase of absorbance with rising temperature. 
Melting curves show a sigmoidal shape (Fig. 6.2) because of the melting being a coop-
erative effect: If some base pairs are already broken up, adjacent base pairs will break 
up easier. 
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Fig. 6.2: Melting Curve of PNA Ac6-c-6K i DNA 3’6-G-115’ 
 
The melting temperature TM is defined as the temperature at which 50% of the species 
in solution is hybridized, meaning equal amounts of base-paired and unpaired single 
strands are present. It is determined by the maximum of the first derivative melting 
curve. The α value of a system describes the fraction of single strands in the duplex 
state; α will be 0.5 at TM (Fig. 6.3). 
 
Fig. 6.3: Melting Curve (black) of PNA Ac6-c-6K i DNA 3’6-G-115’ and its First Derivative (red) 
 
TM has been found to correlate well with the thermodynamic equilibrium constant, K, 
and is, thus, generally a good measure for duplex stability.281, 282 
Fro DNA iDNA, TM is strongly dependent on the concentration of oligonucleotides and 
the salt concentration, because the repulsion of negatively charged single strands is 
compensated by metal ions. As a result, TM decreases with decreasing salt concentra-
tion. For that reason, a phosphate buffer with 0.1M NaCl is used for melting experi-
ments. Under physiological conditions, Zn2+ & Mg2+ can take over the role of those 
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counter ions. In the case of PNA, melting is relatively independent of the salt concentra-
tion because of PNA being an uncharged molecule.157, 283 PNA oligomers readily hy-
bridize with complementary DNA strands, preferably in an antiparallel way.156, 284 
The antiparallel PNA iDNA duplex forms a DNA like, right-handed double 
helix,150, 285, 286 but with a tighter coiling than in the case of dsDNA (Fig. 6.4). B-DNA 
has 10 base pairs in one turn, whereas in PNA iDNA duplexes, the major groove is 
enlarged at the expense of the minor groove, which leads to a coil of 13 bp. 
 
According to NMR experiments, PNA iDNA mixed-sequence duplexes adopt a struc-
ture possessing features of both A-form and B-form DNA.283  
 
 
Fig. 6.4: Models illustrating the three different types of duplexes. From left to right: DNA i DNA, 
PNA i DNA, and PNA i PNA, with side views in the upper row and top views in the lower284 
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If a nucleobase within a sequence is replaced with another one not matching to the 
complementary strand (mutation), this is called a mismatch. The difference between the 
melting temperature of a fully complementary duplex and the melting temperature of a 
duplex with one or more mismatches is referred to as ∆TM. PNA possesses a higher 
mismatch-sensitivity than DNA,287 leading to a ∆TM (DNA iPNA) of up to 15°C in de-
camers. 
This results in a higher sequence selectivity143, 158 and binding specificity288 due to the 
fact that PNAs will preferably bind to their perfect complementary sequence, because 
the affinity to a single mismatch sequence will be significantly lower. 
The higher melting temperature of PNA iDNA duplexes in contrast to DNA iDNA du-
plexes157, 288 makes even short sequences suitable for targeting.  
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6.2 Melting Curve Analysis 
 
Because of the melting temperature of an oligonucleotide being defined as the point of 
highest slope in the absorbance melting curve, the maximum of the first derivative indi-
cates this temperature. Each experiment was carried out at least four times with fresh 
solutions, the inflection point for each curve was determined by this means, and the av-
erage was calculated after leaving out mavericks. In this Chapter and in the Appendix, 
only one example of each duplex is displayed; average data is given in Chapter 6.4. 
 
 
Significance 
The mere consideration of the melting temperature turned out to be not significant 
enough for comparing different sequences. 
Melting curves of apparently inferior matching strands sometimes showed a higher 
melting temperature than obtained from the 100% matching experiment. 
For example, a curve from an obviously not hybridizing system (concerning the shape 
of the melting curve) was transformed into a quite nice first derivative curve by simply 
cropping the melting data at both ends, and a melting point was obtained (Fig. 6.5). 
 
 
Fig. 6.5: Melting Curve of PNA Ac6-GF-6K i DNA 3’6-G-115’ – Different Data Ranges 
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Also by rescaling the y-axis and cutting the first derivative curve, the result could be 
embellished (Fig. 6.6). 
 
Fig. 6.6: Melting Curve of PNA Ac6-GF-6K i DNA 3’6-G-115’ – Cropped 1st Derivative 
 
The same experiment with the corresponding DNA match sequence (with the central 
guanine omitted; these results are forestalled and will be discussed later) showed a 
lower melting temperature, but a clear sigmoidal shape (Fig. 6.7). 
 
Fig. 6.7: Melting Curve of PNA Ac6-GF-6K i DNA 3’6-115’ 
 
By only indicating the melting temperatures of these two examples, one could conclude 
that the first PNA iDNA duplex is more stable than the second one which is not coher-
ent and also not true. 
In order to overcome these problems, the shape of the melting curve was taken into con-
sideration by the development of a factor representing the pertinence of the curve. 
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Aspects of a significant melting process besides the melting temperature are: 
 
Melting Curve: 
• Difference between Upper and Lower Baseline 
(Offset / Increase of Absorbance) 
 
1st Derivative: 
• Maximum (representing the slope of 
the melting curve at TM) 
• Minima (left & right) 
• Peak Height (Max minus Average Min) 
• Max/Min-Ratio 
• Full Width at Half Maximum (FWHM) 
• Ratio between Peak Height and FWHM 
 
The latter coefficient is higher with increasing height and decreasing width of the first 
derivative melting curve. Those two values directly depend on the sigmoidality. The 
first derivative of a highly curved graph is very sharp and clear cut, and the ratio peak 
height / FWHM is high. This quotient therefore was deemed to be a valuable measure 
for the relevance of a melting curve and will be referred to as fM in the following. Every 
value was multiplied with 104 and indicated as nondimensional. 
 
Another important aspect is the so-called self-melting of PNA. 
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Self-melting 
The concentration of PNA solutions has to be determined at 70°C. The reason for this is 
the self-stacking of nucleobases in PNA oligomer strands (which is not observed for 
DNA), so that only at higher temperature, the absorbance of PNA solutions will signifi-
cantly represent its concentration. Stacking of nucleobases causes a decrease of absorb-
ance (hypochromicity) and therefore falsifies the concentration. 
 
A PNA iDNA melting experiment with two non-match single strands can result in a 
change of absorbance suggesting hybridization. 
Literature does not provide any information about the significance of melting curves, 
only mentioning melting points or thermodynamical data. The fact that single stranded 
PNA has a melting temperature for itself was mentioned by Ray and Nordén,151 only 
specifying the TM of the single strand (44.7°C) without comparison or valuation. This 
TM is even higher than that obtained from a duplex melting experiment (39.0°C), but the 
authors do not comment this fact, so that no information is given whether hybridization 
or only self-melting takes place. 
The self-stacking of PNA oligomers has little impact, however, on the hyperchromicity 
of the melting curves of PNA iDNA duplexes, as they will typically melt at tempera-
tures above 45°C.149, 284 Normally, the effect of single-strand order at low temperatures 
should not represent a severe complication when analyzing absorbance melting curves. 
At low temperatures, the duplex is strongly favoured over the isolated single strand and 
as the temperature (and consequently the number of single strands) increases, the order 
of the single strands decreases.289 In the case of shorter sequences and disturbed com-
plementarity as in this Thesis, this fact has to be implied, because if no hybridization 
occurs, the self-melting effect (giving a sigmoidal curve even without hybridization) 
could be mistaken for a melting which does in fact not take place at all. 
In order to evaluate this, each PNA monomer was “molten” without addition of the cor-
responding DNA strand. The ratio between fM of the double-strand melting curve and fM 
of the single strand melting experiment (qM) provides information about the signifi-
cance of the melting curve in comparison to the self-melting effect (qM = fMds/fMsm). 
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Buffer Baseline 
 
In order to prove that only PNA is responsible for sigmoidality, absorbance curves both 
of pure buffer (Fig. 6.8) and pure DNA (Fig. 6.9) were measured. 
  
Fig. 6.8: Absorbance Curve of Pure Buffer Fig. 6.9: Absorbance Curve of Pure DNA 3’6-G-115’ 
 
The buffer curve shows hyperchromicity which turns out to be negligible, because it 
only amounts to a total of 3%. Experiments with a blank cuvette filled with buffer only, 
being subtracted from the actual absorbance values, did not reveal any significant dif-
ference in the shape of the melting curve, and the TM values were similar to the uncor-
rected ones. 
Tab. 6.1: Typical Hyperchromicity Values 
 A80°C - A5°C 
buffer only 0.035 (3%)  
DNA only 0.065 (13%) 
PNA only 0.05-0.10 (20-30%) 
PNA iDNA 0.25-0.30 (20-30%) 
DNA iDNA 0.30-0.40 (25-35%) 
 
The percentage increases of absorbance (hyperchromicity) values are indicated below 
the particular melting curves in the Appendix. 
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Concentration Accuracy 
 
In order to examine the influence of concentration inaccuracies on the melting tempera-
ture, hybridization experiments were carried out with 20% excess of DNA and 20% 
excess of PNA, respectively. Surprisingly, the melting temperature was only changed 
by an average value of 1.3°C, so that this potential systematic error did not have to be 
worried about. 
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6.3 Measurements 
 
Every melting experiment was done at least four times according to the procedure de-
scribed in the Experimental Part. 3µM solutions of the HPLC purified oligomers were 
prepared in phosphate buffer with 0.1M NaCl, and the mixtures were heated from 5°C 
to 80°C with a rate of 0.5°C/min, measuring the absorbance at 260nm. The resulting 
melting curves were differentiated and polynomially fitted (9th order / 1000 data points). 
The TM values obtained from the melting curves were averaged (Eq. 1) after deleting 
mavericks, and standard deviations were determined according to Eq. 2: 
 
ixx
N
= ∑  (1) N 2x i
i 1
1 (x x)
N =
σ = −∑ (2) 
 
All PNA oligomers were readily soluble in phosphate buffer, except as indicated. 
 
Self-melting experiments were carried out once on every single strand sequence and 
DNA iDNA hybridization was performed for every combination, as well. 
 
PNA iDNA melting experiments were performed with the prepared oligomers and 
compared with the results obtained from self-melting curves and the corresponding 
DNA iDNA duplexes. 
 
In the Appendix, one example of each curve is shown; the averaged TM data and the fM 
values of the particular example curve are collected and discussed in Chapter 6.4. 
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The following DNA oligonucleotides were used for hybridisation: 
 
DNA targets  
3’-TAATGGGACAATAGGGAT-5’ 3’6-G-115’ 
3’-TAATGG   ACAATAGGGAT-5’ 3’6-115’ 
                   3’-ACAATAGG-5’ 3’85’ 
                   3’-ACAATAGGGAT-5’ 3’115’ 
3’-TAATGG-5’ 3’65’ 
 
 
DNA as PNA representatives  
        5’-TGTTATCC-3’ 5’83’ 
        5’-TGTTATCCC-3’ 5’93’ 
        5’-TGTTATCCCT-3’ 5’103’ 
     5’-TACCCTGTT-3’ 5’4-C-43’ 
   5’-TTACCCTGTTA-3’ 5’5-C-53’ 
5’-ATTACCCTGTTAT-3’ 5’6-C-63’ 
     5’-TACC   TGTT-3’ 5’4-43’ 
   5’-TTACC   TGTTA-3’ 5’5-53’ 
5’-ATTACC   TGTTAT-3’ 5’6-63’ 
 
 
Be careful not to mix 3’85’ and 5’83’ – they are complementary and do NOT represent the 
same sequence. 
Distinguishing between them will be easy in the context of the experiments. 
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6.3.1 Terminal Sequences 
 
 
As a comparison, DNA iDNA hybridization experiments were carried out with the fol-
lowing sequences and DNA 3’6-G-115’: 
 
terminal DNA 
5’-TGTTATCC-3’ 5’83’ 
5’-TGTTATCCC-3’ 5’93’ 
5’-TGTTATCCCT-3’ 5’103’ 
 
For all sequences with and without ligand, melting was investigated for PNA alone 
(self-melting) and PNA iDNA 3’6-G-115’: 
 
terminal PNA 
      Ac-tgttatcc-Lys Ac8K 
      Ac-tgttatccc-Lys Ac9K 
      Ac-tgttatccct-Lys Ac10K 
    tpy*-tgttatcc-Lys tpy8K 
    tpy*-tgttatccc-Lys tpy9K 
    tpy*-tgttatccct-Lys tpy10K 
    bpa*-tgttatcc-Lys bpa’8K 
 
In order to examine the influence of a DNA overhang on the hybridization behaviour of 
the substituted and unsubstituted PNA oligomers, additional melting experiments were 
undertaken for the following combinations as a comparison: 
 
PNA tpy8K iDNA 3’85’ PNA Ac8K iDNA 3’85’ 
PNA bpa’8K iDNA 3’85’ DNA 5’83’ iDNA 3’85’ 
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6.3.2 Central Sequences 
 
6.3.2.1 Unmodified PNA Oligomers 
 
Balasubramanian et al.81 published results suggesting the hybridization of only one half 
of the PNA sequence when a central ligand is attached. In order to obtain more informa-
tion about the influence of an internal disturbing factor on the melting behaviour, melt-
ing experiments were performed for all possible combinations of omitted / present cen-
tral nucleobases within the sequences for central functionalization. 
 
As a comparison, DNA iDNA hybridization experiments were carried out with the fol-
lowing sequences and DNA 3’6-G-115’ & 3’6-115’: 
 
central DNA 
     5’-TACCCTGTT-3’ 5’4-C-43’ 
   5’-TTACCCTGTTA-3’ 5’5-C-53’ 
5’-ATTACCCTGTTAT-3’ 5’6-C-63’ 
     5’-TACC   TGTT-3’ 5’4-43’ 
   5’-TTACC   TGTTA-3’ 5’5-53’ 
5’-ATTACC   TGTTAT-3’ 5’6-63’ 
 
With the following PNA sequences, melting was performed for PNA alone (self-
melting), PNA iDNA 3’6-G-115’ and PNA iDNA 3’6-115’: 
 
central PNA 
           Ac-taccctgtt-Lys Ac4-c-4K 
          Ac-ttaccctgtta-Lys Ac5-c-5K 
        Ac-attaccctgttat-Lys Ac6-c-6K 
             Ac-tacctgtt-Lys Ac4-4K 
            Ac-ttacctgtta-Lys Ac5-5K 
          Ac-attacctgttat-Lys Ac6-6K 
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6.3.2.2 PNA Oligomers with Central Dipeptide 
 
For all three PNA sequences with an internal GlyPhe unit, TM curves were determined 
for PNA alone, PNA iDNA 3’6-G-115’ and PNA iDNA 3’6-115’: 
 
central PNA 
   Ac-tacc-GlyPhe-tgtt-Lys Ac4-GF-4K 
  Ac-ttacc-GlyPhe-tgtta-Lys Ac5-GF-5K 
Ac-attacc-GlyPhe-tgttat-Lys Ac6-GF-6K 
 
 
G-rich Sequences 
 
In the presence of TFA, the synthesized guanine rich sequences (Acg1-GF-g2K, 
Acg3-GF-g4K) were clearly soluble, but they turned out to be nearly insoluble in phos-
phate buffer used for hybridization experiments. As a consequence, it was impossible to 
reach a concentration sufficing for UV-Vis spectroscopy. This fact corresponds to the 
experience Nielsen et al. gained with several PNA sequences;290 purine rich sequences 
tend to aggregate despite of the protonation of the amino groups (lysine residues) at 
neutral pH. In order to rise the G/C content of the sequence, the synthesis of cytosine 
rich sequences thus should be much more promising. 
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6.3.2.3 DNA Cleavage Fragments 
 
The basic concept behind the development of cleavage moieties attached to the center of 
a sequence is its potential catalytic activity based on the assumption that the binding 
affinity of a PNA iDNA duplex will decrease after the reaction, leading to a dehybridi-
zation.291 In order to investigate this concept, melting experiments were undertaken with 
“cleaved” DNA oligomers meaning fragments of the target sequence from both sides of 
the cleavage spot. 
 
The following DNA and PNA sequences were hybridized with both halves of the DNA 
target (3’65’ and 3’115’): 
 
central DNA 
5’-ATTACCCTGTTAT-3’ 5’6-C-63’ 
5’-ATTACC   TGTTAT-3’ 5’6-63’ 
 
 
central PNA 
       Ac-attaccctgttat-Lys Ac6-c-6K 
         Ac-attacctgttat-Lys Ac6-6K 
Ac-attacc-GlyPhe-tgttat-Lys Ac6-GF-6K 
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6.3.2.4 PNA Sequences with Central Ligand 
 
The internally functionalized PNA oligomers (Ac4-GFtpy-4K, Ac5-GFtpy-5K, 
Ac6-GFtpy-6K, Ac4-GFbpa-4K, Ac5-GFbpa-5K) turned out to be insoluble in buffer, al-
though they did not resist being purified by HPLC in aqueous TFA/acetonitrile. 
Several attempts were undertaken to examine the hybridization properties of these com-
pounds (because the next step would have been to let them cleave DNA). A change of 
pH was out of the question; protonation of the DNA templates would have prevented 
significant results. A well-known way to get badly soluble oligonucleotides into solu-
tion is the addition of DMSO (the changing solvent effect could have been neglected). 
All compounds were clearly soluble in pure DMSO, but after adding one single drop of 
water (which is inevitable for hybridization because of the hydration equilibrium), the 
oligomers precipitated immediately. 
This deficiency could be remedied by adding more lysine residues to the oligomer 
chain; an increased solubility could be achieved by this means. 
Future research will be headed towards this direction. 
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6.4 Results 
 
In this Chapter, only the data is discussed (apart from some examples); for plots of the 
particular melting curves, please refer to the Appendix. 
 
6.4.1 Overview 
 
Terminal 
 
Tab. 6.2: Overview of Melting Data for Terminal Sequences with DNA 
TM[°C]±SD (fM) self-melting iDNA 3’6-G-115’ iDNA 3’85’ 
PNA Ac8K 31.3 (0.18) 27.6±0.1 (1.21) 18.2±0.3 (1.27) 
PNA tpy8K 44.4 (0.08) 38.4±0.3 (1.01) 24.8±0.4 (0.81) 
PNA bpa’8K n.o. 29.7±0.3 (1.54) 22.3±0.7 (1.38) 
DNA 5’83’ n.m. 27.9±0.3 (2.06) 23.2±0.4 (1.86) 
PNA Ac9K 49.2 (0.20) 38.9±0.1 (1.80) n.m. 
PNA tpy9K 49.9 (0.05) 46.8±0.2 (0.73) n.m. 
DNA 5’93’ n.m. 38.1±0.02 (2.76) n.m. 
PNA Ac10K 29.0 (0.10) 43.8±0.4 (1.74) n.m. 
PNA tpy10K 45.6 (0.15) 50.0±0.2 (1.76) n.m. 
DNA 5’103’ n.m. 41.8±0.1 (3.33) n.m. 
 
(n.m. = not measured; n.o. = not observed) 
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Central 
 
Tab. 6.3: Overview of Melting Data for Central Sequences with DNA Fragments 
TM[°C]±SD (fM) iDNA 3’65’ iDNA 3’115’  
PNA Ac6-c-6K 44.0±0.1 (0.28) 44.3±2.6 (0.40)  
DNA 5’6-C-63’ (22.7) (0.29) (26.0) (0.36)  
PNA Ac6-6K 44.0±1.0 (0.20) 48.2±1.3 (0.32)  
DNA 5’6-63’ (~4) (n.o.) (33.3) (0.14)  
PNA Ac6-GF-6K 40.4±0.1 (0.26) 41.2±1.1 (0.68)  
 
Tab. 6.4: Overview of Melting Data for Central Sequences with DNA 
TM[°C]±SD (fM) self-melting iDNA 3’6-G-115’ iDNA 3’6-115’ 
PNA Ac4-c-4K 40.2 (0.10) 41.8±0.5 (0.94) 18.6±1.0 (0.25) 
DNA 5’4-C-43’ n.m. 34.2±0.2 (2.62) 13.1±0.1 (1.00) 
PNA Ac4-4K n.o. 24.3±1.6 (0.54) 25.1±0.02 (0.81) 
DNA 5’4-43’ n.m. (~17) (1.91) 26.1±0.1 (1.86) 
PNA Ac4-GF-4K 22.0 (0.21) (~31) (0.29) 11.0±0.1 (0.59) 
PNA Ac5-c-5K 39.1 (0.21) 47.4±0.3 (1.28) 29.9±2.8 (0.44) 
DNA 5’5-C-53’ n.m. 41.1±0.2 (3.32) 23.4±0.3 (1.96) 
PNA Ac5-5K 56.0 (0.15) 29.4±1.6 (1.11) 35.3±0.1 (1.07) 
DNA 5’5-53’ n.m. 23.5±0.5 (1.86) 34.5±0.1 (3.45) 
PNA Ac5-GF-5K 23.7 (0.35) (~27) (0.47) 21.5±0.1 (1.41) 
PNA Ac6-c-6K 47.5 (0.25) 52.1±0.2 (2.55) 28.7±0.5 (0.42) 
DNA 5’6-C-63’ n.m. 47.4±0.1 (5.94) 32.9±0.1 (3.97) 
PNA Ac6-6K 48.2 (0.53) 35.0±0.7 (0.99) 43.2±0.2 (1.59) 
DNA 5’6-63’ n.m. 33.3±0.1 (3.96) 42.2±0.1 (4.88) 
PNA Ac6-GF-6K 44.2 (0.29) (~33) (0.40) 30.7±0.2 (1.50) 
 
(n.m. = not measured; n.o. = not observed) 
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6.4.2 Self-Melting 
 
In Chapter 6.2, the aspect of significance was mentioned, and the coefficients fM and qM 
were introduced. On the basis of the obtained TM data, the self-melting effect will be 
elaborated. Tab. 6.5 and Tab. 6.6 show the self-melting data of the PNA oligomers and 
the melting temperatures of the particular PNA iDNA duplexes, including the fM values, 
written in brackets. The difference in TM and the ratio between fMds and fMsm (qM) are 
indicated, providing information concerning the significance of a melting curve in com-
parison to the PNA single strand self-melting. 
 
Tab. 6.5: Terminal PNA Sequences – Self-Melting and Hybridization Data 
PNA TMsm (fMsm) 
iDNA 
3’6-G-115’ 
TMds (fMds) 
∆Tsm/ds 
(qM) 
iDNA 
3’85’ 
TMds (fMds) 
∆Tsm/ds 
(qM) 
Ac8K 31.3 (0.18) 27.6 (1.21) -3.7 (6.7) 18.2 (1.27) -13.1 (7.1) 
tpy8K 44.4 (0.08) 38.4 (1.01) -6.0 (12.6) 24.8 (0.81) -19.6 (10.1) 
Ac9K 49.2 (0.20) 38.9 (1.80) -10.3 (9.0) n.m. / 
tpy9K 49.9 (0.05) 46.8 (0.73) -3.1 (14.6) n.m. / 
Ac10K 29.0 (0.10) 43.8 (1.74) 14.8 (17.4) n.m. / 
tpy10K 45.6 (0.15) 50.0 (1.76) 4.4 (11.7) n.m. / 
 
For terminal oligomers, fMds significantly differs from fMsm (fMds ranges from 0.73-1.80, 
fMsm from 0.05-0.20). As a consequence, qM has values of 6.7-14.6 and increases with 
growing chain length. ∆Tsm/ds does not provide any information about stability; it differs 
as the case arises and is invalid as long as TMsm is not significant according to the corre-
sponding fM values. It can be concluded that melting in fact takes place, and qM of more 
than 5-6 can be regarded as significant. 
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Tab. 6.6: Central PNA Sequences – Self-Melting and Hybridization Data 
PNA TMsm (fMsm) 
iDNA 
3’6-G-115’ 
TMds (fMds) 
∆Tsm/ds 
(qM) 
iDNA 
3’6-115’ 
TMds (fMds) 
∆Tsm/ds 
(qM) 
Ac4-c-4K 40.2 (0.10) 41.8 (0.94) 1.6 (9.4) 18.6 (0.25) -21.6 (2.5) 
Ac4-4K n.o. 24.3 (0.54) / 25.1 (0.81) / 
Ac4-GF-4K 22.0 (0.21) (~31) (0.29) (9.0) (1.4) 11.0 (0.59) -11.0 (2.8) 
Ac5-c-5K 39.1 (0.21) 47.4 (1.28) 8.3 (6.1) 29.9 (0.44) -9.2 (2.1) 
Ac5-5K 56.0 (0.15) 29.4 (1.11) 26.6 (7.4) 35.3 (1.07) -20.7 (7.1) 
Ac5-GF-5K 23.7 (0.35) (~27) (0.47) (3.3) (1.3) 21.5 (1.41) -2.2 (4.0) 
Ac6-c-6K 47.5 (0.25) 52.1 (2.55) 4.6 (10.2) 28.7 (0.42) -18.8 (1.7) 
Ac6-6K 48.2 (0.53) 35.0 (0.99) -13.2 (1.9) 43.2 (1.59) -5.0 (3.0) 
Ac6-GF-6K 44.2 (0.29) (~33) (0.40) (11.2) (1.4) 30.7 (1.50) -13.5 (5.2) 
 
Similar to the terminal sequences, the self-melting temperatures of the central PNA sin-
gle strands appear to be coincidental. The fMsm values are higher than the terminal ones 
(0.10-0.53), which can be explained by partial self-complementarity. An antiparallel 
hybridization of two similar PNA strands e.g. for Ac6-c-6K shows eight matches that 
increase the stability of the duplex, albeit they form double matches that are not adja-
cent to each other (and therefore not cooperative). Eight separated complements in a 
strand are not sufficient for the self-aggregation of PNA, but obviously intensify the 
self-melting effect. fMsm increases with growing chain length, because more matches are 
present: 
Lys- t a t t g t c c c a t t a -Ac 
Ac- a t t a c c c t g t t a t -Lys 
Ac6-C-6K 
 
For the terminal sequences, only four matches can be expected: 
Lys- t c c c t a t t g t -Ac 
Ac- t g t t a t c c c t -Lys 
Ac10K 
 
As a consequence for the central sequences, fMsm increases, and qM is smaller on aver-
age, reaching from 1.4-10.2. As a preliminary conclusion, it can be stated that fM can at 
the most serve for comparison, and should be carefully used as an absolute value. 
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6.4.3 Terminal Sequences 
 
Comparison of Chain Lengths 
 
With increasing length, the melting temperature of oligonucleotide duplexes usually 
rises, because more base pairs cooperatively contribute to the overall stability. 
Tab. 6.7 shows that for PNA and DNA, the increase in TM between 8- and 9mers is ap-
proximately twice as high as between 9- and 10mers. The fM values tendentially in-
crease with the chain length. 
 
 
Tab. 6.7: Comparison of Terminal Chain Lengths 
iDNA 3’6-G-115’ TM[°C] (fM) ∆TM 
PNA Ac8K 27.6 (1.21) 
PNA Ac9K 38.9 (1.80) 
PNA Ac10K 43.8 (1.74) 
11.3 
4.9 
PNA tpy8K 38.4 (1.01) 
PNA tpy9K 46.8 (0.73) 
PNA tpy10K 50.0 (1.76) 
8.4 
3.2 
DNA 5’83’ 27.9 (2.06) 
DNA 5’93’ 38.1 (2.76) 
DNA 5’103’ 41.8 (3.33) 
10.2 
3.7 
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Comparison of PNA and DNA 
 
Tab. 6.8: Comparison of Terminal PNA and DNA With (left) and Without Overhang (right) 
TM[°C] iDNA 3’6-G-115’  iDNA 3’85’ 
 DNA PNA ∆TM  DNA PNA ∆TM 
5’83’ / Ac8K 27.9 27.6 -0.3  23.2 18.2 -5.0 
5’83’ / tpy8K 27.9 38.4 10.5  23.2 24.8 1.6 
5’83’ / bpa8K 27.9 29.7 1.8  23.2 22.3 -0.9 
5’93’ / Ac9K 38.1 38.9 0.8  n.m. n.m. n.m. 
5’93’ / tpy9K 38.1 46.8 8.7  n.m. n.m. n.m. 
5’103’ / Ac10K 41.8 43.8 2.0  n.m. n.m. n.m. 
5’103’ / tpy10K 41.8 50.0 8.2  n.m. n.m. n.m. 
 
Compared to DNA iDNA duplexes, PNA iDNA hybrids in general show a higher sta-
bility because of the lack of charge repulsion due to the neutral PNA backbone. In fact, 
this can be affirmed in line with the results displayed in Tab. 6.8. Some examples show 
a lower TM for PNA iDNA. This is in the range of measuring inaccuracies, which are 
probable especially for short sequences with low TM values. The acetylated PNA oli-
gomers display only small ∆TM, which might be explainable by a repulsive and destabi-
lizing effect of the acetyl group. This effect decreases with growing chain length, be-
cause the attractive influence of the double strand gets the upper hand. 
In the case of tpy-substitution, the melting temperatures show a more significant in-
crease of TM relative to the corresponding DNA iDNA values in comparison to acety-
lated oligomers (∅=9.1°C). This leads to the conclusion that terpyridine must have a 
stabilizing effect on the particular duplex which is not observed in the case of bpa. The 
complementary DNA sequence without overhang (DNA 3’85’) does not reveal this re-
sult, so that a single strand effect can be reasoned – an overhang should not cause any 
difference if tpy-interaction with the PNA iDNA double strand (groove binding) took 
place. On the other hand, the stabilizing effect of lysine is not present any more. In con-
trast to repulsion, stabilizing interactions decrease with growing chain length, as in this 
case. 
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Comparison of Substitution 
 
As shown on the basis of Tab. 6.8, a terminal tpy ligand seems to have a stabilizing ef-
fect on the PNA iDNA duplex in comparison with DNA iDNA melting experiments. 
This is confirmed by regarding ∆TM of different substituents (Tab. 6.9). Furthermore, 
the influence of an overhang of target DNA was examined by performing melting ex-
periments with DNA 3’85’. 
 
Tab. 6.9: Comparison of Terminally Substituted Sequences 
    
TM[°C] 
PNA iDNA x=Ac x=tpy ∆TM 
x8K i 3’6-G-115’ 27.6 38.4 10.8 
x9K i 3’6-G-115’ 38.9 46.8 7.9 
x10K i 3’6-G-115’ 43.8 50.0 6.2 
x8K i 3’85’ 18.2 24.8 6.6 
    
TM[°C] 
PNA iDNA x=Ac x=bpa ∆TM 
x8K i 3’6-G-115’ 27.6 29.7 2.1 
x8K i 3’85’ 18.2 22.3 4.1 
    
TM[°C] 
PNA iDNA x=bpa x=tpy ∆TM 
x8K i 3’6-G-115’ 29.7 38.4 8.7 
x8K i 3’85’ 22.3 24.8 2.5 
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The stabilizing effect of tpy in comparison to a terminal acetyl group is much higher 
than for bpa. Again, ∆TM decreases with growing chain length, representing the evanes-
cent influence in comparison to the attractive base-pairing interaction. In addition to 
that, the overhang interacting with the lysine residue becomes shorter. The difference 
between the TMs of bpa- and tpy-substituted sequences is inter alia explainable by the 
enhanced flexibility of the tpy-linker in contrast to the more rigid bpaBzl, so that the 
stabilizing effect of bpa is reduced to its electrostatic interaction with the DNA phos-
phate backbone due to protonation of the pyridine nitrogen atoms. 
 
 
Comparison of DNA 3’6-G-115’ and DNA 3’85’ (Overhang Influence) 
 
Tab. 6.10: Terminal DNA Targets With and Without Overhang 
TM[°C] iDNA 3’6-G-115’ iDNA 3’85’ ∆TM 
PNA Ac8K 27.6 18.2 -9.4 
PNA tpy8K 38.4 24.8 -13.6 
PNA bpa8K 29.7 22.3 -7.4 
DNA 5’83’ 27.9 23.2 -4.7 
 
Similar to the observed effect whether a DNA overhang is present or not, the increase of 
stability of the bpa-PNA duplex in comparison to the Ac-PNA can be explained by elec-
trostatic attractions similar to those between Lys residues and the complementary DNA 
strand. In the case of terpyridine, this circumstance is not sufficient enough to elucidate 
a ∆TM of more than 10°C. Intercalation (which is, per definitionem, the insertion of 
molecules between the stacked nucleobases of double stranded DNA) by terpyridine is 
only known from its metal complexes (Pt(II), Ru(II)) which insert one of their ligands 
between two base pairs.292-294 In addition, intercalation usually leads to destabilization 
of double strands, not to an increase of melting temperature. A valid explanation for the 
enhanced binding affinity of tpy-PNA could be the π-stacking of its pyridine rings be-
tween the nucleobases of the overhanging DNA single strand which is, certainly, a kind 
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of intercalation. This interaction takes place in the single strand region, because a miss-
ing overhang has a significant influence. The attractive interaction of the ligand with the 
complementary strand is promoted, because the partners are already close to each other 
due to the hybridization of the particular strands. 
Intercalation usually is favoured for large π-systems. For example, ethidium bromide 
(Fig. 6.10), the prime intercalator example, possesses an expanded aromatic ring system 
which enables it to interact with and thus stack between nucleobases. In the case of ter-
pyridine, this π-system is combined with an enhanced flexibility which enables the in-
tercalator to adapt to a binding pocket. A model for the intercalation of an internally 
linked intercalator is shown in Fig. 6.11. 
 
N
NH2
H2N
Br
  
N
N N  
Fig. 6.10: Structures of the Intercalators Ethidium Bromide and Terpyridine 
 
 
 
Fig. 6.11: Intercalation of Anthraquinone into a PNA:DNA Double Strand155 
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6.4.4 Central Sequences 
 
In Tab. 6.11 and Tab. 6.12, only the fully complementary data is displayed; partial non-
complementarity should not be taken into account in this context and will be discussed 
later. 
 
Comparison of Chain Lengths 
 
Tab. 6.11: Comparison of Central Chain Lengths 
iDNA 3’6-G-115’ TM[°C] ∆TM  iDNA 3’6-115’ TM[°C] ∆TM 
PNA Ac4-c-4K 41.8  PNA Ac4-4K 25.1 
PNA Ac5-c-5K 47.4  PNA Ac5-5K 35.3 
PNA Ac6-c-6K 52.1 
5.6 
4.5  PNA Ac6-6K 43.2 
10.2 
7.9 
DNA 5’4-C-43’ 34.2  DNA 5’4-43’ 26.1 
DNA 5’5-C-53’ 41.1  DNA 5’5-53’ 34.5 
DNA 5’6-C-63’ 47.4 
6.9 
6.3  DNA 5’6-63’ 42.2 
8.4 
7.7 
 
For the central sequences, the increase of TM is similar in nearly all cases and as high as 
for the terminal sequences, although the number of base pairs is each time raised by 
two. For DNA 3’6-115’, the differences are higher. 
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Comparison of PNA and DNA 
 
Tab. 6.12: Comparison of Central PNA and DNA With and Without Guanine 
TM[°C] iDNA 3’6-G-115’ 
 DNA PNA ∆TM 
5’4-C-43’ / Ac4-c-4K 34.2 41.8 7.6 
5’5-C-53’ / Ac5-c-5K 41.1 47.4 6.3 
5’6-C-63’ / Ac6-c-6K 47.4 52.1 4.7 
 
TM[°C] iDNA 3’6-115’ 
 DNA PNA ∆TM 
5’4-43’ / Ac4-4K 26.1 25.1 -1.0 
5’5-53’ / Ac5-5K 34.5 35.3 0.8 
5’6-63’ / Ac6-6K 42.2 43.2 1.0 
 
The fully matching sequences show a difference of ~5-8°C for DNA 3’6-G-115’ and 
nearly no difference for DNA 3’6-115’ (±1°C). Nevertheless, a decrease of ∆TM is ob-
served in the first case and an increase in the second one. 
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Comparison of Cleavage Fragments 
 
In order to prove that after a hypothetical oligonucleotide cleavage, the fragments will 
dehybridize again to release the PNA conjugate for further turnovers in a catalytic 
sense, both halves of the DNA target were investigated. 
 
Tab. 6.13: Comparison of Cleavage Fragments 
TM[°C] (qM) iDNA 3’65’ iDNA 3’115’ 
PNA Ac6-c-6K 44.0 (1.1) 44.3 (1.6) 
PNA Ac6-6K 44.0 (0.4) 48.2 (0.6) 
PNA Ac6-GF-6K 40.4 (0.9) 41.2 (2.3) 
 
At first glance, one could conclude that even with the short sequences, melting takes 
place, because a melting profile is observed. Concerning the shape of the melting curves 
(see Appendix), represented by fM, those conclusion is disproved, because the observed 
sigmoidality must be only due to self-melting (similar fM values; qM~1). In addition, the 
corresponding DNA iDNA experiments (not indicated in Tab. 6.13) showed no melting 
at all. Furthermore, the overhang only present in the case of DNA 3’115’ does not make 
any difference in melting behaviour, compared to DNA 3’65’ (without overhang). It can 
be concluded that after an assumed cleavage, the fragments would dehybridize again, 
and centrally derivatized PNA oligomers can be used as catalyst for DNA cleavage. 
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Internal Modifications – Bulge Formation 
 
For some central sequences, internal modifications were carried out, comprising the 
omission of one central nucleobase and incorporation of a dipeptidic abasic site, so that 
destabilization of the duplexes is expected. As a matter of fact, all those changes are 
reflected in a decrease of qM in comparison to a fully matching duplex. 
On this occasion, the observations will be discussed considering the melting curves. 
 
The first example depicts the influence of a PNA bulge on the hybridization (Fig. 6.12). 
 
 
 
 
PNA Ac6-c-6K self-melting (fM=0.25) 
  
PNA Ac6-c-6K iDNA 3’6-G-115’ 
(fM=2.55; qM=10.4) 
PNA Ac6-c-6K iDNA 3’6-115’ 
(fM=0.42; qM=1.7) 
Fig. 6.12: Influence of a PNA Bulge on Hybridization 
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The self-melting curve of PNA Ac6-c-6K shows a sigmoidal shape and an fM value of 
0.25. As one can clearly see at first glance, this oligomer hybridizes with the 
complementary DNA like a textbook example. Don’t be confused by the deceiving 
shape of the self-melting curve – it looks more sigmoidal than it is, because its 
hyperchromic offset is much lower than in the case of a duplex experiment. This is 
reflected by fM of the matching experiment which is more than ten times higher in 
comparison to self-melting (qM=10.4). In contrast to that, a DNA gap (in other words: 
PNA bulge) leads to a decrease of TM and qM at the same time. 
 
The converse experiment was carried out with a DNA bulge, and the results turned out 
to be vice versa; the DNA bulge (PNA gap) is tolerated, but leads to a significant 
decrease of stability. Again, it must be concluded that considering fM and qM may only 
serve as a comparison as the case arises. 
 
PNA Ac6-6K self-melting (fM=0.53) 
  
PNA Ac6-6K iDNA 3’6-G-115’ 
(fM=0.99; qM=1.9) 
PNA Ac6-6K iDNA 3’6-115’ 
(fM=1.59; qM=3.0) 
Fig. 6.13: Influence of a DNA Bulge on Hybridization 
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In the case of an internal dipeptide spacer as an abasic site, the experiments with the 
complementary DNA sequences resulted in nearly linear absorbance curves (see Ap-
pendix). Depending on the data range used for the derivative, the curves appeared in a 
completely different shape, although maxima are obtained. This was an important hint 
for the dubiety of a mere melting temperature without taking the shape into account. 
This point has been already discussed elaborately in Chapter 6.2. 
The shape of the melting curves (see Appendix) and the random values of the melting 
temperature lead to the conclusion that no hybridization has taken place at all. Reflect-
ing on the influence of the amino acids preventing the single strands from hybridization 
lead to the idea of omitting the corresponding nucleobases in the DNA sequence in or-
der to investigate if a bulge formation is taking place. One example of these experi-
ments is displayed in Fig. 6.14 (the same curves already were shown in Chapter 6.2). 
 
 
PNA Ac6-GF-6K self-melting (fM=0.29) 
 
PNA Ac6-GF-6K iDNA 3’6-G-115’ 
(fM=0.40; qM=1.4) 
PNA Ac6-GF-6K iDNA 3’6-115’ 
(fM=1.50; qM=5.1) 
Fig. 6.14: Influence of a Dipeptide Bulge on Hybridization 
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Concerning the qM values of the two melting experiments, the toleration of the dipeptide 
bulge is obvious. The higher melting temperature for PNA Ac6-GF-6K iDNA 3’6-G-115’ 
is voted down by the higher qM for PNA Ac6-GF-6K iDNA 3’6-115’.  
The observations were similar for all other chain lengths. Both for PNA- and DNA 
bulges, a decrease of TM was measured, although the bulge qM values indicate an im-
proper melting. The pretended decrease of stability for the dipeptide bulges is disproved 
by considering fM and qM. 
 
Tab. 6.14: Destabilization by a PNA Bulge 
TM[°C] (qM) iDNA 3’6-G-115’ iDNA 3’6-115’  iDNA 3’6-115’  
PNA Acx-c-xK ∆TM Acx-xK Acx-c-xK ∆TM 
x=4 41.8 (9.4) 18.6 (2.5) -23.2 25.1 (/) 18.6 (2.5) -6.5 
x=5 47.4 (6.1) 29.9 (2.1) -17.5 35.3 (7.1) 29.9 (2.1) -5.4 
x=6 52.1 (10.2) 28.7 (1.7) -23.4 43.2 (3.0) 28.7 (1.7) -14.5 
 
Tab. 6.15: Destabilization by a DNA Bulge 
TM[°C] (qM) iDNA 3’6-115’ iDNA 3’6-G-115’  iDNA 3’6-G-115’  
PNA Acx-xK ∆TM Acx-c-xK Acx-xK ∆TM 
x=4 25.1 (/) 24.3 (/) -0.8 41.8 (9.4) 24.3 (/) -17.5 
x=5 35.3 (7.1) 29.4 (7.4) -5.9 47.4 (6.1) 29.4 (7.4) -18.0 
x=6 43.2 (3.0) 35.0 (1.9) -8.2 52.1 (10.2) 35.0 (1.9) -17.1 
 
Tab. 6.16: Stabilization by a Dipeptide Bulge 
TM[°C] (qM) iDNA 3’6-G-115’ iDNA 3’6-115’  iDNA 3’6-115’  
PNA Acx-GF-xK ∆TM Acx-xK Acx-GF-xK ∆TM 
x=4 (~31) (1.4) 11.0 (2.8) (-20) 25.1 (/) 11.0 (2.8) -14.1 
x=5 (~27) (1.3) 21.5 (4.0) (-5.5) 35.3 (7.1) 21.5 (4.0) -13.8 
x=6 (~33) (1.4) 30.7 (5.2) (-2.3) 43.2 (3.0) 30.7 (5.2) -12.5 
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6.5 Summary 
 
Due to the doubtful consideration of duplex melting temperatures without any ancillary 
information, the first task in this project was to develop an objective and comparable 
criterion for the significance of (de)hybridization experiments. 
The ratio between height and full width at half maximum fM was shown to correlate 
well with the sigmoidality of a first derivative melting curve and therefore can be con-
sulted for comparison. The effect of PNA self-melting was included into these thoughts, 
and the coefficient qM was established to distinguish between this effect and real duplex 
formation. Partial self-complementarity was found to contribute to the mere stacking 
aspect of self-melting. 
 
Melting experiments were undertaken with the PNA oligomers described in Chapter 5 
and miscellaneous DNA targets. As a comparison, DNA iDNA hybrids were investi-
gated, as well. To summarize the vast number of data discussed in this Chapter, the fol-
lowing main aspects can be concluded: 
 
• As known from literature, PNA iDNA duplexes show higher melting tempera-
tures than the corresponding DNA iDNA duplexes. 
 
• An increase of chain length increases the melting temperature as expected. 
 
• Terminally PNA-bound terpyridine was found to intercalate in the single strand 
region of DNA and is therefore able to stabilize PNA iDNA duplexes. 
 
• The sequences with internal functionalization are suitable for potential catalytic 
nuclease activity, because target fragments will dehybridize after cleavage. 
 
• The destabilizing impact of an internal abasic site, consisting of a dipeptide 
spacer, can be compensated by the omitting of its DNA counterpart nucleobase. 
The formation of a bulge structure by the amino acids can be assumed. 
 
7 Conclusion & Outlook 
One of the most important actions in the context of replication in vivo and genetic engi-
neering in vitro is the cutting of genes. The genetic information in every living organism 
is located in the DNA, whose oligonucleotide sequence encodes the structure of en-
zymes and peptides in general as a blueprint. In nature, the cleavage is performed by 
nucleases, catalytically hydrolyzing the phosphodiester backbone of the DNA. Often, 
metal atoms are involved in that process. 
In a biotechnological laboratory, the cutting of oligonucleotides is carried out with re-
striction enzymes, isolated from bacteria. The limitation of those biotools to certain 
promoter sequences strongly demands the development of universal, artificial nucleases 
which are able to act at any desired sequence. Such a construct should consist of two 
main parts: a recognition domain and a cleavage domain. 
The aim of this Thesis was the development of new ligand systems being able to bind 
copper ions, which is predestined as a catalytic metal center for oligonucleotide hy-
drolysis. In order to act in a sequence-specific way, PNA (peptide nucleic acid), a DNA 
mimic with a pseudopeptide backbone, was chosen to be connected to the ligand moi-
ety. The ligands terpyridine, bis-picolylamine and phenanthroline (Fig. 7.1), which are 
known to cleave phosphodiester bonds in collaboration with copper, were functional-
ized in order to enable them to be incorporated into solid phase peptide synthesis 
(SPPS), which is the method of choice to generate a desired PNA sequence. The ligands 
were obtained in high purity and good yield, and characterized by NMR and MS tech-
niques. 
 
N
O
OH
O
N N3.5  
N
N
N
O
OH
3.6  
N N
NH2
3.8  
Fig. 7.1: Overview of Functionalized Nitrogen Ligands 
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The suitability of the ligands 3.5 and 3.6 for their coupling to amino groups was shown 
by the synthesis of conjugates with the amino acid phenylalanine. Furthermore, the 
ligands could be successfully connected to the peptide pseudoneurotensin, which may 
provide new metal markers for diagnosis and therapy (Fig. 7.2). 
 
3.11: R=Hex
3.12: R=tpy*
3.13: R=bpa*
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Fig. 7.2: Pseudoneurotensin Conjugates 
 
Copper complexes of the free ligands and their conjugates were synthesized, and mass 
spectrometry revealed their ability to bind the metal center selectively in their nitrogen 
binding pockets. In order to obtain detailed information about the binding modes of 
these compounds, the particular conjugates were titrated with copper, measuring the 
change of absorbance in UV-Vis. These experiments disclosed different binding modes 
of the ligands; terpyridine was shown to form bivalent complexes with two ligands 
complexing one copper center (Fig. 7.3, left; Fig. 7.4). This was not observed for the 
peptide conjugate of this ligand (Fig. 7.3, right), so that incorporation into PNA oli-
gomers seemed to be reasonable, as well. In the case of bis-picolylamine, the bivalent 
complex was formed irreversibly even with the peptide conjugate (Fig. 7.5; Fig. 7.6). 
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Fig. 7.3: UV-Vis Copper Titration Curves for 3.5 (left) and 3.12 (right) 
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Fig. 7.4: Binding Modes of Terpyridine 
 
 
Fig. 7.5: UV-Vis Copper Titration Curves for 3.6 (left) and 3.13 (right) 
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Fig. 7.6: Binding Modes of Bis-Picolylamine 
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Concerning the sequence specific recognition domain of a potential artificial nuclease, 
the synthesis of PNA monomers with base labile side chain protecting groups was opti-
mized in the second part of this Thesis. The practicability of this system was shown on a 
random sequence. 
 
The ligands mentioned above were connected to the amino terminus of PNA oligomers. 
Several sequences were synthesized by Fmoc SPPS, characterized by MALDI-TOF 
spectrometry and hybridized to complementary DNA strands, recording absorbance 
melting curves at 260nm. In the case of N-terminal terpyridine substitution, an interca-
lating effect of the uncomplexed ligand increased the stability of the PNA iDNA du-
plex, resulting in higher melting temperature in comparison to unsubstituted sequences 
and N-terminal bpa-conjugates. 
 
Another important task in the context of this Thesis was the coupling of the ligands to 
the center of a PNA sequence in order to provide building blocks for catalytic artificial 
nucleases with multiple turnovers. This was achieved by the incorporation of a dipep-
tide (GlyPhe) into PNA SPS, whose phenylalanine was easy to functionalize by the use 
of its p-nitro derivative 5.2. The chain assembly was interrupted after the glycine 
spacer, the aromatic nitro group was reduced on resin, and the activated carboxyl acid 
ligand was coupled to the resulting amino group, followed by finalization of the se-
quence and cleavage from the resin (Fig. 7.7). 
 
The concept of a dehybridization of oligonucleotide cleavage fragments and thus a po-
tential catalytic mode of action was proven by the fact that melting for DNA target 
fragments could not be observed. 
 
Melting experiments with DNA and PNA monomers with an internal, unfunctionalized 
GlyPhe spacer revealed the formation of a bulge structure by the dipeptidic abasic site. 
Investigations in the future should examine the influence of varying chain lengths on the 
duplex formation. Molecular modelling could provide information about structure and 
stability. 
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Fig. 7.7:  Synthesis Strategy for Internal Ligand Coupling to PNA 
 
Conjugates with internally attached ligands turned out to be insoluble in the buffer re-
quired for hybridization. This could be remedied by the incorporation of two or more 
lysine residues to the oligomers which should enhance solubility. Future research will 
be headed towards this direction. Nevertheless, in contrast to the time-consuming syn-
thesis of a cleavage site in solution, this method is based on solid phase methods, exclu-
sively, and can be applied on a large variety of ligands, organometallic moieties, fluo-
rescent markers and every kind of biomolecule bearing a carboxylic group and is thus 
very promising for the future. 
Another promising concept not mentioned in this Thesis is the use of Sonogashira cou-
pling for the introduction of alkynyl functionalized ligands into PNA. Fmoc-protected 
p-iodophenylalanine was successfully incorporated into a PNA sequence, and a terpyri-
dine alkyne was attempted to be coupled. This method provides another feasible method 
for the introduction of ligands. 
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The fact that PNA single strands alone show a sigmoidal absorbance melting curve due 
to base stacking (self-melting effect) was taken into consideration by the development 
of the coefficient fM, helping to distinguish between self-melting and duplex formation. 
These examinations were shown to be indispensable for the assessment of hybridization 
data and should be incorporated into every melting curve analysis. 
Theoretical calculations of the melting temperatures for the particular oligomers should 
provide additional information about the aspect of significance. Insights into thermody-
namics could be obtained by further data processing of the melting curves. 
 
The terpyridine ligand 3.5 will be coupled to DNA oligonucleotides in the future within 
a project in our institute. 
 
Furthermore, the examination of the cleavage abilities of the compounds in this Thesis 
will provide information about their usability as real artificial nucleases. 
 
 
 
8 Experimental Section / Materials & Methods 
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8.1 General Procedures 
8.1.1 Synthesis & Workup 
8.1.1.1 Chemicals 
All chemicals and solvents were purchased from Acros (Geel, Belgium), Al-
drich/Sigma/Fluka (Deisenhofen, Germany), Novabiochem (Laufelfingen, Switzerland), 
Roth (Karlsruhe, Germany) and IRIS Biotech (Marktredwitz, Germany) and used with-
out further purification. 
The preloaded polymer resins were purchased from Rapp Polymers (Tübingen, Ger-
many), the acid labile PNA monomers from Applied Biosystems (Darmstadt, Ger-
many), and the DNA oligonucleotides from IBA (Göttingen, Germany) in HPLC purity. 
All solutions were freshly prepared before use. 
 
8.1.1.2 HPLC Purification 
High Performance Liquid Chromatography (HPLC) purifications were performed on a 
Varian ProStar 210 System, equipped with column heater, PDA detector and auto sam-
pler, using Varian DynaStar C-18 reverse phase columns for analytical (250·8mm) and 
preparative (250·21mm) runs. Water (Millipore®) and MeCN (Baker, HPLC-grade) 
were used as eluents, each containing 0.1% TFA. All analytical samples were measured 
at a flowrate of 1ml/min using the standard gradient indicated in Chapter 8.6. For puri-
fications, the flowrate was 8ml/min. The samples were filtrated before injection using a 
0.22µm syringe filter. Spectra were recorded at 254nm and 25°C. 
 
8.1.1.3 Lyophilisation 
All HPLC fractions were frozen in liquid nitrogen and lyophilized before subsequent 
processing using an Edwards Modulyo freeze dryer. 
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8.1.2 Physical Measurements 
 
8.1.2.1 Elemental Analysis 
 
Elemental Analysis were performed on a Foss Heraeus Vario EL Elementar Analysator 
in C,H,N mode. 
 
8.1.2.2 Infrared Spectra 
 
Infrared spectra were recorded on a Brucker Equinox 55 FT-IR spectrometer between 
NaCl windows in distilled CHCl3, or as KBr discs, with a spectral resolution of 2.0cm-1. 
Wavenumbers, ν, are given in cm-1. 
 
8.1.2.3 NMR spectra 
 
NMR spectra were determined either on a Bruker AM 360 spectrometer, 1H operating at 
360.14MHz and 13C operating at 90.56MHz or on a Bruker AM 300 with frequencies of 
300.16MHz (1H) and 75.47MHz (13C). Peak positions in both 1H and 13C are reported in 
ppm relative to TMS, the internal standard. Spectra of peptides are referenced to the 
residual DMSO signal (2.50ppm in 1H, 39.52ppm in 13C). All other compounds are 
referenced to the residual CHCl3 signal (7.26ppm in 1H, 77.16ppm in 13C). Coupling 
constants, J, are given in Hz. Individual peaks are marked as: singlet (s), dublet (d), 
triplet (t) or multiplet (m). All chemical shifts are indicated in ppm. 
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8.1.2.4 Mass Spectrometry 
 
The MALDI-TOF spectra were recorded on a Bruker Biflex III spectrometer at the In-
stitute for Inorganic Chemistry (University of Heidelberg), using sinapinic acid as a 
matrix which was prepared by dissolving 6mg of sinapinic acid (from Bruker Daltonics, 
Leipzig, Germany) in 1ml of a mixture of MeCN and water (2:1) with 0.1% TFA added. 
The sample was dissolved in 0.1% TFA in water, and 1µl of probe solution was mixed 
with 2-3µl of matrix solution in a small Eppendorf tube. The ratio between these two 
components sometimes had to be adjusted in order to optimize the resulting spectrum. 
2µl of this mixture were placed onto the plate and subjected to the measurement. Most 
of the spectra were measured in positive linear mode, thus suppressing fragmentation. 
Depending on the requirements, reflector mode was used, as well. The number of shots 
and the attenuation were adjusted as the case arised. For an overview of the use of 
MALDI-TOF spectrometry for the analysis of PNA oligomers, see Ref.238. EI (70eV) 
and FAB (glycerol or NBA matrix) spectra were measured on a MAT8200 instrument. 
Characteristic mass fragments with probable composition are given in brackets. For 
fragments containing metals only the isotopomer with highest intensity was described. 
All ESI (neg./pos.) spectra were recorded on a Finnigan TSQ700 at 4.5kV. 
 
8.1.2.5 UV-Visible Spectrometry 
 
All spectra were recorded on a Varian Cary 100 Conc UV-Vis spectrophotometer using 
1cm quarz Suprasil cuvettes. Standard measurements were performed in dual beam 
mode with a cuvette filled with solvent serving as a blank sample. Before measuring, 
the instrument was zeroed without cuvettes, and after that, a baseline was recorded with 
both cuvettes filled with pure solvent. Data was saved in ASCII format and processed 
with ORIGIN.j Absorption maxima, λmax and molar absorption coefficients, ε, are given 
in nm and l·mol-1·cm-1, respectively. 
                                                 
 
 
j V7.0303 © OriginLab Corporation 1991-2002 
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General procedure for UV-Vis titration: 
In order to obtain absorbance curves in dependence of the Cu/L ratio, solutions were 
prepared allowing to titrate the reactants in a reasonable range of value. 
Preliminary tests suggested the following course of action (20°C): 
• Prepare a 10mM solution of the compound to be titrated 
• Provide 400µl (4µmol) of this solution in the measuring cuvette 
• Record a blank spectrum with pure analyte 
• Add a 50mM solution of titer subsequently in 5µl-steps 
• Let the mixture each time equilibrate for 3min 
• Record a UV-Vis spectrum 
• After 16 steps (80µl·50mM = 4µmol), equimolarity should be reached 
• Record spectra up to τ > 1.5 
• Plot Amax versus titrant/analyte ratio 
• Perform a linear fit on each line 
• Determine the intersection point 
All Amax values were determined after performing a polynomial fit (9th order; 1000 data 
points) on the curve and corrected according to 
corr
400 l n 5 lA A
400 l
µ + ⋅ µ= ⋅ µ  
in order to compensate the dilution effect by adding solvent during the titration. 
 
The molar extinction coefficient ε at each state of the titration could be calculated with 
the formula A A (400 l n 5 l)
c n 0.25 mol
⋅ µ + ⋅ µε = =⋅ ⋅ µA  [l·mol
-1·cm-1= 10-3 cm2·µmol-1] 
(with ℓ = 1cm and n = number of 50mM equivalents added, each one having a volume 
of 5µl and containing 0.25µmol of titrant). 
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8.1.2.6 Absorbance Melting Curves – General procedure 
 
All melting curves were recorded at 260nm on a Varian Cary 100 Conc UV-Vis spec-
trophotometer equipped with peltier thermostatted multicell holders in order to assure a 
high probe throughput and a reproducible temperature control (high stability over time 
and a variation of ±0.05°C). Nitrogen purging was indispensable in order to prevent the 
cuvettes from steaming up at low temperatures. 
Each melting curve was recorded at least four times in order to eliminate mavericks and 
to obtain weighted averages of melting points. 
 
All samples were dissolved in phosphate buffer prepared as follows: 
0.1M KH2PO4, 1.3609g per 100ml 
0.1M Na2HPO4·2H2O, 1.7799g per 100ml 
0.1M NaCl, 584.4mg per 100ml 
Before use, the buffer was filtered through a 0.22µm syringe filter in order to remove 
bacteriological and other contaminations. 
 
1) Determination of Extinction Coefficients at 260nm 
The ε-values were calculated from the increments according to: 
oligo x x
x
nε = ⋅ ε∑  (εoligo = nA·εA + nG·εG + nC·εC + nT·εT etc.) 
Incremental extinction coefficients for the PNA and DNA monomers were obtained 
from literature:149, 280 
cm2·µmol-1 εA εG εC εT 
DNA 15.3 12.2 7.6 8.7 
PNA 13.7 11.7 6.6 8.6 
In order to include the aromatic chromophores of the ligands and of phenylalanine into 
the calculations, the absorbance of known concentrations of the free building blocks 
was measured, and ε was calculated according to Lambert-Beer’s law (A = ε·c·ℓ). 
cm2·µmol-1 εPhe εtpy εbpa 
PNA 0.2 17.9 9.4 
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2) Determination of Concentration 
PNA stock solutions were prepared by dissolving the lyophilisate of the pure HPLC 
fraction in buffer. DNA stock solutions were used as received from IBA. 
The DNA and PNA stock concentrations were determined according to the following 
protocol which allows measuring a whole UV-Vis spectrum from 190-900nm and a 
number of absorbance values at 260nm at a time without preparing new sample solu-
tions: 
• Zero the instrument in the “Scan” mode without samples, adjust temperature 
• Put 950µl of buffer in each of the two cuvettes and place them in slots 1 & 7 
• Let buffer reach temperature for at least 5min. (DNA: 25°C – PNA: 70°C) 
• Record a baseline in “Scan” mode 
• Zero the instrument in “Simple Reads” mode (260nm) 
• Add 50µl of DNA or PNA stock solution into the cuvette in slot 1 
• Let mixture reach temperature at least for 5 min. (!) 
• Perform 20 scans in „Simple Reads“ mode and determine the average (Excel) 
• Perform a scan in “Scan” mode with baseline being activated 
Be sure that A260(verd) will be between 0.3 & 1.5 (best signal-to-noise ratio) 
Calculate the stock concentration according to 260(verd)
A
c 20= ⋅ ε  [mM]. 
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3) Probe Composition 
All melting experiments were carried out with 3µM solutions. 
Based on the known stock concentrations, the required volumes were calculated follow-
ing 3V
c
=  [µl], and the respective amounts of each stock solution were mixed in the 
cuvette already containing the amount of buffer required for topping up to 1ml (and 
used before for multizeroing – see below). 
 
4) General Procedure for Melting Curves: 
Using the multicell holder of the Cary 100 Conc allows to measure 12 curves (3 differ-
ent experiments, 4 times each). Proceed as follows: 
• Multizero the instrument with all four cuvettes filled with buffer (20°C) 
• Add the calculated amounts of DNA & PNA stock solutions 
• Seal the cuvettes with a Teflon plug in order to avoid the use of silicon oil 
• Heat the cuvettes in a water bath to 70°C for 3min (this will completely dehy-
bridize the strands and saturate the space above the solution with solvent) 
• Supersonicate and cool down to ambient temperature 
• Record A260, starting at 20°C along the following profile: 
    
Data Rate End Hold 
0.5 1 5 15 
0.5 0.5 80 5 
2 5 20 0 
     
• Ensure nitrogen purging below room temperature – steamy cuvettes will make 
the result useless 
Data was collected as indicated, the files were saved in ASCII format and processed 
with ORIGIN.k In all cases, the cooling, holding and re-annealing data was discarded. 
For interpretational details, see Chapter 6.2. 
                                                 
 
 
k V7.0303 © OriginLab Corporation 1991-2002 
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8.2 Synthesis of Ligands and Peptide Conjugates Thereof 
 
Synthesis of 6-[4’-oxa-(2,2’:6’,2’’-terpyridinyl)]hexanoic acid 3.5 
 
N
O
OH
O
N N
N
Cl
N N
O
O
DMSO
KOH
H2O
C15H10ClN3
Exact Mass: 267,06
Mol. Wt.: 267,71
C21H21N3O3
Exact Mass: 363,16
Mol. Wt.: 363,41
C6H10O2
Exact Mass: 114,07
Mol. Wt.: 114,14
3.5
 
 
ε-Caprolactone (0.48g 99%, 4.2mmol) and powdered KOH (1.50g, 27mmol) were sus-
pended in DMSO (25ml). After heating the slurry to 60°C, 4’-chloro-2,2’:6’,2’’-
terpyridine (1.13g 99%, 4.2mmol) and H2O (75µl, 4.2mmol) were added. The mixture 
clouded and the KOH-particles turned red (caused by iron contamination). Refluxing at 
60°C resulted in a red and clear solution, which clouded again after some days. After 
7-10d of refluxing, the suspension was allowed to cool to RT and poured into 300ml of 
H2O giving a light yellow and clear solution. The product was precipitated by adjusting 
the pH to 7 with 10% HCl. After 30min of stirring, the white solid was collected by 
filtration, washed with water (2x80ml) and dried in vacuo. 
Yield: 1.186g (3.26mmol, 78%) 
 
The synthesis of the tpy-derivatives with shorter chain lengths was carried out similar to 
this procedure. 
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Fig. 8.1: Overview of tpy-Carboxylic Acids with various Chain Lengths 
 Lactone Mlactone Mproduct Yield 
3.2 Glycolic acid 76.04 307.30 50% 
3.3 γ-Butyrolactone 86.09 335.35 57% 
3.4 δ-Valerolactone 100.12 349.39 69% 
3.5 ε-Caprolactone 114.14 363.41 78% 
 
 
4’-Chloro-2,2’:6’,2’’-terpyridine 
1H-NMR (360MHz, DMSO-d6): δ = 8.74 (2H, d, H6tpy, H6’’tpy), 8.62 (2H, d, H3tpy, 
H3’’tpy), 8.42 (2H, s, H3’tpy, H5’tpy), 8.03 (2H, m, H4tpy, H4’’tpy), 7.55 (2H, m, H5tpy, H5’’tpy). 
13C-NMR (90.56MHz, DMSO-d6): δ = 156.64 (s, C2’tpy, C6’tpy), 153.62 (s, C2tpy, C2’’tpy), 
149.47 (d, C6tpy, C6’’tpy), 145.28 (d, C4’tpy), 137.64 (d, C4tpy, C4’’tpy), 125.08 (d, C3tpy, 
C3’’tpy), 121.13 (d, C5tpy, C5’’tpy), 120.17 (d, C3’tpy, C5’tpy). 
 
4’-Hydroxy-2,2’:6’,2’’-terpyridine 3.1 
1H-NMR (360MHz, DMSO-d6): δ = 8.72 (2H, d, H6tpy, H6’’tpy), 8.59 (2H, d, H3tpy, 
H3’’tpy), 8.02 (2H, m, H4tpy, H4’’tpy), 7.88 (2H, s, H3’tpy, H5’tpy), 7.51 (2H, m, H5tpy, H5’’tpy). 
13C-NMR (90.56MHz, DMSO-d6): δ = 166.59 (d, C4’tpy), 155.61 (s, C2’tpy, C6’tpy), 
154.36 (s, C2tpy, C2’’tpy), 148.97 (d, C6tpy, C6’’tpy), 137.68 (d, C4tpy, C4’’tpy), 124.52 (d, 
C3tpy, C3’’tpy), 120.98 (d, C5tpy, C5’’tpy), 108.51 (d, C3’tpy, C5’tpy). MS (EI, 70eV, 275°C): 
m/z (%) = 249 (100) [M+], 221 (88), 193 (4), 167 (8.4). 
 
2-[4’-Oxa-(2,2’:6’,2’’-terpyridinyl)]acetic acid 3.2 
1H-NMR (360MHz, DMSO-d6): δ = 8.72 (2H, d, H6tpy, H6’’tpy), 8.59 (2H, d, H3tpy, 
H3’’tpy), 8.02 (2H, m, H4tpy, H4’’tpy), 7.95 (2H, s, H3’tpy, H5’tpy), 7.50 (2H, m, H5tpy, H5’’tpy), 
2.08 (2H, s, H2alk). 13C-NMR (90.56MHz, DMSO-d6): δ = 174.32 (s, C1alk), 166.59 (d, 
C4’tpy), 156.62 (s, C2’tpy, C6’tpy), 154.88 (s, C2tpy, C2’’tpy), 149.27 (d, C6tpy, C6’’tpy), 137.32 
(d, C4tpy, C4’’tpy), 124.44 (d, C3tpy, C3’’tpy), 120.82 (d, C5tpy, C5’’tpy), 106.74 (d, C3’tpy, 
C5’tpy), 67.66 (t, C2alk). 
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4-[4’-Oxa-(2,2’:6’,2’’-terpyridinyl)]butanoic acid 3.3 
1H-NMR (360MHz, DMSO-d6): δ = 8.73 (2H, d, H6tpy, H6’’tpy), 8.58 (2H, d, H3tpy, 
H3’’tpy), 7.99 (2H, m, H4tpy, H4’’tpy), 7.94 (2H, s, H3’tpy, H5’tpy), 7.49 (2H, m, H5tpy, H5’’tpy), 
4.27 (2H, t, J=6.3, H4alk), 2.27 (2H, t, J=7.2, H2alk), 1.66 (2H, pseudo-quint, J=6.8, H3alk). 
13C-NMR (90.56MHz, DMSO-d6): δ = 174.05 (s, C1alk), 166.63 (d, C4’tpy), 156.60 (s, 
C2’tpy, C6’tpy), 154.80 (s, C2tpy, C2’’tpy), 149.13 (d, C6tpy, C6’’tpy), 137.34 (d, C4tpy, C4’’tpy), 
124.34 (d, C3tpy, C3’’tpy), 120.78 (d, C5tpy, C5’’tpy), 106.76 (d, C3’tpy, C5’tpy), 67.21 (t, 
C4alk), 30.08 (t, C2alk), 24.04 (t, C3alk). MS (EI, 70eV, 275°C): m/z (%) = 335 [M+] (3.9), 
291 (68), 276 (55), 261 (84), 249 (98), 233 (50), 221 (100), 193 (22)  
 
5-[4’-Oxa-(2,2’:6’,2’’-terpyridinyl)]pentanoic acid 3.4 
1H-NMR (360MHz, DMSO-d6): δ = 8.71 (2H, d, H6tpy, H6’’tpy), 8.60 (2H, d, H3tpy, 
H3’’tpy), 8.02 (2H, m, H4tpy, H4’’tpy), 7.96 (2H, s, H3’tpy, H5’tpy), 7.49 (2H, m, H5tpy, H5’’tpy), 
4.25 (2H, t, J=6.3, H5alk), 2.32 (2H, t, J=6.4, H2alk), 1.81 (2H, pseudo-quint, J=7.1, H3alk), 
1.70 (2H, pseudo-quint, J=6.8, H4alk). 13C-NMR (90.56MHz, DMSO-d6): δ = 174.28 (s, 
C1alk), 166.62 (d, C4’tpy), 156.58 (s, C2’tpy, C6’tpy), 154.78 (s, C2tpy, C2’’tpy), 149.14 (d, 
C6tpy, C6’’tpy), 137.27 (d, C4tpy, C4’’tpy), 124.40 (d, C3tpy, C3’’tpy), 120.78 (d, C5tpy, C5’’tpy), 
106.66 (d, C3’tpy, C5’tpy), 33.22 (t, C2alk), 27.80 (t, C4alk), 21.01 (t, C3alk). MS (EI, 70eV, 
275°C): m/z (%) = 348 [M+] (0.9), 332 (0.7), 305 (30), 276 (19), 262 (41), 249 (78), 233 
(14), 221 (100), 193 (4), 155 (1.7), 117 (7.2), 78 (14). 
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6-[4’-Oxa-(2,2’:6’,2’’-terpyridinyl)]hexanoic acid 3.5 
1H-NMR (360MHz, DMSO-d6): δ = 8.71 (2H, d, H6tpy, H6’’tpy), 8.60 (2H, d, H3tpy, 
H3’’tpy), 7.99 (2H, m, H4tpy, H4’’tpy), 7.95 (2H, s, H3’tpy, H5’tpy), 7.49 (2H, m, H5tpy, H5’’tpy), 
4.22 (2H, t, J=6.3, H6alk), 2.26 (2H, t, J=7.2, H2alk), 1.80 (2H, pseudo-quint, J=6.8, H5alk), 
1.60 (2H, pseudo-quint, J=7.1, H3alk), 1.48 (2H, pseudo-quint, J=6.9, H4alk). 
13C-NMR (90.56MHz, DMSO-d6): δ = 174.46 (s, C1alk), 166.73 (d, C4’tpy), 156.66 (s, 
C2’tpy, C6’tpy), 154.87 (s, C2tpy, C2’’tpy), 149.24 (d, C6tpy, C6’’tpy), 137.36 (d, C4tpy, C4’’tpy), 
124.49 (d, C3tpy, C3’’tpy), 120.88 (d, C5tpy, C5’’tpy), 106.72 (d, C3’tpy, C5’tpy), 67.85 (t, 
C6alk), 33.62 (t, C2alk), 28.14 (t, C5alk), 25.01 (t, C4alk), 24.22 (t, C3alk). MS (EI, 70eV, 
275°C): m/z (%) = 362 [M+] (7.9), 319 (79), 304 (27.4), 290 (37), 276 (79), 262 (100), 
249 (89), 233 (71.4), 221 (97.3), 193 (11.5). MS (ESI-pos, MeOH): m/z = 364.3 
[M+H]+. MS (ESI-neg, MeOH): m/z = 361.98 [M–H]-, 247.91 [M–C5H10COOH]-  
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1H-NMR (360MHz, DMSO-d6) 
δ (ppm) tpy-Cl 3.1 3.2 3.3 3.4 3.5 
H2alk – – 2.08 2.27 2.32 2.26 
H3alk – – – 1.66 1.81 1.60 
H4alk – – – 4.27 1.70 1.48 
H5alk – – – – 4.25 1.80 
H6alk – – – – – 4.22 
H5tpy, H5’’tpy 7.55 7.51 7.50 7.49 7.49 7.49 
H3’tpy, H5’tpy 8.42 7.88 7.95 7.94 7.96 7.95 
H4tpy, H4’’tpy 8.03 8.02 8.02 7.99 8.02 7.99 
H3tpy, H3’’tpy 8.62 8.59 8.59 8.58 8.60 8.60 
H6tpy, H6’’tpy 8.74 8.72 8.72 8.73 8.71 8.71 
 
13C-NMR (90.56MHz, DMSO-d6) 
δ (ppm) tpy-Cl 3.1 3.2 3.3 3.4 3.5 
C2alk – – 67.66 30.08 33.22 33.62 
C3alk – – – 24.04 21.01 24.22 
C4alk – – – 67.21 27.80 25.01 
C5alk – – – – 67.61 28.14 
C6alk – – – – – 67.85 
C3’tpy, C5’tpy 120.17 108.51 106.74 106.76 106.66 106.72 
C5tpy, C5’’tpy 121.13 120.98 120.82 120.78 120.78 120.88 
C3tpy, C3’’tpy 125.08 124.52 124.44 124.34 124.40 124.49 
C4tpy, C4’’tpy 137.64 137.68 137.32 137.34 137.27 137.36 
C6tpy, C6’’tpy 149.47 148.97 149.27 149.13 149.14 149.24 
C2tpy, C2’’tpy 153.62 154.36 154.88 154.80 154.78 154.87 
C2’tpy, C6’tpy 156.64 155.61 156.62 156.60 156.58 156.66 
C4’tpy 145.28 166.59 166.59 166.63 166.62 166.73 
C1alk – – 174.32 174.05 174.28 174.46 
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Synthesis of N-(p-carboxybenzyl)bis(2-picolyl)amine 3.6 
 
N
N
N
O
OH
NH
N
N
O
O
Br+
3.6
C12H13N3
Exact Mass: 199,11
Mol. Wt.: 199,25
C9H9BrO2
Exact Mass: 227,98
Mol. Wt.: 229,07
C20H19N3O2
Exact Mass: 333,15
Mol. Wt.: 333,38  
 
Methyl ester 
NEt3 (0.69ml, 5.00mmol) was added to a solution of bis(2-picolyl)amine (1.0g, 
5.0mmol) and methyl p-(bromomethyl)benzoate (1.15g, 5.00mmol) in THF (35ml), and 
the mixture was refluxed for 1.5h. The mixture was allowed to reach RT and subse-
quently filtered to remove a white precipitate. After removal of the solvent under re-
duced pressure, the oily residue was redissolved in Et2O (40ml) and filtered to remove a 
red solid. Evaporation of the solvent yielded 1.4g (81%) of a light orange oil, which was 
used as such in the next step. M = 347.4 (C21H21N3O2). 
 
1H-NMR (250.1MHz, CDCl3): δ = 8.49 (app. d, 2H, Hpyr), 7.95 (d, 3JH,H=8.3Hz, 2H, 
HAr), 7.62 (pseudo t, 2H, Hpyr), 7.52 (pseudo d, 2H, Hpyr), 7.46 (d, 3J=8.3Hz, 2H, HAr), 
7.12 (pseudo t, 2H, Hpyr), 3.87 (s, 3H, OCH3), 3.78 (s, 4H, CH2,picolyl), 3.71 (s, 2H, CH2). 
13C-NMR (CDCl3, 100.6MHz): δ = 166.9 (C-O), 159.3 (Cqpyr), 148.9 (CPyr), 144.5 
(CAr,q), 136.3 (CPyr), 129.5 (CAr), 128.9 (CAr,q), 128.6 (CAr), 122.7 (CPyr), 122.0 (CPyr), 
60.0 (CH2, picolyl), 58.1 (CH2), 51.9 (OCH3). MS (EI, 70eV, 170°C): m/z (%) = 347 (2) 
[M+], 316 (2) [M-OCH3]+, 255 (100) [M-C6H6N]+.  
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Saponification 
1.4g (4.0mmol) of the product obtained from step 1 was dissolved in MeOH (20ml), a 
solution of NaOH (0.8g, 20mmol) in 5ml of H2O was added, and the mixture was 
stirred for 2h at ambient temperature. The pH was adjusted to 7 by dropwise addition of 
2M HCl, followed by removal of the solvent under reduced pressure. The sticky white 
residue was triturated with CHCl3 (200ml), followed by filtration to remove NaCl. The 
CHCl3 solution was dried with MgSO4. Removal of the solvent under reduced pressure 
afforded a yellow sticky oil, to which CH3CN (30ml) was added, followed by vigorous 
stirring. After approximately 15-30 min, a white precipitate formed. The solution was 
stored at 0°C for 2h, to effect further precipitation and the white solid was then isolated 
by filtration and dried in vacuo. Yield: 0.7g (53%).  
 
1H-NMR (250.1MHz, CDCl3): δ = 11.35 (br, 1H, CO2H), 8.59 (app. d, 2H, HPyr), 8.01 
(d, 3JH,H=8.0Hz, 2H, HAr), 7.66 (pseudo t, 2H, HPyr), 7.59 (app. d, 2H, HPyr), 7.44 (d, 
3JH,H=7.7Hz, 2H, HAr), 7.80 (pseudo t, 2H, HPyr), 3.85 (s, 4H, CH2), 3.73 (s, 2H, CH2,Bz). 
13C-NMR (62.9MHz, CDCl3): δ = 169.3 (C-O), 159.8, 148.4, 143.1, 137.2, 130.0, 
128.8, 123.4, 122.4, 122.0 (all CAr), 59.3 (CH2), 58.2 (CH2,Bz). MS (EI, 70eV, 175°C): 
m/z (%) = 333 (1) [M]+, 241 (100) [M-C6H6N]+. 
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Synthesis of 5-nitro-1,10-phenanthroline 3.7 
 
N N N N
NO2
C12H8N2
Exact Mass: 180,07
Mol. Wt.: 180,21
C12H7N3O2
Exact Mass: 225,05
Mol. Wt.: 225,2
3.7
 
 
In a 500ml three-necked flask equipped with thermometer, 100ml dropping funnel and 
reflux condenser, 1,10-Phenanthroline (25.45g 99%, 139mmol) was slowly dissolved in 
conc. H2SO4 (180ml) at 0°C resulting in a brown, clear solution which was allowed to 
reach RT. 90ml of conc. HNO3 was added quickly, but carefully over a dropping funnel 
in a way letting the solution reach, but not exceed 95°C. The resulting mixture was 
stirred for another 30min, changing its colour to light yellow. It was heated to 115°C by 
a heating mantle for 1h to complete the reaction and get rid of nitric gases. After cooling 
down to RT, the solution was carefully poured over 2kg of crushed ice under continuous 
stirring. The resulting yellow suspension was brought to pH 7 with 320g of NaOH dis-
solved in 1.8L of water, changing its colour from yellow to orange. The precipitate was 
sucked off, washed with water and dried in vacuo for 24h. Yield: 23.3g (103mmol, 
74%); Melting point: 202-204°C. 
 
1,10-Phenanthroline 
1H-NMR (360MHz, DMSO-d6): δ = 9.09 (2H, dd, J=1.71, 4.26, H2, H9), 8.44 (2H, dd, 
J=1.71, 8.07, H4, H7), 7.92 (2H, s, H5, H6), 7.73 (2H, pseudo-q, J=4.29, H3, H8). 
13C-NMR (90.56MHz, DMSO-d6): δ = 123.23 (C3, C8), 136.15 (C4, C7), 128.37 (C4a, 
C6a), 126.58 (C5, C6), 145.39 (C10a, C10b), 149.84 (C2, C9). MS (EI, 70eV, 275°C): 180 
[M+] (100), 154 (17.9), 127 (9.1). 
 
5-Nitro-1,10-phenanthroline 3.7 
1H-NMR (360MHz, DMSO-d6): δ = 9.28 (1H, dd, J=1.39, 4.15, H9), 9.24 (1H, dd, 
J=1.07, 4.01, H2), 9.04 (1H, s, H6), 8.89 (1H, dd, J=1.10, 8.54, H7), 8.78 (1H, dd, 
J=1.30, 8.08, H4), 7.95 (2H, m, H3, H8). 13C-NMR (90.56MHz, DMSO-d6): δ = 153.38 
(C9), 151.19 (C2), 146.79 (C10a), 145.43 (C5), 143.85 (C10b), 138.12 (C7), 132.12 (C4), 
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126.00 (C6), 125.56 (C6a), 124.58 (C3), 124.50 (C8), 120.37 (C4a). MS (EI, 70eV, 
275°C): m/z (%) = 225 [M+] (74.6), 196 (1.1), 179 (100), 167 (25.1), 152 (37.4), 125 
(28.3), 99 (12.8), 75 (20.8), 63 (2.8), 51 (17.1), 28 (15.8). 
 
Synthesis of 5-amino-1,10-phenanthroline 3.8 
 
N N
NO2
N N
NH2
C12H7N3O2
Exact Mass: 225,05
Mol. Wt.: 225,2
C12H9N3
Exact Mass: 195,08
Mol. Wt.: 195,22
3.7 3.8
 
 
In a 500ml three-necked round-bottomed flask equipped with a gas inlet tube and a 
bubble counter, 5-nitro-1,10-phenanthroline (9.52g, 42.27mmol) was dissolved in 
210ml EtOH giving a yellow solution. 25% NH3 (30ml) was added, and under stirring, 
H2S was passed into the solution which became cloudy and warm and changed its col-
our to a brownish green. After saturation of the solution being complete, stirring was 
continued for 3d, saturating the solution with H2S from time to time. 100ml EtOH and 
20ml NH3 were added, and the procedure was continued for another 4d. The clear and 
brown mixture was heated to 60°C on an oil bath, and the excess of gases and the sol-
vents were removed with a water jet pump, followed by coevaporation with EtOH 
(2x200ml). The orange-coloured residue was suspended in 2% HCl (360ml), and the red 
solution was separated from the yellow solid. The filtrate was brought to pH8 with 25% 
NH3, the yellow product was sucked off, dried in vacuo and recrystallized from isopro-
panol. Yield: 3.19g (16.2mmol, 39%) 
 
1H-NMR (360MHz, DMSO-d6): δ = 9.04 (1H, d, H2), 8.68 (1H, d, H9), 8.62 (1H, d, H4), 
8.02 (1H, d, H7), 7.72 (1H, dd, H3), 7.50 (1H, dd, H8), 6.86 (1H, s, H6), 6.13 (2H, s, 
NH2). 13C-NMR (90.56MHz, DMSO-d6): δ = 149.33 (C2), 146.17 (C5), 144.81 (C9), 
142.65 (C10a), 140.50 (C10b), 132.69 (C4), 130.79 (C7), 130.55 (C6a), 123.19 (C3), 122.06 
(C8), 121.80 (C4a), 101.75 (C6). MS (EI, 70eV, 275°C): m/z (%) = 195 [M+] (100), 168 
(14.9), 140 (6.8), 114 (2.3). 
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1H-NMR (360MHz, DMSO-d6) 
δ (ppm) phen 3.7 3.8 
H2 9.09 9.24 9.04 
H3 7.73 7.95 7.72 
H4 8.44 8.78 8.62 
H5 7.92 – – 
H6 7.92 9.04 6.86 
H7 8.44 8.89 8.02 
H8 7.73 7.95 7.50 
H9 9.09 9.28 8.68 
NH2 – – 6.13 
 
13C-NMR (90.56MHz, DMSO-d6) 
δ (ppm) phen 3.7 3.8 
C2 149.84 151.19 149.33 
C3 123.23 124.58 123.19 
C4 136.15 132.12 132.69 
C4a 128.37 120.37 121.80 
C5 126.58 145.43 146.17 
C6 126.58 126.00 101.75 
C6a 128.37 125.56 130.55 
C7 136.15 138.12 130.79 
C8 123.23 124.50 122.06 
C9 149.84 153.38 144.81 
C10a 145.39 146.79 142.65 
C10b 145.39 143.85 140.50 
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Synthesis of tpy*-Phe-OMe 3.9 
N
O
OH
O
N N
N
O
H
N
O
N N
O
O
3.5 3.9
C21H21N3O3
Exact Mass: 363,16
Mol. Wt.: 363,41
C31H32N4O4
Exact Mass: 524,24
Mol. Wt.: 524,61  
 
Phenylalanine methyl ester hydrochloride (108mg, 0.5mmol) was dissolved in DMF 
(15ml), and ligand 3.5 (186mg, 0.5mmol) was added, resulting in a clear, light yellow 
solution. EDC·HCl (100mg, 0.55mmol) was added, and the solution was stirred at RT 
overnight. The solvent was removed in vacuo to leave a pink oil which was coevapo-
rated with MeOH (3x). H2O (10ml) was added, followed by stirring overnight at RT. 
The slurry was filtrated, whereupon a pink filtrate and a white precipitate were sepa-
rated. Yield: 205mg (78%) 
 
1H-NMR (360MHz, DMSO-d6): δ = 8.72 (2H, d, H6tpy, H6’’tpy), 8.62 (2H, d, H3tpy, 
H3’’tpy), 8.30 (1H, d, NH), 7.96-8.02 (4H, m, H4tpy, H4’’tpy, H3’tpy, H5’tpy), 7.50 (2H, m, 
H5tpy, H5’’tpy), 7.20-7.28 (7H, m, HPhe-o, HPhe-m, HPhe-p), 4.46-4.52 (1H, m, HPhe-α), 4.24 
(2H, m, H6alk), 3.60 (3H, s, HOMe), 3.19-3.03 (2H, m, HPhe-β). 2.28 (t, 2H, H2alk), 1.81 
(2H, pseudo-quint, J=6.8, H5alk), 1.74 (2H, pseudo-quint, J=7.1, H3alk), 1.50 (2H, 
pseudo-quint, J=6.9, H4alk). 13C-NMR (90.56MHz, DMSO-d6): δ = 174.35 (s, C1alk), 
172.10 (COPhe), 166.65 (d, C4’tpy), 156.58 (s, C2’tpy, C6’tpy), 154.78 (s, C2tpy, C2’’tpy), 
149.15 (d, C6tpy, C6’’tpy), 137.28 (d, C4tpy, C4’’tpy), 128.94 (CPhe-o), 128.08 (CPhe-m), 126.35 
(CPhe-p), 124.41 (d, C3tpy, C3’’tpy), 120.79 (d, C5tpy, C5’’tpy), 106.63 (d, C3’tpy, C5’tpy), 67.77 
(t, C6alk), 53.25 (CPhe-α), 51.70 (COMe), 36.57 (CPhe-β). 33.52 (t, C2alk), 28.05 (t, C5alk), 
24.91 (t, C4alk), 24.27 (t, C3alk). MS (EI, 70eV, 265°C): m/z (%) = 525 (32) [M]+, 494 (2) 
[M-OMe]+, 466 (38) [M-COOMe]+, 434 (25) [M-Bzl]+, 391 (5), 347 (3), 319 (16) 
[tpyOC5H10]+305 (9) [tpyOC4H8]+291 (6) [tpyOC3H6]+277 (16) [tpyOC2H4]+263 (53) 
[tpyOCH2]+, [M-tpyOCH2]+251 (100) [tpyO]+ 248 (5) [M-tpyOC2H4]+235 (7) [M-
tpyOC3H6]+ 221 (24) [M-tpyOC4H8]+. 
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Synthesis of bpa*-Phe-OMe 3.10 
 
O
OH
O
O
3.6 3.10 O
H
N
N
N
N
N
N
N
C20H19N3O2
Exact Mass: 333,15
Mol. Wt.: 333,38
C30H30N4O3
Exact Mass: 494,23
Mol. Wt.: 494,58  
 
Acid 3.6 (333mg, 1.00mmol) was suspended in acetonitrile (10ml), and phenylalanine 
methyl ester hydrochloride (216mg, 1.00mmol), TBTU (323mg, 1.00mmol) and DIPEA 
(1.20ml, 7.20mmol) were added. The yellow reaction mixture was stirred for 1h at room 
temperature and thereafter the solvent was evaporated in vacuo. To the residue di-
chloromethane (75ml) was added and washed with saturated NaHCO3 solution (75ml) 
and water (2×75ml). After drying the organic phase over Na2SO4 and filtration, the sol-
vent was removed in vacuo and the crude product purified by column chromatography 
on silica (35g, ∅=2.5 cm, ethyl acetate:acetonitrile = 9:1), Rf(3.10)=0.12. Yield: 400mg 
(80.9mmol, 80.9%) of colorless oil. 
 
1H-NMR (360MHz, DMSO-d6): δ = 8.82 (1H, d, NH, J=7.7), 8.50-8.47 (2H, m, H6Py), 
7.87-7.69 (4H, m, H3Bzl, H4Py), 7.57 (2H, d, J=7.6, H3Py), 7.49 (2H, d, J=7.9, H2Bzl), 
7.31-7.22 (7H, m, HPhe-o, HPhe-m, HPhe-p, H5Py), 4.68-4.60 (1H, m, HPhe-α), 3.70 (4H, s, 
HPy-α), 3.67 (2H, s, H1), 3.62 (3H, s, HOMe), 3.19-3.03 (2H, m, HPhe-β). 13C-NMR 
(90.56MHz, DMSO-d6): δ = 172.2 (C=OPhe), 166.4 (C=OBzl), 158.9 (C2Py), 148.9 (C6Py), 
142.6 (C1Bzl), 137.7 (CPhe-i), 136.7 (C4Py), 132.5 (C4Bzl) 129.1 (C2Bzl), 128.4 (C3Bzl), 
128.3 (CPhe-o), 127.4 (CPhe-m), 126.5 (CPhe-p), 122.6 (C3Py), 122.2 (C5Py), 59.1 (CPy-α), 
57.1 (C1), 54.3 (CPhe-α), 52.0 (COMe), 36.2 (CPhe-β). HRMS (EI, 70eV): 494.2317. MS 
(EI, 70eV, 265°C): m/z (%) = 494 (6) [M]+, 463 [M-OMe]+, 402 (100) [M-Bzl]+, 198 
(31) [bpa]+, 134 (5) [PyCH2N(CH2)2]+, 121 (1) [PyCH2NHCH2]+, 107 (1) [PyCH2NH]+, 
93 (64) [PyCH2]+, 78 (2) [Py]+. 
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Synthesis of Pseudoneurotensin-Conjugates 
 
The assembly of the pnt conjugates 3.11-3.13 was performed according to the standard 
SPPS procedure described in Chapter 8.6 including the modified ligand coupling proto-
col explained in that context. A preloaded Fmoc-Leu-Wang resin (0.68mmol/g) was 
used instead of the resin mentioned there. 
A 1H-NMR spectrum was obtained of the hexanoic acid capped pnt derivative 3.11. The 
assignment of the proton signals was done with the help of HH-COSY. 
 
H
N
O
OH
H
N
O
N
H
H
N
O
N
O
N
H O O O
OH
NH2
NH2
C44H74N8O9
Exact Mass: 858,56
Mol. Wt.: 859,11
1
2
3
4
5
6
7
3.11
8
9
10 11
12
13 14
15 16
17 18
19
20
2122
23
24
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27
28 29
31
32
3334
35
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30 42
 
 
1H-NMR (360MHz, DMSO-d6): δ = 8.18 (1H, d, NH24Tyr), 8.00 (1H, d, NH6Lys), 7.92 
(1H, d, NH30Ile), 7.83 (1H, d, NH13Lys), 7.76 (4H, br, NH212Lys, NH219Lys), 7.72 (NH36Leu), 
6.97 (2H, d, CH27Tyr), 6.60 (2H, d, H28Tyr), 4.38-4.42 (2H, br, CH7Lys, CH14Lys), 4.31 
(1H, d, CH31Ile), 4.18-4.23 (4H, br, CH25Tyr, CH37Leu), 2.52 (2H, m, CH223Pro), 2.87 (1H, 
t, CH20Pro), 2.65-2.78 (6H, br, CH211Lys, CH218Lys, CH226Tyr), 2.09 (2H, t, CH25Hex), 1.94 
(1H, m, CH39Leu), 1.78 (4H, br, CH221Pro, CH222Pro), 1.42-1.18 (15H, br. m, (CH238Leu, 
CH234Ile, CH28Lys, CH29Lys CH210Lys, CH215Lys, CH216Lys, CH217Lys), 1.15-1.40 (6H, br. m, 
CH22Hex, CH23Hex, CH24Hex,), 1.05 (1H, m, CH32Ile), 0.76-0.90 (15H, m, CH31Hex, 
CH333Ile, CH335Ile, CH340Leu, CH341Leu). MS (ESI-pos): m/z = 859.8, 430.5. 
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8.3 Synthesis of Copper Complexes 
 
For the in situ preparation of Cu complexes, equimolar amounts of ligand / bioconjugate 
and copper solution were mixed to obtain a 10mM dilution which was subjected to MS. 
This procedure was performed for all tpy-substituted compounds and for bpa*-pnt (see 
Chapter 3.5.1 for MS data). The short-chain bpa*-conjugate complexes were isolated 
according to the following. 
 
Synthesis of (bpa*-OMe)Cu(NO3)2 
 
Solutions of bpa*-OMe (86.8mg, 0.25mmol) and Cu(NO3)2·3H2O (60.4mg, 0.25mmol) 
in methanol (10ml each) were mixed at 50°C and cooled down slowly. After 2 days, the 
product was collected by filtration. Yield 73.0mg (0.14mmol, 55%) of blue crystals. 
Mr (C21H21N5O8Cu) = 534.99. MS (ESI-pos): m/z 472 [M-NO3]+, 455 [M-Py]+, 441 [M-
PyCH2]+, 427 [M-PyCH2-Me]+, 410 [M-2NO3]+, 346 [M–Cu(NO3)2]+, 317 [M-2NO3-
PyCH2]+, 260 [Cu-bpa]+. MS (FAB-pos, glycerol): m/z 472 [M-NO3]+, 410 [M-2NO3]+, 
346 [M-Cu(NO3)2]+, 317 [M-2NO3-PyCH2]+, 260 [Cu-bpa]+. HRMS (FAB-pos, glyc-
erol, PEG300): m/z exp 472.0819 and calc. 472.0808 for [C21H21N4O563Cu]+, exp. 
410.0915 and calc. 410.0930 for [C21H21N3O263Cu]+. 
 
Synthesis of (bpa*-OH)CuNO3 3.6Cu 
 
Solutions of ligand 3.6 (83.4mg, 0.25 mmol) and Cu(NO3)2·3H2O (60.4mg, 0.25mmol) 
in methanol (10ml each) were mixed at 50°C and cooled down slowly. After standing 
overnight, product 3.6Cu was collected by filtration. Yield 89mg (0.17mmol, 68%) of 
blue crystals. 
Mr (C20H18N4O5Cu) = 457.93. MS (ESI-pos): m/z 396 [M-NO3]+. MS (FAB-pos, glyc-
erol): m/z 458 [M]+, 396 [M-NO3]+, 352 [M-NO3-CO2]+, 303 [M-NO3-PyCH2]+ 260 
[Cu–bpa]+. HRMS (FAB-pos, glycerol, PEG300): m/z exp. 458.0585 and calc. 
458.0651 for [C20H19N4O563Cu]+, exp. 396.0780 and calc. 396.0773 for 
[C20H19N3O263Cu]+. 
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Synthesis of (bpa*-Phe-OMe)Cu(NO3)2 3.10Cu  
 
Solutions of 3.10 (49.5mg, 0.10mmol) and Cu(NO3)2·3H2O (24.2mg, 0.10mmol) in 
ethanol (5ml each) were mixed at 50°C and cooled down slowly. After 4 days, product 
3.10Cu was collected by filtration. Yield: 23mg (34µmol, 34%) of blue powder. 
Mr (C30H30N6O9Cu) = 682.17. MS (ESI-pos): 619 [M-NO3]+, 602 [M-Py]+, 588 [M-
NO3-OMe]+, 557 [M-2NO3]+, 496 [M - Cu(NO3)2]+. MS (FAB-pos, glycerol): m/z 619 
[M-NO3]+, 557 [M-2NO3]+, 497 [M-Cu(NO3)2]+, 351 [Cu-bpaBzl]+, 260 [Cu-bpa]+. 
HRMS (FAB-pos, NBA, PEG600): m/z exp. 619.1451 and calc. 619.1492 for 
[C30H30N5O663Cu]+, exp. 557.1575 and calc. 557.1614 for [C30H30N4O363Cu]+. 
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8.4 Synthesis of Modified Amino Acids 
 
Synthesis of p-nitro-phenylalanine 5.1 
 
H2N
OH
O
H2N
OH
O
NO2
C9H11NO2
Exact Mass: 165,08
Mol. Wt.: 165,19
C9H10N2O4
Exact Mass: 210,06
Mol. Wt.: 210,19
5.1
 
 
At 0°C, conc. H2SO4 (120ml) was slowly added under stirring to 120ml of conc. HNO3. 
H-Phe-OH (100g, 605mmol) was added in portions over a period of 20min., giving a 
yellow, sticky solution. Stirring was continued overnight, the resulting slurry was 
poured over crushed ice and brought to pH7 with NaOH. The white precipitate was 
separated by filtration and dried in vacuo. Yield: 92.6g (441mmol, 72.8%) 
 
Phenylalanine 
1H-NMR (360MHz, DMSO-d6): δ = 7.26 (5H, m, H2Bz, H3Bz, H4Bz, H5Bz, H6Bz), 3.74 
(1H, t, Hα), 3.18 (2H, m, Hβ). 13C-NMR (90.56MHz, DMSO-d6): δ = 169.31 (CO), 
137.85 (C1Bz), 129.29 (C4Bz), 128.25 (C2Bz, C6Bz), 126.32 (C3Bz, C5Bz), 55.60 (Cα), 37.13 
(Cβ). 
 
p-Nitro-phenylalanine 5.1 
1H-NMR (360MHz, DMSO-d6): δ = 8.16 (2H, d, H3Bz, H5Bz), 7.45 (2H, d, H2Bz, H6Bz), 
3.98 (1H, t, Hα), 3.27 (2H, m, Hβ). 13C-NMR (90.56MHz, DMSO-d6): δ = 173.86 
(CO), 144.41 (C1Bz, C4Bz), 131.42 (C2Bz, C6Bz), 125.01 (C3Bz, C5Bz), 56.52 (Cα), 37.24 
(Cβ). MS (EI, 70eV, 210°C): m/z (%) = 210 [M+] (0.5), 165 (38.1), 137 (63.7), 119 
(27.0), 107 (23.6), 90 (31.1), 74 (100.0), 46 (26.6), 28 (70.7). 
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Synthesis of Fmoc-p-nitro-phenylalanine 5.2 
 
O N
H
OH
O
O
H2N
OH
O
NO2 NO2
C9H10N2O4
Exact Mass: 210,06
Mol. Wt.: 210,19
C24H20N2O6
Exact Mass: 432,13
Mol. Wt.: 432,43
5.1 5.2
 
 
5.45g (25mmol) of p-nitro-phenylalanine was dissolved in a mixture of each 50ml of 
H2O and CH3CN and treated with 1 equivalent of NEt3 (2.5g, 25mmol). After 10min. of 
stirring, 8.0g (23.75mmol 95%) of Fmoc-ONSu in 50ml of CH3CN was added dropwise 
over a period of 20min, while pH was adjusted to 8.5-9.0. After 2h of continuous stir-
ring and successive filtration, the solvents were removed in vacuo and a red oil re-
mained. The residue was again dissolved in water and afterwards neutralized using 
1N HCl until the crude product precipitated. Recrystallization from EtOAc yielded 5.9g 
(53%) of pure product as a white solid. 
 
1H-NMR (360 MHz, DMSO-d6): δ = 8.11 (2H, d, H3Bz, H5Bz), 7.84 (2H, d, H4Fmoc, 
H5Fmoc), 7.78 (1H, d, NH), 7.60 (2H, d, H1Fmoc, H8Fmoc), 7.53 (2H, d, H2Bz, H6Bz), 7.38 
(2H, m, H3Fmoc, H6Fmoc), 7.27 (2H, m, H2Fmoc, H7Fmoc), 4.30 (2H, d, H10Fmoc), 4.23 (1H, t, 
H9Fmoc), 4.15 (1H, t, Hα), 3.25 (2H, m, Hβ). 13C-NMR (90.56 MHz, DMSO-d6): δ = 
172.91 (CO), 155.97 (C11Fmoc), 146.46 (C1Bz), 146.23 (C4Bz) 143.71 (C8aFmoc, C9aFmoc), 
140.72 (C4aFmoc, C4bFmoc), 130.46 (C2Bz, C6Bz), 127.62 (C1Fmoc, C8Fmoc), 127.06 (C4Fmoc, 
C5Fmoc), 125.11 (C2Fmoc, C7Fmoc), 123.23 (C3Bz, C5Bz), 120.18 (C3Fmoc, C6Fmoc), 65.67 
(C10Fmoc), 54.84 (Cα), 46.69 (C9Fmoc), 36.17 (Cβ). MS (FAB-pos): m/z = 433 [M+H]+, 
255 [M-Fluorenyl]+, 165 [Fluorenyl]+. 
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Synthesis of Fmoc-p-amino-phenylalanine 5.3 
 
O N
H
OH
O
O
NO2
O N
H
OH
O
O
NH2
C24H20N2O6
Exact Mass: 432,13
Mol. Wt.: 432,43
C24H22N2O4
Exact Mass: 402,16
Mol. Wt.: 402,44
5.2 5.3
 
 
In a three-necked, round-bottomed flask, equipped with a gas inlet tube and a bubble 
counter, Fmoc-Phe(NO2)-OH 5.2 (3g, 6.9mmol) was dissolved in a mixture of 200ml 
dioxane and 30ml EtOH. After some heating, a clear solution of light yellow colour 
formed. 200mg of Pd/C catalyst was added, followed by the inlet of dihydrogen. The 
progress of the reaction was monitored by HPLC, taking 0.2ml samples from the reac-
tion mixture every 30min. These samples were diluted with MeCN (1:50), the catalyst 
was removed with a syringe filter, and the solution was centrifuged. Each sample was 
subjected to HPLC, using a standard gradient with MeCN/H2O. After 24h, the HPLC 
peaks showed the completeness of the reduction, and the mixture was filtrated. After 
removal of the solvents on a rotary evaporator and drying of the residue in vacuo, a light 
brown solid was obtained. Yield: 2.18g (5.4mmol, 78%) 
 
1H-NMR (360 MHz, DMSO-d6): δ = 7.88 (2H, d, H4Fmoc, H5Fmoc), 7.68 (2H, d, H1Fmoc, 
H8Fmoc), 7.58 (1H, d, NH), 7.43 (2H, m, H3Fmoc, H6Fmoc), 7.32 (2H, m, H2Fmoc, H7Fmoc), 
6.90 (2H, d, H2Bz, H6Bz), 6.47 (2H, d, H3Bz, H5Bz), 4.24 (2H, d, H10Fmoc), 4.19 (1H, t, 
H9Fmoc), 4.15 (1H, t, Hα), 4.03 (2H, m, NH2), 2.88 (2H, m, Hβ). 13C-NMR (90.56 MHz, 
DMSO-d6): δ = 173.57 (CO), 155.87 (C11Fmoc), 146.99 (C1Bz), 143.77 (C8aFmoc, C9aFmoc), 
140.65 (C4aFmoc, C4bFmoc), 129.52 (C2Bz, C6Bz), 127.61 (C1Fmoc, C8Fmoc), 127.04 (C4Fmoc, 
C5Fmoc), 125.29 (C2Fmoc, C7Fmoc), 124.75 (C4Bz), 124.16 (C3Bz, C5Bz), 120.07 (C3Fmoc, 
C6Fmoc), 65.26 (C10Fmoc), 56.10 (Cα), 46.64 (C9Fmoc), 35.86 (Cβ). MS (EI, 70eV, 210°C): 
m/z = 402 (1.3) [M+H]+, 324 (0.5), 252 (0.4), 224 (3.0), 206 (1.5), 194 (5.6), 178 (49), 
165 (21), 152 (5.5), 106 (100). MS (FAB-pos, NBA): m/z = 403 [M+H]+, 391, 307, 289, 
252, 240, 179, 154, 136. 
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1H-NMR (360MHz, DMSO-d6) 
δ (ppm) H-Phe-OH 5.1 5.2 5.3 
NH2 – – – 4.03 
H4Bz 7.26 – – – 
H3Bz, H5Bz 7.26 8.16 8.11 6.47 
H2Bz, H6Bz 7.26 7.45 7.53 6.90 
NH – – 7.78 7.58 
H4Fmoc, H5Fmoc – – 7.84 7.88 
H1Fmoc, H8Fmoc – – 7.60 7.68 
H3Fmoc, H6Fmoc – – 7.38 7.43 
H2Fmoc, H7Fmoc – – 7.27 7.32 
Hα 3.74 3.98 4.15 4.15 
Hβ 3.18 3.27 3.25 2.88 
H10Fmoc – – 4.30 4.24 
H9Fmoc – – 4.23 4.19 
 
13C-NMR (90.56MHz, DMSO-d6) 
δ (ppm) H-Phe-OH 5.1 5.2 5.3 
CO 169.31 173.86 172.91 173.57 
C1Bz 137.85 144.41 146.46 146.99 
C3Bz, C5Bz 126.32 125.01 123.23 124.16 
C2Bz, C6Bz 128.25 131.42 130.46 129.52 
C4Bz 129.29 144.41 146.23 124.75 
Cα 55.60 56.52 54.84 65.26 
Cβ 37.13 37.24 36.17 35.86 
C1Fmoc, C8Fmoc – – 127.62 127.61 
C2Fmoc, C7Fmoc – – 125.11 125.29 
C3Fmoc, C6Fmoc – – 120.18 120.07 
C4Fmoc, C5Fmoc – – 127.06 127.04 
C4aFmoc, C4bFmoc – – 140.72 140.65 
C8aFmoc, C9aFmoc – – 143.71 143.77 
C9Fmoc – – 46.69 46.64 
C10Fmoc – – 65.67 65.26 
C11Fmoc – – 155.97 155.87 
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8.5 Synthesis of PNA-Monomers 
 
 
The numbering of atoms for PNA monomers is conceived according to IUPAC: 
 
Cytosine Thymine Adenine Guanine PG 
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Synthesis of ethylendiamine acetic acid tBu-ester 4.1 
 
H2N
NH2 Br
O
O H
N
O
O
H2N
+
C2H8N2
Exact Mass: 60,07
Mol. Wt.: 60,1
C6H11BrO2
Exact Mass: 193,99
Mol. Wt.: 195,05
C8H18N2O2
Exact Mass: 174,14
Mol. Wt.: 174,24
4.1
 
 
55.3g (62ml, 920mmol, 8.5eq.) of ethylenediamine (d=0.89g/ml) (which does not nec-
essarily have to be distilled before use, even if yellow) was dissolved in 400ml CH2Cl2 
in a 1L round-bottomed flask. At 0°C, a solution of 16ml (21.1g, 108mmol) tert-Butyl-
bromoacetate in 80ml CH2Cl2 was added dropwise under stirring over 3-4h forming a 
white precipitate. Sometimes, two phases may occur, which can be ignored. The solu-
tion was allowed to slowly reach room temperature and stirred overnight. After that, it 
was washed three times with 100ml of water in order to remove the excess of ethyl-
enediamine and the HBr formed during the reaction. These 300ml of water were washed 
with 100ml CH2Cl2, and the combined (clear and colourless) organic phases were dried 
over MgSO4. The yellow aqueous phase was discarded. After removing the MgSO4, the 
solution was used directly for the next step assuming a yield of 80% (86mmol). 
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Synthesis of backbone·HCl 
(9H-fluoren-9-yl)methyl-2-((tert-butoxycarbonyl)methylamino)ethylcarbamate 4.2 
 
H
N
O
O
H2N
H
N
O
O
N
H
O
O
HCl
C8H18N2O2
Exact Mass: 174,14
Mol. Wt.: 174,24
4.1 4.2
C23H29ClN2O4
Exact Mass: 432,18
Mol. Wt.: 432,94  
 
After adding 15ml (86mmol) DIPEA to the solution of 4.1 obtained from the previous 
step, a solution of 29g (86mmol) Fmoc-ONSu in 150ml of CH2Cl2 was added at RT 
over a period of 3h, followed by stirring overnight. The solution was washed 5 times 
with 100ml 1N HCl and once with 100ml brine. The aqueous phases were combined, 
washed with 100ml of CH2Cl2 and the combined organic phases were dried over 
MgSO4. After filtering the solid, the solution was concentrated to ¼ by evaporation. The 
product crystallized out of the clear solution overnight at -10°C forming white crystals 
which were separated and washed with 30ml of hexane. The product was dried in vacuo 
yielding 20.45g (48mmol, 55%) the hydrochloride as white, amorphous powder. 
 
1H-NMR (360MHz, DMSO-d6): δ = 9.54 (2H, br, NHBB), 7.88 (2H, d, H4Fmoc, H5Fmoc), 
7.70 (2H, d, H1Fmoc, H8Fmoc), 7.40 (2H, m, H3Fmoc, H6Fmoc), 7.30 (2H, m, H2Fmoc, H7Fmoc), 
4.28 (2H, d, H10Fmoc), 4.20 (1H, t, H9Fmoc), 3.85 (2H, s, H14BB), 3.37 (2H, t, H12BB), 3.02 
(2H, t, H13BB), 1.44 (9H, s, H17BB). 13C-NMR (90.56MHz, DMSO-d6): δ = 165.57 
(C15BB), 156.28 (C11Fmoc), 143.80 (C8aFmoc, C9aFmoc), 140.74 (C4aFmoc, C4bFmoc), 127.64 
(C1Fmoc, C8Fmoc), 127.08 (C4Fmoc, C5Fmoc), 125.20 (C2Fmoc, C7Fmoc), 120.12 (C3Fmoc, 
C6Fmoc), 82.97 (C16BB), 65.68 (C10Fmoc), 47.24 (C14BB), 46.66 (C9Fmoc), 46.42 (C13BB), 
36.62 (C12BB), 27.61 (C17BB). MS (EI, 70eV, 165°C): m/z (%) = 396 (1.7) [M+-HCl], 351 
(0.2), 340 (9.0), 322 (10.1), 295 (61.4), 196 (2.5), 178 (100.0), 165 (24.8), 152 (6.2), 
117 (19.1), 99 (13.0), 88 (89.4), 73 (24.6), 57 (47.3), 44 (19.3), 30 (12.5). 
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1H-NMR (360MHz, DMSO-d6) 
δ (ppm) 4.2 
NHBB 9.54 
H4Fmoc, H5Fmoc 7.88 
H1Fmoc, H8Fmoc 7.70 
H3Fmoc, H6Fmoc 7.40 
H2Fmoc, H7Fmoc 7.30 
H10Fmoc 4.28 
H9Fmoc 4.20 
H14BB 3.85 
H12BB 3.37 
H13BB 3.02 
H17BB 1.44 
 
 
 
 
 
13C-NMR (90.56MHz, DMSO-d6) 
δ (ppm) 4.2 
C1Fmoc, C8Fmoc 127.64 
C2Fmoc, C7Fmoc 125.20 
C3Fmoc, C6Fmoc 120.12 
C4Fmoc, C5Fmoc 127.08 
C4aFmoc, C4bFmoc 140.74 
C8aFmoc, C9aFmoc 143.80 
C9Fmoc 46.66 
C10Fmoc 65.68 
C11Fmoc 156.28 
C12BB 36.62 
C13BB 46.42 
C14BB 47.24 
C15BB 156.57 
C16BB 82.97 
C17BB 27.61 
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Synthesis of thymine-acetic acid 4.3 
 
HN
N
O
O
OH
O
HN
N
H
O
O
C7H8N2O4
Exact Mass: 184,05
Mol. Wt.: 184,15
C5H6N2O2
Exact Mass: 126,04
Mol. Wt.: 126,11
4.3
 
 
In a 1L round-bottomed flask, a solution of KOH (17.15g, 0.3mol) in H2O (50ml) was 
heated to 40-50°C. After dissolving 10.1g (80.2mmol) of thymine, a solution of 16.5g 
(118.7mmol, 1.5eq.) bromo-acetic acid in 25ml H2O was added dropwise during 1h, 
maintaining the temperature at 40-50°C. After stirring overnight at RT, the pH was ad-
justed to 5.5 with conc. HCl. The flask was stored at -10°C for 2h, and the excess of 
thymine was filtered off. The pH was brought to 2 with conc. HCl, and the white prod-
uct precipitated. After storage for 2h at -10°C, it was filtered and dried in vacuo yielding 
a white powder. Yield: 11.8g (64mmol, 80%) 
 
1H-NMR (360MHz, D2O): δ = 11.29 (1H, s, NHTh), 7.38 (1H, s, H6Th), 4.48 (2H, s, 
HαAc); 1.83 (3H, s, MeTh). 1H-NMR (360MHz, DMSO-d6): 11.29 (1H, s, NHTh), 7.48 
(1H, s, H6Th); 4.33 (2H, s, HαAc); 1.75 (3H, s, MeTh). 13C-NMR (90.56MHz, DMSO-d6): 
δ = 170.94 (COAc), 165.92 (C4Th), 152.25 (C2Th), 143.06 (C6Th), 109.82 (C5Th), 49.58 
(CαAc), 12.94 (MeTh). MS (EI, 70eV, 165°C): m/z (%) = 184 (32.9), 140 (54.9), 126 
(1.3), 113 (4.0), 96 (100.0), 82 (4.3), 68 (16.9), 55 (13.2), 41 (39.5), 28 (6.6). 
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Synthesis of thymine-backbone 4.4 
 
HN
N
O
O
N
O
O
O
O
N
H
O
HN
N
O
O
OH
O
H
N
O
O
O
N
H
O
C30H34N4O7
Exact Mass: 562,24
Mol. Wt.: 562,61
C7H8N2O4
Exact Mass: 184,05
Mol. Wt.: 184,15
4.3 4.4
4.2
C23H28N2O4
Exact Mass: 396,2
Mol. Wt.: 396,48
 
 
Backbone·HCl 4.2 (3.25g, 7.5mmol) was suspended in dichloromethane (30ml) in an 
extraction funnel and NaHCO3 (sat. aq, 30ml) was added. After extraction, the di-
chloromethane layer was dried over MgSO4 for 10min. and the solvent was removed on 
a rotary evaporator. The resulting solid was dissolved in a dry 250ml Schlenk flask in 
DMF (50ml, dried over molecular sieves), and thymine-acetic acid 4.3 (4.03g, 22mmol) 
was added. After complete dissolution, 3.41g (22mmol) EDC was added in two portions 
within 30min, followed by stirring overnight at RT. The solvent was evaporated in 
vacuo, and the residue was coevaporated with 2x40ml methanol. 100ml of degassed 
water was added under stirring. The precipitate was filtered off, washed again with 
100ml of degassed water and dried in vacuo. Yield: 4.03g (7.2mmol, 72%) 
 
Flash Chromatography: 
Crude Fmoc-T-PNA-OtBu 4.4 (1.7g) and dichloromethane were stirred overnight. Then 
silica (0.040-0.063mm, 1g) was added and dichloromethane removed under reduced 
pressure. The solvent mixture was prepared (CH2Cl2:MeOH=97.5:2.5) and a flash col-
umn filled with fresh silica (0.040-0.063mm, 40g). Flash chromatography was carried 
out and the fractions (20ml) analyzed by TLC. Fractions 8-13 were combined and 
evaporated under reduced pressure yielding 542mg of pure product as a white powder. 
Fractions containing impurities were chromatographed again. 
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1H-NMR δ (360MHz, DMSO-d6): δ = 11.26 (2H, br, NHTh), 7.90 (2H, d, H4Fmoc, 
H5Fmoc), 7.69 (2H, d, H1Fmoc, H8Fmoc), 7.42 (2H, m, H3Fmoc, H6Fmoc), 7.32 (2H, m, H2Fmoc, 
H7Fmoc), 7.26 (1H, s, H6Th), 4.65 (1.2H, s, HαmajAc), 4.47 (0.8H, s, HαminAc), 4.35 (2H, d, 
H10Fmoc), 4.22 (1H, t, H9Fmoc), 3.93 (2H, s, H14BB), 3.40 (1.2H, t, H12majBB), 3.31 (0.8H, t, 
H12minBB), 3.25 (1.2H, t, H13majBB), 3.09 (0.8H, t, H13minBB), 1.74 (3H, s, MeTh), 1.46 
(3.6H, s, H17minBB), 1.41 (5.4H, s, H17majBB). 13C-NMR (90.56MHz, DMSO-d6): 
δ = 170.82 (COAc), 167.58 (C15BB), 165.11 (C11Fmoc), 164.64 (C4Th), 151.23 (C2Th), 
143.61 (C8aFmoc, C9aFmoc), 142.42 (C6Th), 140.72 (C4aFmoc, C4bFmoc), 128.03 (C1Fmoc, 
C8Fmoc), 126.87 (C4Fmoc, C5Fmoc), 125.26 (C2Fmoc, C7Fmoc), 120.51 (C3Fmoc, C6Fmoc), 108.53 
(C5Th), 83.14 (C16BB), 65.48 (C10Fmoc), 49.14 (CαAc), 47.65 (C14BB), 46.91 (C13BB), 46.27 
(C9Fmoc), 39.02 (C12BB), 27.55 (C17BB), 11.92 (MeTh).  
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Synthesis of thymine monomer 4.5 
 
HN
N
O
O
N
O
O
O
O
N
H
O
HN
N
O
O
N
O
O
O
O
N
H
OH
C30H34N4O7
Exact Mass: 562,24
Mol. Wt.: 562,61
C26H26N4O7
Exact Mass: 506,18
Mol. Wt.: 506,51
4.4 4.5
 
 
Thymine-backbone 4.4 (584mg, 1mmol) was suspended in a 100ml round-bottomed 
flask in 20ml DCM together with 0.1ml TIS and 0.1ml water and cooled to 0°C. TFA 
(4ml) was added dropwise over a period of 5min, and after 15min of stirring, the mix-
ture was allowed to reach RT. and left under stirring overnight (16h). The solvent was 
removed by rotary evaporation and dried in vacuo. After coevaporation with acetonitrile 
(4x20ml), the resulting white solid was dried for 8h in vacuo giving the product in 
quantitative yield. 
Alternatively, the tBu-ester cleavage can be carried out with HCl, which avoids TFA 
contamination of the product. Thymine-backbone 4.4 (7g, 12.4mmol) was suspended in 
a mixture of 50ml acetic acid and 25ml 4N HCl and stirred for 48h. The solution got 
clear first, and after a while, the product precipitated. The solvent was removed by ro-
tary evaporation, the residue was dissolved in THF and precipitated from hex-
ane:toluene 3:1, followed by drying in vacuo. Yield: 5.8g (11.5mmol, 92%) 
 
1H-NMR δ (360MHz, DMSO-d6): δ = 11.24 (2H, br, NHTh), 7.87 (2H, d, H4Fmoc, 
H5Fmoc), 7.67 (2H, d, H1Fmoc, H8Fmoc), 7.40 (2H, m, H3Fmoc, H6Fmoc), 7.32 (2H, m, H2Fmoc, 
H7Fmoc), 7.25 (1H, s, H6Th), 4.64 (1.2H, s, HαmajAc), 4.46 (0.8H, s, HαminAc), 4.31 (2H, d, 
H10Fmoc), 4.21 (1H, t, H9Fmoc), 3.97 (2H, s, H14BB), 3.38 (1.2H, t, H12majBB), 3.30 (0.8H, t, 
H12minBB), 3.22 (1.2H, t, H13majBB), 3.05 (0.8H, t, H13minBB), 1.72 (3H, s, MeTh). 
13C-NMR (90.56MHz, DMSO-d6): δ = 170.73 (COAc), 167.58 (C15BB), 165.31 (C11Fmoc), 
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164.38 (C4Th), 150.95 (C2Th), 143.81 (C8aFmoc, C9aFmoc), 142.04 (C6Th), 140.69 (C4aFmoc, 
C4bFmoc), 127.59 (C1Fmoc, C8Fmoc), 127.04 (C4Fmoc, C5Fmoc), 125.01 (C2Fmoc, C7Fmoc), 
120.08 (C3Fmoc, C6Fmoc), 108.08 (C5Th), 65.42 (C10Fmoc), 49.32 (CαAc), 47.64 (C14BB), 
46.86 (C13BB), 46.68 (C9Fmoc), 38.81 (C12BB), 11.86 (MeTh). MS (ESI-neg): m/z = 1011.5 
[2M-H]-, 506.3 [M-H]-. MALDI-TOF (pos, CCA): m/z = 507.2 [M+H]+, 529.2 
[M+Na]+, 545.2 [M+K]+, 551.2 [M-H+2Na]+, 567.2 [M-H+Na+K]+. 
 
 
 
1H-NMR (360MHz, DMSO-d6) 
δ (ppm) 4.3 4.4 4.5 
NHTh 11.29 11.26 11.24 
H4Fmoc, H5Fmoc – 7.90 7.87 
H1Fmoc, H8Fmoc – 7.69 7.67 
H3Fmoc, H6Fmoc – 7.42 7.40 
H2Fmoc, H7Fmoc – 7.32 7.32 
H6Th 7.48 7.26 7.25 
HαAcmaj 4.33 4.65 4.64 
HαAcmin 4.33 4.47 4.46 
H10Fmoc – 4.35 4.31 
H9Fmoc – 4.22 4.21 
H14BB – 3.93 3.97 
H12majBB – 3.40 3.38 
H12minBB – 3.31 3.30 
H13majBB – 3.25 3.22 
H13minBB – 3.09 3.05 
MeTh 1.75 1.74 1.72 
H17majBB – 1.46 – 
H17minBB – 1.41 – 
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13C-NMR (90.56MHz, DMSO-d6) 
δ (ppm) 4.3 4.4 4.5 
COAc 170.94 170.82 170.73 
C2Th 152.25 151.23 150.95 
C4Th 165.92 164.64 164.38 
C5Th 109.82 108.53 108.08 
C6Th 143.06 142.42 142.04 
CαAc 49.58 49.14 49.32 
MeTh 12.94 11.92 11.86 
C1Fmoc, C8Fmoc – 128.03 127.59 
C2Fmoc, C7Fmoc – 125.26 125.01 
C3Fmoc, C6Fmoc – 120.51 120.08 
C4Fmoc, C5Fmoc – 126.87 127.04 
C4aFmoc, C4bFmoc – 140.72 140.69 
C8aFmoc, C9aFmoc – 143.61 143.81 
C9Fmoc – 46.27 46.68 
C10Fmoc – 65.48 65.42 
C11Fmoc – 165.11 165.31 
C12BB – 39.02 38.81 
C13BB – 46.91 46.86 
C14BB – 47.65 47.64 
C15BB – 167.58 167.58 
C16BB – 83.14 – 
C17BB – 27.55 – 
 
198 Experimental Section / Materials & Methods 
 
 
Synthesis of N4-(4-methoxybenzoyl)cytosine 4.6 
 
N
N
H
O
NH2
N
N
H
O
HN
O
O
C4H5N3O
Exact Mass: 111,04
Mol. Wt.: 111,1
C12H11N3O3
Exact Mass: 245,08
Mol. Wt.: 245,23
4.6
 
 
Cytosine (29.2g, 99%, 180mmol) was suspended in 650ml dry or freshly distilled pyri-
dine in a 1L three-necked flask under stirring. Anisoylchloride (30.7g, 23ml, 180mmol) 
was added over a dropping funnel over a period of 30min. The solution gets clear at 
first, but after some time a white, sticky precipitate forms, eventually affording the addi-
tion of some more solvent. After stirring overnight at RT, the mixture was refluxed for 
1h to 80-100°C, giving a clear solution which precipitates again. After that, stirring was 
continued overnight at RT, followed by evaporation of the pyridine at HV (40°C) and 
coevaporation with MeOH (2x250ml). The white powder was dried in vacuo and turned 
out to be nearly insoluble in any common solvent. For that reason, no NMR spectrum 
was prepared, and the product was used for the next step without further purification. 
Yield: 39,60g (161.5mmol, 90%) 
 
1H-NMR (360MHz, DMSO-d6): δ = 9.48 (2H, br. s, NH1Cy, NH4Cy), 8.01 (2H, d, H2Bz, 
H6Bz), 7.74 (1H, d, H6Cy), 6.93 (2H, d, H3Bz, H5Bz), 7.41 (2H, d, H5Cy), 3.83 (9H, s, 
MeBz). 13C-NMR (90.56MHz, DMSO-d6): δ = 166.72 (COBz), 162.92 (C4Cy), 155.89 
(C2Cy), 163.62 (C4Bz), 151.08 (C6Cy), 124.98 (C1Bz), 130.58 (C2Bz, C6Bz), 113.81 (C3Bz, 
C5Bz), 96.03 (C5Cy), 55.49 (MeBz). MS (EI, 80eV, 165°C): m/z (%) = 245 (27) [M]+, 223 
(12), 197 (17), 154 (2.9), 135 (100). 
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Synthesis of N4-(4-methoxybenzoyl)-1-(methoxycarbonylmethyl)cytosine 4.7 
 
N
N
H
O
HN
O
O N
NO
HN
O
O
O
O
C12H11N3O3
Exact Mass: 245,08
Mol. Wt.: 245,23
4.6
C15H15N3O5
Exact Mass: 317,1
Mol. Wt.: 317,3
4.7
 
 
The crude product N4-(4-methoxybenzoyl)cytosine 4.6 (39.60g, 161.5mmol) was sus-
pended in dry DMF (500ml), and K2CO3 (22.3g, 161.5mmol) and methylbromoacetate 
(15.5ml, 161.5mmol) was added. After stirring at RT overnight, a yellow suspension 
was obtained. The KBr was filtered off, washed with DMF and discarded; the filtrated 
was reduced to dryness. After the addition of 160ml of water and 7.2ml 4N HCl, stirring 
was continued for 20min. The precipitate was collected by filtration and dried in vacuo. 
Yield: 41.0g (129.2mmol, 80%) 
 
1H-NMR (360MHz, DMSO-d6): δ = 11.10 (2H, br. s, NH4Cy), 8.03 (2H, d, H2Bz, H6Bz), 
8.11 (1H, d, H6Cy), 7.07 (2H, d, H3Bz, H5Bz), 7.34 (2H, d, H5Cy), 3.84 (3H, s, MeBz), 3.70 
(3H, s, MeAc), 4.68 (2H, s, HαAc). 13C-NMR (90.56MHz, DMSO-d6): δ = 168.44 
(COAc), 166.65 (COBz), 162.89 (C4Cy), 155.16 (C2Cy), 163.80 (C4Bz), 150.30 (C6Cy), 
125.19 (C1Bz), 130.65 (C2Bz, C6Bz), 113.75 (C3Bz, C5Bz), 96.14 (C5Cy), 50.57 (CαAc), 
55.42 (MeBz), 52.27 (MeAc). MS (EI, 80eV, 160°C): m/z (%) = 317 (26.9) [M]+, 288 
(9.1), 244 (3.5), 210 (2.9), 135 (100). 
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Synthesis of N4-(4-methoxybenzoyl)-1-(carboxymethyl)cytosine 4.8 
 
N
NO
HN
O
O N
NO
HN
O
O
O
O O
OH
C15H15N3O5
Exact Mass: 317,1
Mol. Wt.: 317,3
4.7
C14H13N3O5
Exact Mass: 303,09
Mol. Wt.: 303,27
4.8
 
 
N4-(4-Methoxybenzoyl)-1-(methoxycarbonylmethyl)cytosine 4.7 (41.0g, 129.2mmol) 
was added under stirring to a solution of NaOH (9.36g, 234mmol, 1.5eq.) in water 
(350ml) in a beaker. After stirring for 1h, the product was precipitated by adding 
4M HCl (54ml, 260mmol). The product was isolated by filtration, coevaporated with 
MeOH and dried in vacuo. Yield: 28.2g (93.0mmol, 72%) 
 
1H-NMR (360MHz, DMSO-d6): δ = 11.07 (2H, br. s, NH4Cy), 8.02 (2H, d, H2Bz, H6Bz), 
8.08 (1H, d, H6Cy), 7.04 (2H, d, H3Bz, H5Bz), 7.30 (2H, d, H5Cy), 3.84 (3H, s, MeBz), 4.56 
(2H, s, HαAc). 13C-NMR (90.56MHz, DMSO-d6): δ = 169.30 (COAc), 166.67 (COBz), 
162.87 (C4Cy), 155.19 (C2Cy), 163.59 (C4Bz), 150.44 (C6Cy), 125.24 (C1Bz), 130.62 (C2Bz, 
C6Bz), 113.76 (C3Bz, C5Bz), 95.90 (C5Cy), 50.61 (CαAc), 55.54 (MeBz). MS (EI, 80eV, 
216°C): m/z (%) = 303 (5.1) [M]+, 259 (15.0), 230 (3.5), 152 (9.8), 135 (100). 
 
8.5  Synthesis of PNA-Monomers 201 
 
 
Synthesis of N4-(4-t-butylbenzoyl)cytosine 4.9 
 
N
N
H
O
NH2
N
N
H
O
HN
O
C4H5N3O
Exact Mass: 111,04
Mol. Wt.: 111,1
4.9
C15H17N3O2
Exact Mass: 271,13
Mol. Wt.: 271,31  
 
In a 1L three-necked flask, cytosine (22.2g, 99%, 200mmol) was suspended under stir-
ring in 750ml dry or freshly distilled DMF together with triethylamine (30.8ml, 
0.22mol). 4-tert-butylbenzoylchloride (37.2ml, 200mmol) was added over a dropping 
funnel over a period of 30min. After 4h of stirring, additional 4-tert-
Butylbenzoylchloride (7.4ml, 40mmol) was added, and the mixture was stirred over-
night at RT. The DMF was removed in vacuo using glassware, exclusively because of 
the weakening of the hoses by the solvent. The residue was coevaporated twice with 
MeOH. DCM was added, and the product was separated by filtration, followed by 
washing with DCM and after that with water until the filtrate being colourless. The 
white product was dried in vacuo. Yield: 40-60% 
 
1H-NMR (360MHz, DMSO-d6): δ = 11.25 (2H, br. s, NH1Cy, NH4Cy), 7.98 (2H, d, H2Bz, 
H6Bz), 7.88 (1H, d, H6Cy), 7.51 (2H, d, H3Bz, H5Bz), 7.22 (2H, d, H5Cy), 1.32 (9H, s, 
tBuBz). 13C-NMR (90.56 MHz, DMSO-d6): δ = 166.68 (COBz), 164.82 (C4Cy), 155.82 
(C2Cy), 129.68 (C1Bz), 128.4 (C2Bz, C6Bz), 125.92 (C3Bz, C5Bz), 93.50 (C5Cy), 34.75 (CqBz), 
31.24 (tBuBz). MS (FAB-pos, glycerol): m/z = 272.1 [M+H]+, 185.1, 161.1 [M-Cy]+, 
112.1 [M-Bz]+, 93.1. 
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Synthesis of N4-(4-t-butylbenzoyl)-1-(methoxycarbonylmethyl)cytosine 4.10 
 
N
N
H
O
HN
O
N
NO
HN
O
O
O
4.9 4.10
C15H17N3O2
Exact Mass: 271,13
Mol. Wt.: 271,31
C18H21N3O4
Exact Mass: 343,15
Mol. Wt.: 343,38  
 
N4-(4-t-Butylbenzoyl)cytosine 4.9 (20g, 73.73mmol) was suspended in dry DMF 
(330ml). NaH (1.76g, 77.33mmol, 1.05eq.) was added in two portions. The suspension 
was stirred for 2-3h at 50°C. Methylbromoacetate (6.9ml, 74.66mmol) was added over a 
dropping funnel over a period of 1h and stirred overnight at 50°C, leading to a light pink 
slurry. The solvent was removed in vacuo and the residue was suspended in DCM 
which was washed with water (5x). The colourless organic phase and was dried over 
Na2SO4 and reduced to 1/4. After crystallisation at 5°C, the precipitate was collected by 
filtration and recrystallized from isopropanole yielding a white product. 
Yield: 30-40% 
 
1H-NMR (360MHz, DMSO-d6): δ = 11.11 (1H, s, NH4Cy), 8.10 (1H, d, H6Cy), 7.94 (2H, 
d, H2Bz, H6Bz), 7.51 (2H, d, H3Bz, H5Bz), 7.34 (2H, d, H5Cy), 4.66 (2H, s, HαAc), 3.68 (3H, 
s, MeAc), 1.31 (9H, s, tBuBz). 13C-NMR (90.56 MHz, DMSO-d6): δ = 157.06 (C2Cy), 
151.16 (C6Cy), 128.89 (C2Bz, C6Bz), 126.12 (C3Bz, C5Bz), 97.32 (C5Cy), 51.47 (MeBz), 
49.21 (CαAc), 31.14 (tBuBz). MS (FAB-pos, Glycerol): m/z = 344.1 [M]+, 161.1 [Bz]+. 
 
8.5  Synthesis of PNA-Monomers 203 
 
 
Synthesis of N4-(4-t-butylbenzoyl)-1-(carboxymethyl)cytosine 4.11 
 
N
NO
HN
O
N
NO
HN
O
O
O O
OH
4.10 4.11
C18H21N3O4
Exact Mass: 343,15
Mol. Wt.: 343,38
C17H19N3O4
Exact Mass: 329,14
Mol. Wt.: 329,35  
 
N4-(4-t-Butylbenzoyl)-1-(methoxycarbonylmethyl)cytosine 4.10 (8.0g, 24mmol) ob-
tained from step 2 was suspended in a mixture of dioxane (50ml) and water (10ml) and 
brought to pH11 with 2N NaOH, resulting in a colour change to yellow and the dissolu-
tion of the compound. The mixture was stirred overnight at RT. Then, the pH was ad-
justed to 3 with 1N HCl, forming a white precipitate. A pH below 3 will dissolve the 
product again. After some time, the product was separated by filtration and dissolved in 
NaHCO3 (sat., aq) (sometimes, some 2N NaOH has to be added to complete the dissolu-
tion). After that, the product was precipitated again by addition of 1N HCl until pH 3 
was reached. The white product was separated by filtration, washed with water and 
dried in vacuo. Yield: 5.53g (16.8mmol, 70%) 
 
1H-NMR (360MHz, DMSO-d6): δ = 11.05 (1H, s, NH4Cy), 8.10 (1H, d, H6Cy), 7.94 (2H, 
d, H2Bz, H6Bz), 7.50 (2H, d, H3Bz, H5Bz), 7.30 (2H, d, H5Cy), 4.55 (2H, s, HαAc), 1.29 (9H, 
s, tBuBz). 13C-NMR (90.56MHz, DMSO-d6): δ = 169.34 (COAc), 167.16 (COBz), 163.55 
(C4Cy), 155.85 (C2Cy), 155.24 (C4Bz), 150.64 (C6Cy), 130.36 (C1Bz), 128.39 (C2Bz, C6Bz), 
125.33 (C3Bz, C5Bz), 95.94 (C5Cy), 50.66 (CαAc), 34.80 (CqBz), 30.85 (tBuBz).  
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Synthesis of cytosine-backbone 4.12 
 
N
NO
N
O
O
HN
O
O
N
H
O
O
N
NO
HN
O
O
OH
4.11
C17H19N3O4
Exact Mass: 329,14
Mol. Wt.: 329,35
H
N
O
O
O
N
H
O
4.2
C40H45N5O7
Exact Mass: 707,33
Mol. Wt.: 707,81
4.12
C23H28N2O4
Exact Mass: 396,2
Mol. Wt.: 396,48
 
 
Cytosine-acetic acid 4.11 (4.0g, 12.15mmol), TBTU (7.8g, 24.3mmol) and HOBt (3.7g, 
24.3mmol) were suspended in DMF (120ml). Meanwhile, backbone·HCl 4.2 (10.5g, 
24.3mmol) was suspended in dichloromethane (160ml) in an extraction funnel and Na-
HCO3 (sat. aq, 80ml) was added. After extraction, the dichloromethane layer was dried 
over MgSO4 for 10min. Then DIPEA (4.3g, 24.3mmol) was added to the DMF solution, 
and the colour changed to yellow. After 2min of activation, the organic phase was fil-
tered into the DMF solution, and the extraction funnel was washed with dichloro-
methane (20ml). This mixture was stirred at RT for 20h. After evaporation of the sol-
vent in vacuo (10-2mbar, 50°C), the orange-yellow residue was resolved in dichloro-
methane (180ml), washed with HCl (1M, 3x100ml), NaHCO3 (sat. aq, 3x100ml) and 
brine (100ml). The clear and dark yellow organic extract was dried over MgSO4, fil-
tered and evaporated to yield the crude product (10.47g) as a yellow oil. 
TLC (EtOAc) of the crude product showed two significant spots, Rf 0.30 (unreacted 
backbone) and Rf 0.15 (product). Both absorb at 254nm, but only the product absorbs at 
366nm. The crude product was purified by flash chromatography (SiO2, 60g, Ø2.5cm, 
tube volume 20ml, 3.0g of crude) with EtOAc, until the spot with Rf 0.30 has been 
washed out. Then the eluent was changed to EtOAc:MeOH = 9:1 and two coloured 
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bands started moving. The faster is slightly yellow (product), while the later one is 
green. Fractions with Rf 0.15 in EtOAc were evaporated and dried. 
 
Alternatively to Flash chromatography, the crude product can be washed with MeOH 
leading to similar purity. 
 
1H-NMR (360MHz, DMSO-d6): δ = 8.67 (1H, s, NH4Cy), 7.81 (2H, d, H2Bz, H6Bz), 7.75 
(1H, d, H6Cy), 7.89 (2H, d, H4Fmoc, H5Fmoc), 7.61 (2H, d, H1Fmoc, H8Fmoc), 7.51(1H, t, 
NHBB), 7.49 (2H, d, H3Bz, H5Bz), 7.40 (1H, d, H5Cy), 7.38 (2H, m, H3Fmoc, H6Fmoc), 7.30 
(2H, m, H2Fmoc, H7Fmoc), 4.62 (1.2H, s, HαmajAc), 4.58 (0.8H, s, HαminAc), 4.44 (2H, d, 
H10Fmoc), 4.22 (1H, t, H9Fmoc), 3.96 (2H, s, H14BB), 3.60 (1.2 H, t, H12majBB), 3.45 (2H, br. 
m, H12minBB, H13majBB), 3.39 (0.8H, t, H13minBB), 1.30 (9H, s, tBuBz), 1.42 (3.6H, s, 
H17minBB), 1.38 (5.4H, s, H17majBB). 13C-NMR (90.56MHz, DMSO-d6): δ = 167.05 
(C15BB), 163.33 (C4Cy), 155.71 (C4Bz), 143.80 (C8aFmoc, C9aFmoc), 140.66 (C4aFmoc, 
C4bFmoc), 130.30 (C1Bz), 128.30 (C2Bz, C6Bz), 127.00 (C4Fmoc, C5Fmoc), 125.22 (C3Bz, C5Bz), 
125.05 (C2Fmoc, C7Fmoc), 120.05 (C10Fmoc), 95.67 (C10Fmoc), 65.43 (C10Fmoc), 49.50 (CαAc), 
46.65 (C9Fmoc), 34.70 (CqBz), 30.40 (tBuBz), 27.60 (tBuBB). MS (FAB-pos, NBA): m/z = 
708.0 [M+H]+, 397.0 [BB]+, 341.0, 179.0, 161.0 [Bz]+. 
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Synthesis of cytosine monomer 4.13 
 
N
NO
N
O
O
HN
O
O
N
H
O
O
C40H45N5O7
Exact Mass: 707,33
Mol. Wt.: 707,81
4.12
N
NO
N
O
O
HN
O
O
N
H
OH
O
C36H37N5O7
Exact Mass: 651,27
Mol. Wt.: 651,71
4.13
 
 
A suspension of cytosine-backbone 4.12 (708mg, 1mmol), TIS (0.1ml) and water 
(0.1ml) in dichloromethane (20ml) was cooled to 0°C in a round-bottomed flask (50ml). 
TFA (4.75ml) was added over a period of 5min, and after 15min, the ice-bath was re-
moved. After stirring overnight at RT, the volatiles were removed under reduced pres-
sure, coevaporated with acetonitrile until the colour of the residue changed from yellow 
to white (>10x20ml) followed by drying for 16h (20°C, 5·10-3mbar) forming a white 
solid in quantitative yield. 
 
1H-NMR (360MHz, DMSO-d6): δ = 11.08 (1H, s, NH4Cy), 7.98 (2H, d, H2Bz, H6Bz), 7.94 
(1H, d, H6Cy), 7.89 (2H, d, H4Fmoc, H5Fmoc), 7.68 (2H, d, H1Fmoc, H8Fmoc), 7.53 (2H, d, 
H3Bz, H5Bz), 7.51(1H, t, NHBB), 7.43 (1H, d, H5Cy), 7.41 (2H, m, H3Fmoc, H6Fmoc), 7.33 
(2H, m, H2Fmoc, H7Fmoc), 4.88 (1.2H, s, HαmajAc), 4.70 (0.8H, s, HαminAc), 4.35 (2H, d, 
H10Fmoc), 4.26 (1H, t, H9Fmoc), 4.02 (2H, s, H14BB), 3.48 (1.2 H, t, H12majBB), 3.37 (0.8H, 
br. m, H12minBB), 3.31 (1.2H, br. m, H13majBB), 3.14 (0.8H, t, H13minBB), 1.30 (9H, s, 
tBuBz). 13C-NMR (90.56MHz, DMSO-d6): δ = 170.63 (COAc), 167.73 (C15BB), 167.37 
(COBz), 163.57 (C4Cy), 156.61 (C11Fmoc), 156.03 (C2Cy), 155.26 (C4Bz), 151.32 (C6Cy), 
144.13 (C8aFmoc, C9aFmoc), 140.97 (C4aFmoc, C4bFmoc), 130.63 (C1Bz), 128.61 (C2Bz, C6Bz), 
127.84 (C1Fmoc, C8Fmoc), 127.30 (C4Fmoc, C5Fmoc), 125.50 (C3Bz, C5Bz), 125.36 (C2Fmoc, 
C7Fmoc), 120.33 (C3Fmoc, C6Fmoc), 95.97 (C5Cy), 65.77 (C10Fmoc), 49.83 (CαAc), 48.00 
(C14BB), 47.20 (C13BB), 46.97 (C9Fmoc), 38.21 (C12BB), 35.02 (CqBz), 31.06 (tBuBz). MS 
(FAB-pos, NBA): m/z =652.0 [M]+, 312.0, 272.0 [9+H]+, 178.0 [Fmoc]+, 161.0 [Bz]+. 
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1H-NMR (360MHz, DMSO-d6) 
δ (ppm) 4.6 4.7 4.8 4.9 4.10 4.11 4.12 4.13 
MeBz 3.83 3.84 3.84 – – – – – 
tBuBz – – – 1.32 1.31 1.29 1.30 1.30 
H3Bz, H5Bz 6.93 7.07 7.04 7.51 7.51 7.50 7.49 7.53 
H2Bz, H6Bz 8.01 8.03 8.02 7.98 7.94 7.94 7.81 7.98 
NH1Cy 9.48 – – 11.25 – – – – 
NH4Cy 9.48 11.10 11.07 11.25 11.10 11.05 8.67 11.08 
H5Cy 7.41 7.34 7.30 7.22 7.34 7.30 7.40 7.43 
H6Cy 7.74 8.11 8.08 7.88 8.10 8.10 7.75 7.94 
MeAc – 3.70 – – 3.68 – – – 
NHBB – – – – – – 7.51 7.51 
H4Fmoc, H5Fmoc – – – – – – 7.89 7.89 
H1Fmoc, H8Fmoc – – – – – – 7.61 7.68 
H3Fmoc, H6Fmoc – – – – – – 7.38 7.41 
H2Fmoc, H7Fmoc – – – – – – 7.30 7.33 
HαmajAc – 4.68 4.56 – 4.66 4.55 4.62 4.88 
HαminAc – 4.68 4.56 – 4.66 4.55 4.58 4.70 
H10Fmoc – – – – – – 4.44 4.35 
H9Fmoc – – – – – – 4.22 4.26 
H14BB – – – – – – 3.96 4.02 
H12majBB – – – – – – 3.60 3.48 
H12minBB – – – – – – 3.45 3.37 
H13majBB – – – – – – 3.45 3.31 
H13minBB – – – – – – 3.39 3.14 
H17minBB – – – – – – 1.42 – 
H17majBB – – – – – – 1.38 – 
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13C-NMR (90.56MHz, DMSO-d6) 
δ (ppm) 4.6 4.7 4.8 4.9 4.10 4.11 4.12 4.13 
MeBz 55.49 55.42 55.54 –  – – – 
CqBz – – – 34.75 34.75 34.80 34.73 35.02 
tBuBz – – – 31.24 31.14 30.85 30.78 31.06 
C1Bz 124.98 125.19 125.24 129.68 n.o. 130.36 130.30 130.63 
C3Bz, C5Bz 113.81 113.75 113.76 125.92 126.12 125.33 125.22 125.50 
C2Bz, C6Bz 130.58 130.65 130.62 128.40 128.89 128.39 128.30 128.61 
C4Bz 163.62 163.80 163.59 164.82 n.o. 155.24 n.o. 155.26 
COBz 166.72 166.65 166.67 166.68 n.o. 167.16 167.05 167.37 
C2Cy 155.89 155.16 155.19 155.82 157.06 155.85 155.71 156.03 
C4Cy 162.92 162.89 162.87 n.o. n.o. 163.55 163.33 163.57 
C5Cy 96.03 96.14 95.90 93.50 97.32 95.94 95.67 95.97 
C6Cy 151.08 150.30 150.44 n.o. 151.16 150.64 n.o. 151.32 
CαAc – 50.57 50.61 – 49.21 50.66 49.50 49.83 
COAc – 168.44 169.30 – n.o. 169.34 n.o. 170.63 
MeAc – 52.27 – – 51.47 – – – 
C1Fmoc, C8Fmoc – – – – – – 127.55 127.84 
C2Fmoc, C7Fmoc – – – – – – 125.05 125.36 
C3Fmoc, C6Fmoc – – – – – – 120.05 120.33 
C4Fmoc, C5Fmoc – – – – – – 127.00 127.30 
C4aFmoc, C4bFmoc – – – – – – 140.66 140.97 
C8aFmoc, C9aFmoc – – – – – – 143.80 144.13 
C9Fmoc – – – – – – 46.65 46.97 
C10Fmoc – – – – – – 65.43 65.77 
C11Fmoc – – – – – – n.o. 156.61 
C12BB – – – – – – n.o. 38.21 
C13BB – – – – – – n.o. 47.20 
C14BB – – – – – – n.o. 48.00 
C15BB – – – – – – n.o. 167.73 
C16BB – – – – – – 80.91 – 
C17BB – – – – – – 27.60 – 
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Synthesis of N6-(4-methoxybenzoyl)adenine 4.14 
 
N
N NH
N
OHN
O
N
N NH
N
NH2
C5H5N5
Exact Mass: 135,05
Mol. Wt.: 135,13
C13H11N5O2
Exact Mass: 269,09
Mol. Wt.: 269,26
4.14
 
 
Adenine (20.3g, 150mmol) was suspended in pyridine (400ml, dried over mol. sieves) 
and 4-methoxybenzoylchloride (20.3ml, 150mmol) was added over a dropping funnel. 
The yellow slurry was heated to 100°C for 3h, changed to a clear, brown-red solution 
and was stirred at RT overnight. Methanol (30ml) was added over a dropping funnel, 
the solvent was removed in vacuo and coevaporated with toluene (2x150ml). The resi-
due was refluxed with i-propanol (300ml) for 3h and left in the fridge overnight. The 
solid was filtered, dried on air overnight and at HV for 3h yielding 37g (92%) of the 
white product being clean enough to be used for the next step without further purifica-
tion. 
 
1H-NMR (360MHz, DMSO-d6): δ = 11.41 (1H, br. s, NH6Ad), 8.76 (1H, s, H8Ad), 8.68 
(1H, s, H2Ad), 8.56 (1H, d, NH9Ad), 8.15 (2H, d, J=8.5, H2Bz, H6Bz), 7.11 (2H, d, J=8.5, 
H3Bz, H5Bz), 3.88 (3H, s, MeBz). 13C-NMR (90.56MHz, DMSO-d6): δ = 165.89 (COBz), 
162.86 (C4Bz), 160.85 (C4Ad), 151.16 (C2Ad), 145.68 (C8Ad), 145.38 (C6Ad), 130.79 (C2Bz, 
C6Bz), 124.79 (C1Bz), 115.28 (C5Ad), 113.80 (C3Bz, C5Bz), 55.56 (MeBz). MS (EI, 70eV, 
165°C): m/z (%) = 269 [M+] (37), 241 (27), 136 (21), 135 (100), 107 (15), 92 (34), 77 
(45), 64 (14).  
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Synthesis N6-(4-methoxybenzoyl)-9-(methoxycarbonylmethyl)adenine 4.15a and 
N6-(4-methoxybenzoyl)-7-(methoxycarbonylmethyl)adenine 4.15b 
 
N
N NH
N
OHN
O
N
N N
N
OHN
O
O
O
N
N N
N
OHN
O
O
O
+
C13H11N5O2
Exact Mass: 269,09
Mol. Wt.: 269,26
C16H15N5O4
Exact Mass: 341,11
Mol. Wt.: 341,32
C16H15N5O4
Exact Mass: 341,11
Mol. Wt.: 341,32
4.14 4.15a 4.15b
 
 
N6-(4-Methoxybenzoyl)adenine 4.14 (2.69g, 10mmol), anhydrous K2CO3 (1.38g, 
10mmol) and anhydrous Cs2CO3 (236mg, 1mmol) were suspended in dry DMF (40ml). 
After stirring for 5min at RT, methyl-bromo acetate (1.05ml, 11mmol) was added over 
a dropping funnel. The almost clear solution (containing some undissolved carbonate) 
becomes a slurry after 15min. After stirring the mixture for 24h, the solvent was re-
moved in vacuo, and the residue was stirred overnight with ethyl acetate (175ml) and 
water (70ml). The white precipitate was isolated by filtration 4.15b and the filtrate was 
separated in a separatory funnel. The ethyl acetate was washed with brine (1x100ml) 
and water (2x100ml), dried over Na2SO4, filtered and the solvent was removed by ro-
tary evaporation. m=1.42g (4.16mmol, 41.6%) 
300mg of the residue was purified by column chromatography (37g SiO2, CH2Cl2:i-
PrOH=92.5:7.5) yielding 73mg (0.21mmol, 2.1%) of pure 4.15a. 
 
4.15a: 
1H-NMR (360MHz, DMSO-d6): δ = 11.05 (1H, br. s, NH6Ad), 8.70 (1H, s, H8Ad), 8.42 
(1H, s, H2Ad), 8.03 (2H, d, J=8.5, H2Bz, H6Bz), 7.07 (2H, d, J=8.5, H3Bz, H5Bz), 5.22 (2H, 
s, HαAc), 3.84 (3H, s, MeBz), 3.72 (3H, s, MeAc). 13C-NMR (90.56MHz, DMSO-d6): δ = 
168.35 (COAc), 165.11 (COBz), 162.69 (C4Bz), 152.51 (C4Ad), 151.76 (C2Ad), 150.52 
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(C6Ad), 144.91 (C8Ad), 130.67 (C2Bz, C6Bz), 125.57 (C5Ad), 124.85 (C1Bz), 113.17 (C3Bz, 
C5Bz), 55.59 (MeBz), 52.67 (Me2Ac), 44.20 (CαAc). MS (EI, 70eV, 170°C): m/z (%) = 341 
[M+] (21), 340 (15), 313 (45), 312 (35), 136 (21), 135 (100), 107 (14), 92 (30), 77 (38), 
64 (10). 
 
4.15b: 
1H-NMR (360MHz, DMSO-d6): δ = 8.67 (1H, br. s, H8Ad), 8.57 (1H, s, H2Ad), 8.06 (2H, 
d, J=8.5, H2Bz, H6Bz), 7.07 (2H, d, J=8.5, H3Bz, H5Bz), 5.33 (2H, br. s, HαAc), 3.86 (3H, s, 
MeBz), 3.61 (s, 3H, Me2Ac). 13C-NMR (90.56MHz, DMSO-d6): δ = 130.33 (C2Bz, C6Bz), 
168.08 (COAc), 162.50 (C4Bz), 113.46 (C3Bz, C5Bz), 55.28 (MeBz), 52.08 (MeAc), 47.69 
(CαAc). MS (EI, 70eV, 165°C): m/z (%) = 341 [M+] (24), 234 (7), 136 (21), 135 (100), 
107 (8), 92 (10), 77 (19), 44 (23). 
 
 
Synthesis of N6-(4-methoxybenzoyl)-9-(t-butoxycarbonylmethyl)adenine 4.16a and 
N6-(4-methoxybenzoyl)-7-(t-butoxycarbonylmethyl)adenine 4.16b 
 
N
N NH
N
OHN
O
N
N N
N
OHN
O
O
O
N
N N
N
OHN
O
O
O
+
4.14 4.16a 4.16b
C13H11N5O2
Exact Mass: 269,09
Mol. Wt.: 269,26
C19H21N5O4
Exact Mass: 383,16
Mol. Wt.: 383,4
C19H21N5O4
Exact Mass: 383,16
Mol. Wt.: 383,4  
 
N6-(4-methoxybenzoyl)adenine 4.14 (23.66g, 88mmol), anhydrous K2CO3 (12.16g, 
88mmol) and anhydrous Cs2CO3 (2.87g, 8.8mmol) were suspended in dry DMF 
(400ml). After stirring for 5min at RT, t-butylbromoacetate (14.11ml, 97mmol) was 
added over a dropping funnel. The almost clear solution (containing some undissolved 
carbonate) becomes a slurry after 15min. After stirring the mixture for 24h, the solvent 
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was removed in vacuo, and the residue was stirred overnight with ethyl acetate (400ml) 
and water (200ml). The white precipitate was isolated by filtration. m=18.54g (54.4%), 
1H-NMR: 4.16a: 4.16b = 2:1. The crude product was recrystallized from ethyl acetate 
(2.25L) yielding 9.58g (28.2%) of 4.16a of >98% purity. 
 
4.16a: 
1H-NMR (360MHz, DMSO-d6): δ = 11.04 (1H, br. s, NH6Ad), 8.72 (1H, s, H8Ad), 8.43 
(1H, s, H2Ad), 8.05 (2H, d, J=8.5, H2Bz, H6Bz), 7.08 (2H, d, J=8.5, H3Bz, H5Bz), 5.10 (2H, 
s, HαAc), 3.86 (3H, s, MeBz), 1.44 (9H, s, tBu2Ac). 13C-NMR (90.56MHz, DMSO-d6): δ 
= 166.67 (COAc), 165.98 (COBz), 162.53 (C4Bz), 152.44 (C4Ad), 151.53 (C2Ad), 150.38 
(C6Ad), 144.85 (C8Ad), 130.53 (C2Bz, C6Bz), 125.60 (C5Ad), 124.81 (C1Bz), 113.67 (C3Bz, 
C5Bz), 82.27 (CqAc), 55.45 (MeBz), 44.79 (CαAc), 27.61 (tBuAc). MS (EI, 70eV, 155°C): 
m/z (%) = 383 [M+] (11), 355 (12), 299 (16), 298 (11), 136 (10), 135 (100), 107 (8), 92 
(11), 77 (19), 57 (14), 44 (14), 41 (11). 
 
4.16b: 
1H-NMR (360MHz, DMSO-d6): δ = 8.66 (1H, s, H8Ad), 8.56 (1H, s, H2Ad), 8.12 (2H, d, 
J=8.5, H2Bz, H6Bz), 7.07 (2H, d, J=8.5, H3Bz, H5Bz), 5.22 (2H, s, HαAc), 3.86 (3H, s, 
MeBz), 1.26 (9H, s, tBu2Ac). 13C-NMR (90.56MHz, DMSO-d6): δ = 166.87 (COAc), 
162.65 (C4Bz), 130.74 (C2Bz, C6Bz), 113.58 (C3Bz, C5Bz), 82.13 (CqAc), 55.49 (MeBz), 
48.52 (CαAc), 27.43 (tBuAc). MS (EI, 70eV, 170°C): m/z (%) = 383 [M+] (9), 327 (5), 
269 (5), 136 (9), 135 (100), 107 (5), 92 (10), 77 (14), 57 (14), 56 (5), 41 (15). 
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Synthesis of N6-(4-methoxybenzoyl)-9-(carboxymethyl)adenine 4.17 
 
N
N N
N
OHN
O
O
O4.16a
C19H21N5O4
Exact Mass: 383,16
Mol. Wt.: 383,4
N
N N
N
OHN
O
O
OH4.17
C15H13N5O4
Exact Mass: 327,1
Mol. Wt.: 327,29  
 
N6-(4-Methoxybenzoyl)-9-(t-butoxycarbonylmethyl)adenine 4.16a (8.74g, 22.8mmol) 
was suspended in dichloromethane (200ml) and triisopropylsilane (0.47ml, 2.3mmol) 
was added. TFA (100ml) was slowly added at 0°C over a period of 1h. The clear solu-
tion was stirred overnight, followed by evaporation of all volatile compounds and 
coevaporation with CH2Cl2 (3x50ml). The crude product, a yellow foam, is pure enough 
for the next step. Yield: 6.82g (92%) 
 
1H-NMR (360MHz, DMSO-d6): δ = 8.73 (1H, s, H8Ad), 8.52 (1H, s, H2Ad), 8.06 (2H, d, 
J=9.0, H2Bz, H6Bz), 7.09 (2H, d, J=9.0, H3Bz, H5Bz), 5.13 (2H, s, HαAc), 3.87 (3H, s, 
MeBz). 13C-NMR (90.56MHz, DMSO-d6): δ = 169.01 (COAc), 165.18 (COBz), 162.66 
(C4Bz), 152.40 (C4Ad), 151.58 (C2Ad), 150.15 (C6Ad), 145.00 (C8Ad), 130.64 (C2Bz, C6Bz), 
125.44 (C5Ad), 124.13 (C1Bz), 113.75 (C3Bz, C5Bz), 55.52 (MeBz), 44.38 (CαAc). MS 
(FAB-pos, NBA): m/z = 366, 328 [M+H+], 192, 155, 154, 149, 137, 136, 135, 107, 90, 
89, 78, 77, 69, 63, 57, 55, 51, 50, 43, 41. MS (EI, 70eV, 161°C): 355 (3), 327 [M+] (8), 
135 (82), 92 (11), 77 (16), 69 (61), 51 (30), 50 (13), 45 (100), 44 (92), 43 (15). 
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Synthesis of adenine-backbone 4.18 
 
H
N
O
O
O
N
H
O
N
N N
N
OHN
O
OH
O
C15H13N5O4
Exact Mass: 327,1
Mol. Wt.: 327,29
C38H39N7O7
Exact Mass: 705,29
Mol. Wt.: 705,76
4.184.17
4.2
C23H28N2O4
Exact Mass: 396,2
Mol. Wt.: 396,48
N
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O
N
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O
N
N
N
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O
O
N
 
 
Adenine-acetic acid 4.17 (1.64g, 5mmol), TBTU (2.41g, 7.5mmol) and HOBt (1.15g, 
7.5mmol) were resolved in DMF (60ml) with orange colour. Meanwhile, backbone·HCl 
4.2 (3.25g, 7.5mmol) was suspended in dichloromethane (30ml) in an extraction funnel 
and NaHCO3 (sat. aq, 30ml) was added. After extraction, the dichloromethane layer was 
dried over MgSO4 for 10min. Then DIPEA (1.7ml, 10mmol) was added to the DMF 
solution, and the colour changed to yellow. After 2min. of activation, the organic phase 
was filtered into the DMF solution and the extraction funnel was washed with di-
chloromethane (10ml). This mixture was stirred at RT for 4h. After evaporation of the 
solvent in vacuo (10-2mbar, 50°C), the residue was resolved in dichloromethane 
(100ml), washed with HCl (1M, 3x100ml), NaHCO3 (sat. aq, 3x100ml) and brine 
(100ml). The organic extract was dried, filtered and evaporated to yield 3.07g (87%) of 
crude product as brownish foam. 
TLC (EtOAc) of the crude product showed two significant spots, Rf 0.30 (unreacted 
Backbone) and Rf 0.15 (product). Both absorb at 254nm, but only the product absorbs at 
366nm. 
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The crude product was purified by flash chromatography (SiO2, 60g, Ø2.5cm, tube vol-
ume 20ml, 3.0g of crude) with EtOAc, until the spot with Rf 0.30 was washed out. Then 
the eluent was changed to EtOAc:MeOH = 9:1 and two coloured bands started moving. 
The faster is slightly yellow (product), while the latter one is green. Fractions with Rf 
0.15 in EtOAc were evaporated and dried. Yield: 2.2g (62%) as a white foam. 
 
1H-NMR (360MHz, DMSO-d6): δ = 10.96 (1H, s, NH6Ad), 8.67 (1H, s, H8Ad), 8.62 (1H, 
s, H2Ad), 8.04 (2H, d, J=9.0, H2Bz, H6Bz), 7.87 (2H, d, H4Fmoc, H5Fmoc), 7.67 (2H, d, 
H1Fmoc, H8Fmoc), 7.49 (1H, t, NHBB), 7.40 (2H, m, H3Fmoc, H6Fmoc), 7.31 (2H, m, H2Fmoc, 
H7Fmoc), 7.07 (2H, d, J=9.0, H3Bz, H5Bz), 5.36 (1.2H, s, HαmajAc), 5.17 (0.8H, s, HαminAc), 
4.43-4.15 (3H , br. m, H9Fmoc, H10Fmoc), 3.97 (2H , s, H14BB), 3.86 (3H, s, MeBz), 3.56 
(1.2 H, t, H12majBB); 3.35 (2H, br. m, H12minBB, H13majBB); 3.13 (0.8H, t, H13minBB), 1.51 
(3.6H, s, H17minBB), 1.44 (5.4H, s, H17majBB). 
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Synthesis of adenine monomer 4.19 
 
N
O
O
O
N
H
OH
C38H39N7O7
Exact Mass: 705,29
Mol. Wt.: 705,76
4.18
C34H31N7O7
Exact Mass: 649,23
Mol. Wt.: 649,65
4.19
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A suspension of adenine-backbone 4.18 (706mg, 1mmol), TIS (0.125ml) and water 
(0.125ml) in CH2Cl2 (10ml) was cooled to 0°C in a round-bottomed flask (50ml). TFA 
(4.75ml) was added over a period of 5min, and after 15min, the ice-bath was removed. 
After stirring overnight at RT, the volatiles were removed under reduced pressure, 
coevaporated with acetonitrile (4x20ml) followed by drying for 16h (20°C, 5·10-3mbar) 
forming a white solid in quantitative yield. 
 
1H-NMR (360MHz, DMSO-d6): δ = 11.14 (1H, s, NH6Ad), 8.71 (1H, s, H8Ad), 8.66 (1H, 
s, H2Ad), 8.06 (2H, d, J=9.0, H2Bz, H6Bz), 7.87 (2H, d, H4Fmoc, H5Fmoc), 7.67 (2H, d, 
H1Fmoc, H8Fmoc), 7.51(1H, t, NHBB), 7.39 (2H, m, H3Fmoc, H6Fmoc), 7.30 (2H, m, H2Fmoc, 
H7Fmoc), 7.08 (2H, d, J=9.0, H3Bz, H5Bz), 5.40 (1.2H, s, HαmajAc), 5.23 (0.8H, s, HαminAc), 
4.37 (2H, d, H10Fmoc), 4.28 (1H, t, H9Fmoc), 4.02 (2H, s, H14BB), 3.85 (3H, s, MeBz), 3.57 
(1.2 H, t, H12majBB), 3.36 (2H, br. m, H12minBB, H13majBB), 3.14 (0.8H, t, H13minBB). 
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1H-NMR (360MHz, DMSO-d6) 
δ (ppm) 4.14 4.15a 4.15b 4.16a 4.16b 4.17 4.18 4.19 
MeBz 3.88 3.84 3.86 3.86 3.86 3.87 3.86 3.85 
H3Bz, H5Bz 7.11 7.07 7.07 7.08 7.07 7.09 7.07 7.08 
H2Bz, H6Bz 8.15 8.03 8.06 8.05 8.12 8.06 8.04 8.06 
NH6Ad 11.41 11.05 n.o. 11.04 n.o. n.o. 10.96 11.14 
H2Ad 8.68 8.42 8.57 8.43 8.56 8.52 8.62 8.66 
H8Ad 8.76 8.70 8.67 8.72 8.66 8.73 8.67 8.71 
NH9Ad 8.56 – – – – – – – 
Me2Ac – 3.72 3.61 – – – – – 
tBu2Ac – – – 1.44 1.26 – – – 
NHBB – – – – – – 7.49 7.51 
H4Fmoc, H5Fmoc – – – – – – 7.87 7.87 
H1Fmoc, H8Fmoc – – – – – – 7.67 7.67 
H3Fmoc, H6Fmoc – – – – – – 7.40 7.39 
H2Fmoc, H7Fmoc – – – – – – 7.31 7.30 
HαmajAc – 5.22 5.33 5.10 5.22 5.13 5.36 5.40 
HαminAc – 5.22 5.33 5.10 5.22 5.13 5.17 5.23 
H10Fmoc – – – – – – 4.43 4.37 
H9Fmoc – – – – – – 4.15 4.28 
H14BB – – – – – – 3.97 4.02 
H12majBB – – – – – – 3.56 3.57 
H12minBB – – – – – – 3.35 3.36 
H13majBB – – – – – – 3.35 3.36 
H13minBB – – – – – – 3.13 3.14 
H17minBB – – – – – – 1.51 – 
H17majBB – – – – – – 1.44 – 
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13C-NMR (90.56MHz, DMSO-d6) 
δ (ppm) 4.14 4.15a 4.15b 4.16a 4.16b 4.17 
MeBz 55.56 55.59 55.28 55.45 55.49 55.52 
C1Bz 124.79 124.85 n.o. 124.81 n.o. 124.13 
C3Bz, C5Bz 113.80 113.17 113.46 113.67 113.58 113.75 
C2Bz, C6Bz 130.79 130.67 130.33 130.53 130.74 130.64 
C4Bz 162.86 162.69 162.50 162.53 162.65 162.66 
COBz 165.89 165.11 n.o. 165.98 n.o. 165.18 
C2Ad 151.16 151.76 n.o. 151.53 n.o. 151.58 
C4Ad 160.85 152.51 n.o. 152.44 n.o. 152.40 
C5Ad 115.28 125.57 n.o. 125.60 n.o. 125.44 
C6Ad 145.38 150.52 n.o. 150.38 n.o. 150.15 
C8Ad 145.68 144.91 n.o. 144.85 n.o. 145.00 
CαAc – 44.20 47.69 44.79 48.52 44.38 
COAc – 168.35 168.08 166.67 166.87 169.01 
MeAc – 52.67 52.08 – – – 
CqAc – – – 82.27 82.13 – 
tBuAc – – – 27.61 27.43 – 
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Synthesis of N2,9-diacetylguanine 4.20 
 
HN
N NH
N
O
H2N
HN
N N
N
O
N
H
O
O
C5H5N5O
Exact Mass: 151,05
Mol. Wt.: 151,13
C9H9N5O3
Exact Mass: 235,07
Mol. Wt.: 235,2
4.20
 
 
Guanine (15.11g, 100mmol) was suspended in 125 ml of dried DMAc. 25ml Ac2O were 
added, and the mixture was stirred at 160°C for 6-7h. The resulting brown solution was 
allowed to reach RT, the crystalline product was filtered and washed with cold EtOH. 
Yield: 16.1g (68.5mmol, 68.5%) 
 
1H-NMR (360MHz, DMSO-d6): δ = 12.02 (1H, br. s, NH1Gu), 8.44 (1H, s, H8Gu), 2.81 
(3H, s, Me9Ac), 2.21 (3H, s, Me2Ac). 13C-NMR (90.56MHz, DMSO-d6): δ = 173.74 
(CO2Ac), 168.00 (CO9Ac), 154.61 (C6Gu), 148.37 (C4Gu), 147.82 (C2Gu), 137.44 (C8Gu), 
121.45 (C5Gu), 24.64 (Me2Ac), 23.82 (Me9Ac). MS (EI, 70eV, 200°C): m/z (%) = 444 
(6.7) (?), 235 (9.9) [M]+, 193 (63.6), 151 (86.5), 109 (30.1). MS (FAB-pos, Glycerol): 
m/z = 236 [M+H]+, 194, 185, 171. 
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Synthesis of N2-acetyl-O6-diphenylcarbamoylguanine 4.21 
 
HN
N N
N
O
N
H
O
O
N
N NH
N
O
N
H
O
O
N
C9H9N5O3
Exact Mass: 235,07
Mol. Wt.: 235,2
C20H16N6O3
Exact Mass: 388,13
Mol. Wt.: 388,38
4.20 4.21
 
 
Diphenylcarbamoylchloride (6.37g, 27.5mmol) was added in portions to a suspension of 
2-N,9-diacetylguanine 4.20 (5.88g, 25mmol) in 8.7ml (50mmol) DIPEA and 120ml dry 
or freshly distilled pyridine. After stirring the mixture for 1h at RT, it was quenched 
with 10ml H2O and stirred for 10min. The solvent was removed in vacuo and coevapo-
rated with toluene (3x50ml). The residue was refluxed at 100°C with 300ml of 
EtOH/H2O (1:1) for 1.5h. The mixture was cooled down again, filtered and the product 
was washed with EtOH to yield a violet solid. Yield: 8.8g (22.7mmol, 90.6%) 
 
1H-NMR (360MHz, DMSO-d6): δ = 13.53 (1H, s, NH9Gu) 10.63 (1H, s, NH2Gu), 8.45 
(1H, s, H8Gu), 7.50 (2H, d, H4Bz), 7.44 (4H, m, H2Bz, H6Bz), 7.31 (4H, m, H3Bz, H5Bz), 
2.17 (3H, s, Me2Ac). 13C-NMR (90.56MHz, DMSO-d6): δ = 168.58 (CO2Ac), 153.54 
(COBz), 151.97 (C6Gu), 150.28 (C4Gu), 141.67 (C1Bz), 119.10 (C2Bz, C6Bz), 148.22 (C2Gu), 
137.51 (C8Gu), 129.40 (C3Bz, C5Bz), 121.26 (C5Gu), 118.32 (C4Bz), 24.43 (Me2Ac). MS (EI, 
70eV, 200°C): m/z (%) = 388 (0.7) [M]+, 346 (0.1) [M-CH3CO]+, 302 (0.4), 269 (1.5) 
[M-CH3CO-C6H5]+, 253 (0.3), 211 (9.6), 196 (7.5), 193 (7.7), 177 (4.3), 169 (100.0). 
MS (FAB-pos, Glycerol): m/z = 389 [M+H]+, 277, 196, 185, 171, 130. 
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Synthesis of N2-acetyl-O6-diphenylcarbamoyl-9-methoxycarbonylmethylguanine 4.22 
 
N
N NH
N
O
N
H
O
O
N
N
N N
N
O
N
H
O
O
N
O
O
C20H16N6O3
Exact Mass: 388,13
Mol. Wt.: 388,38
C23H20N6O5
Exact Mass: 460,15
Mol. Wt.: 460,44
4.21 4.22
 
 
N2-acetyl-O6-diphenylcarbamoylguanine 4.21 (6g, 15.5mmol) was suspended in DMF 
(75ml) together with DIPEA (5.3ml) and heated until a clear solution formed. Methyl-2-
bromoacetate (2.6g, 17mmol) was added, and the solution was stirred overnight at RT. 
The solvent was evaporated in vacuo and the residue was resolved in MeOH (75ml). 
Under vigorous stirring, this solution was poured into water (250ml), and after 30min of 
stirring, the precipitation of the product is complete. The product was separated by fil-
tration, washed with water and resolved in MeOH. The solvent was removed in vacuo, 
washed repeatedly with EtOAc and finally with Et2O to yield 4.4g (9.6mmol, 61.7%) of 
a light violet powder. 
 
1H-NMR (360MHz, DMSO-d6): δ = 10.72 (1H, s, NH2Gu), 8.44 (1H, s, H8Gu), 7.51 (2H, 
d, H4Bz), 7.45 (4H, m, H2Bz, H6Bz), 7.32 (4H, m, H3Bz, H5Bz), 5.16 (2H, s, HαAc), 3.72 
(3H, s, Me9Ac), 2.19 (3H, s, Me2Ac). 13C-NMR (90.56MHz, DMSO-d6): δ = 168.83 
(CO2Ac), 167.95 (CO9Ac), 154.94 (C6Gu), 155.07 (COBz), 152.31 (C4Gu), 148.41 (C2Gu), 
141.57 (C1Bz), 138.22 (C8Gu), 129.38 (C3Bz, C5Bz), 121.78 (C5Gu), 119.37 (C2Bz, C6Bz), 
52.59 (Cα Ac), 44.28 (Me9Ac), 24.50 (Me2Ac). MS (ESI-pos): m/z = 943 [2M+Na]+, 483 
[M+Na]+, 461 [M+H]+ MS (FAB-pos, glycerol): m/z = 461 [M+H]+, 266, 250, 224, 
207, 196, 168. 
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Synthesis of N2-acetyl-O6-diphenylcarbamoyl-9-carboxymethylguanine 4.23 
 
N
N N
N
O
N
H
O
O
N
O
O
N
N N
N
O
N
H
O
O
N
O
OH
C23H20N6O5
Exact Mass: 460,15
Mol. Wt.: 460,44
C22H18N6O5
Exact Mass: 446,13
Mol. Wt.: 446,42
4.22 4.23
 
 
N2-Acetyl-O6-diphenylcarbamoyl-9-methoxycarbonylmethylguanine 4.22 (10g, 
21.7mmol) was suspended in a mixture of MeOH (25ml), 1,4-dioxane (100ml) and wa-
ter (50ml). NaOH (1M, 22ml) was added and the mixture was stirred for 1h at RT. The 
clear, brown solution was adjusted to pH 6 with 1M HCl, followed by removing the 
organic solvents on the rotary evaporator. Water (500ml) was added, and the pH was 
brought to 3 with 1M HCl. A jelly-like precipitate formed which was separated by fil-
tration with difficulty and washed with ice-cold water. Yield: 7.7g (17.2mmol, 79.5%) 
 
1H-NMR (360MHz, DMSO-d6): δ = 10.73 (1H, s, NH2Gu), 8.46 (1H, s, H8Gu), 7.50 (2H, 
d, H4Bz), 7.44 (4H, m, H2Bz, H6Bz), 7.31 (4H, m, H3Bz, H5Bz), 5.02 (2H, s, HαAc), 2.20 
(3H, s, Me2Ac). 13C-NMR (90.56MHz, DMSO-d6): δ = 169.13 (CO2Ac), 168.38 (CO9Ac), 
154.74 (COBz), 154.62 (C6Gu), 151.83 (C4Gu), 146.04 (C2Gu), 141.32 (C1Bz), 137.89 
(C8Gu), 129.07 (C3Bz, C5Bz), 120.99 (C5Gu), 119.59 (C2Bz, C6Bz), 119.10 (C4Bz), 54.58 
(CαAc), 24.17 (Me2Ac). MS (FAB-pos, Glycerol): m/z = 539 [M+glycerol]+, 509, 469 
[M+Na]+, 447 [M+H]+, 405, 274 [M+Na-(C6H5)2NCO]+, 268, 252, 210, 196, 168. 
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Synthesis of guanine-backbone 4.24 
 
N
N N
N
O
N
H
N
O
O
O
O
O
N
H
O
O
N
N
N N
N
O
N
H
O
O
N
O
OH
C22H18N6O5
Exact Mass: 446,13
Mol. Wt.: 446,42
4.23
4.24
H
N
O
O
O
N
H
O
4.2
C45H44N8O8
Exact Mass: 824,33
Mol. Wt.: 824,88
C23H28N2O4
Exact Mass: 396,2
Mol. Wt.: 396,48
 
Guanine-acetic acid 4.23 (3.57g, 8mmol), TBTU (5.14g, 16mmol) and HOBt (2.45g, 
16mmol) were suspended in DMF (80ml). Meanwhile, backbone·HCl 4.2 (3.46g, 
8mmol) was suspended in dichloromethane (80ml) in an extraction funnel and NaHCO3 
(sat. aq, 40ml) was added. After extraction, the dichloromethane layer was dried over 
MgSO4 for 10min. Then DIPEA (2.8ml, 2.08g, 16mmol) was added to the DMF solu-
tion, and the colour changed to yellow. After 2min of activation, the organic phase was 
filtered into the DMF solution, and the extraction funnel was washed with dichloro-
methane (20ml). This mixture was stirred at RT for 2h. After evaporation of the solvent 
in vacuo (10-2mbar, 50°C), the brown residue was filtered and washed with EtOAc 
(3x50ml) until the colour disappears, followed by recrystallisation from EtOH (3L). 
 
1H-NMR (360MHz, DMSO-d6): δ = 10.62 (1H, s, NH2Gu), 8.31 (1H, s, H8Gu), 7.86 (2H, 
d, H4Fmoc, H5Fmoc), 7.65 (2H, d, H1Fmoc, H8Fmoc), 7.43 (1H, t, NHBB), 7.38 (2H, m, H3Fmoc, 
H6Fmoc), 7.31 (2H, m, H2Fmoc, H7Fmoc), 7.28 (4H, d, H3Bz, H5Bz), 7.45 (4H, d, H2Bz, H6Bz), 
7.52 (1H, s, H4Bz), 5.25 (1.2H, s, HαmajAc), 5.08 (0.8H, s, HαminAc), 4.34 (2H, d, H10Fmoc), 
4.20 (1H, t, H9Fmoc), 3.95 (2H, s, H14BB), 3.50 (1.2 H, t, H12majBB), 3.10 (0.8H, t, 
H13minBB), 2.18 (3H, s, Me2Ac). 13C-NMR (90.56MHz): δ = 169.02 (CO2Ac), 168.49 
(CO9Ac), 166.82 (C15BB), 156.30 (C11Fmoc), 155.11 (C6Gu),154.91 (COBz), 150.08 (C4Gu), 
146.14 (C2Gu), 143.77 (C8aFmoc, C9aFmoc), 141.55 (C1Bz), 140.66 (C4aFmoc, C4bFmoc), 138.14 
(C8Gu), 129.34 (C3Bz, C5Bz), 127.52 (C1Fmoc, C8Fmoc), 126.93 (C4Fmoc, C5Fmoc), 124.93 
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(C2Fmoc, C7Fmoc), 121.31 (C5Gu), 120.03 (C3Fmoc, C6Fmoc), 119.96 (C2Bz, C6Bz), 119.29 
(C4Bz), 80.96 (C16BB), 65.34 (C10Fmoc), 54.98 (CαAc), 48.44 (C14BB), 47.12 (C13BB), 46.63 
(C9Fmoc), 38.02 (C12BB), 27.58 (C17BB), 24.49 (Me2Ac). MS (ESI-pos): m/z = 847 
[M+Na]+, 825 [M+H]+. MS (FAB-pos, NBA): m/z = 825 [M+H]+. 
 
Synthesis of guanine monomer 4.25a & 4.25b 
 
N
N N
N
OH
N
H
N
O
OH
O
O
O
N
H
ON
N N
N
O
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O
O
O
O
O
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N
+
C45H44N8O8
Exact Mass: 824,33
Mol. Wt.: 824,88
C41H36N8O8
Exact Mass: 768,27
Mol. Wt.: 768,77
C28H27N7O7
Exact Mass: 573,2
Mol. Wt.: 573,56
4.24 4.25a 4.25b
 
 
Guanine-backbone 4.24 (2g, 2.4mmol) was suspended in CH2Cl2 (30ml), followed by 
addition of 1,3-dimethoxybenzene (0.4ml, 2.9mmol) and TFA (22.6ml, 292mmol). The 
mixture clarified and was stirred for 8h at RT. The volatiles were removed in vacuo, the 
residue was coevaporated with acetonitrile (5x30ml), washed with ethyl acetate and 
recrystallized from EtOH. 
 
1H-NMR (360MHz, DMSO-d6): δ = 7.97 (1H, s, H8Gu), 7.87 (2H, d, H4Fmoc, H5Fmoc), 
7.66 (2H, d, H1Fmoc, H8Fmoc), 7.47 (1H, t, NHBB), 7.40 (2H, m, H3Fmoc, H6Fmoc), 7.35 (2H, 
m, H2Fmoc, H7Fmoc), 7.22 (4H, d, H3Bz, H5Bz), 7.07 (4H, d, H2Bz, H6Bz), 6.81 (1H, s, H4Bz), 
6.49 (NH2Gu), 5.14 (1.2H, s, HαmajAc), 4.98 (0.8H, s, HαminAc), 4.38 (2H, d, H10Fmoc), 
4.28 (1H, t, H9Fmoc), 4.02 (2H, s, H14BB), 3.50 (1.2 H, t, H12majBB), 3.34 (2H, br. m, 
H12minBB, H13majBB), 3.13 (0.8H, t, H13minBB), 2.15 (3H, s, Me2Ac). MS (FAB-pos, Glyc-
erol): m/z = 636 [M(25a)-Fmoc], 574 [M(25b)+H]+. MALDI-TOF (CCA, DMSO): m/z 
= 573.9 
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1H-NMR (360MHz, DMSO-d6) 
δ (ppm) 4.20 4.21 4.22 4.23 4.24 4.25a 
H4Bz – 7.50 7.51 7.50 7.52 6.81 
H3Bz, H5Bz – 7.31 7.32 7.31 7.28 7.07 
H2Bz, H6Bz – 7.44 7.45 7.44 7.45 7.22 
NH1Gu 12.02 – – – – – 
NH2Gu n.a. 10.63 10.72 10.73 10.62 6.49 
H8Gu 8.44 8.45 8.44 8.46 8.31 7.97 
NH9Gu – 13.53 – – – – 
Me2Ac 2.21 2.17 2.19 2.20 2.18 2.15 
Me9Ac 2.81 – – – – – 
Me9Ac – – 3.72 – – – 
NHBB – – – – 7.43 7.47 
H4Fmoc, H5Fmoc – – – – 7.86 7.87 
H1Fmoc, H8Fmoc – – – – 7.65 7.66 
H3Fmoc, H6Fmoc – – – – 7.38 7.40 
H2Fmoc, H7Fmoc – – – – 7.31 7.35 
HαmajAc – – 5.16 5.02 5.25 5.14 
HαminAc – – 5.16 5.02 5.08 4.98 
H10Fmoc – – – – 4.34 4.38 
H9Fmoc – – – – 4.20 4.28 
H14BB – – – – 3.95 4.02 
H12majBB – – – – 3.50 3.50 
H12minBB – – – – n.a. 3.34 
H13majBB – – – – n.a. 3.34 
H13minBB – – – – 3.10 3.13 
H17minBB – – – – 1.48 – 
H17majBB – – – – 1.36 – 
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13C-NMR (90.56MHz, DMSO-d6) 
δ (ppm) 4.20 4.21 4.22 4.23 4.24 
C1Bz – 141.67 141.57 141.32 141.55 
C3Bz, C5Bz – 129.40 129.38 129.07 129.34 
C2Bz, C6Bz – 119.10 119.37 119.59 119.96 
C4Bz – 118.32 118.43 119.10 119.29 
COBz – 153.54 155.07 154.74 154.91 
C2Gu 147.82 148.22 148.41 146.04 146.14 
C4Gu 148.37 150.28 152.31 151.83 150.08 
C5Gu 121.45 121.26 121.78 120.99 121.31 
C6Gu 154.61 151.97 154.94 154.62 155.11 
C8Gu 137.44 137.51 138.22 137.89 138.14 
CαAc – – 52.59 54.58 54.98 
CO2Ac 173.74 168.58 168.83 169.13 169.02 
Me2Ac 24.64 24.43 24.50 24.17 24.49 
CO9Ac 168.00 – 167.95 168.38 168.49 
Me9Ac 23.82 – – – – 
Me9Ac – – 44.28 – – 
C1Fmoc, C8Fmoc – – – – 127.52 
C2Fmoc, C7Fmoc – – – – 124.93 
C3Fmoc, C6Fmoc – – – – 120.03 
C4Fmoc, C5Fmoc – – – – 126.93 
C4aFmoc, C4bFmoc – – – – 140.66 
C8aFmoc, C9aFmoc – – – – 143.77 
C9Fmoc – – – – 46.63 
C10Fmoc – – – – 65.34 
C11Fmoc – – – – 156.30 
C12BB – – – – 38.02 
C13BB – – – – 47.12 
C14BB – – – – 48.44 
C15BB – – – – 166.82 
C16BB – – – – 80.96 
C17BB – – – – 27.58 
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8.6 Synthesis of PNA Oligomers – General Procedure 
Primary attempts in SPPS in our group were carried out on a peptide synthesizer 
(Fig. 8.2), but due to solubility problems of the cytosine monomer, persistent tube leak-
ing and the device requiring permanent surveillance, a “low tech procedure” was estab-
lished comprising a one-way plastic syringe as a reaction vessel (Fig. 8.3) affording 
considerable advantages such as enhanced accessibility and easy customizing. 
 
 
Fig. 8.2: Automated Solid Phase Peptide Synthesizer 
 
 
Fig. 8.3: Mechanical Shaker with PNA Reaction Syringes and 
Syringe for PNA SPS with Coupling Solution (brown) 
and Resin beads (yellow) 
 
All reactions and washings were performed on a mechanical shaker with 640rpm (Fig. 
8.3), soaking approximately 5-8ml of the particular solution into the syringe. Washing 
was always done for at least 15sec. Before starting, all solutions were freshly prepared: 
• Deprotection solution: 20% piperidine in DMF 
• Activation mixture: 0.3M lutidine & 0.2M DIPEA in DMF 
• Capping solution: 5% acetic anhydride & 6% DIPEA in DMF 
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Amino acids and linkers were incorporated into the sequence exactly like PNA mono-
mers, except as indicated. For the synthesis of PNA oligomers with base labile side 
chain protection (Chapter 4), the whole procedure was similar, except for the use of a 
different resin and the final cleavage which was carried out with 5% hydrazine in DMF. 
 
132.35mg of TentaGel R RAM-Lys(Boc)Fmoc resin (0.17mmol/g) (22.5µmol of load-
ing) were placed in a 10ml syringe equipped with a frit (“batch reactor”) and washed 
five times with DMF, followed by swelling in DMF for 1h. 
 
1) Deprotection 
The preloaded resin was deprotected with 20% piperidine in DMF for 2x3min, 
washed with DMF (3x), DCM (3x) and again DMF (3x). 
2) Coupling 
HATU (4.5 equivalents in order to avoid HATU capping) was dissolved in 
0.6ml of activation mixture (cytosine: 1.8ml !), added to an excess of 5 equiva-
lents (112.5µmol) of PNA monomer and shaken for 3min. until a clear solution 
was obtained. Cytosine sometimes afforded longer activation and vigorous shak-
ing and triturating because of decreased solubility. All containers were rinsed 
with 0.2ml of activation mixture. 
The coupling was performed for 1h, and the resin was washed with DMF (5x). 
3) Kaiser test 
In order to assure the coupling being quantitative, a Kaiser test was performed 
after each coupling step. 
4) Capping 
Free amine groups were capped once with 5% acetic anhydride & 6% DIPEA in 
DMF (3min), followed by washing with DMF (5x). 
Whenever the synthesis had to be interrupted overnight, the reactor with the 
resin was sealed with parafilm and stored in the fridge after this step. 
(repeat steps 1 - 4 for further monomers) 
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Fig. 8.4: Synthesis Cacle for PNA Oligomers 
 
After the last coupling step, the final amine group was either acetylated or equipped 
with the particular ligand (see next chapter). The synthesis of oligomers with a central 
modification will also be described below. 
5) Deprotection 
The final oligomer was deprotected with 20% piperidine in DMF for 2x3min, 
washed with DMF (3x), DCM (3x) and again DMF (3x). 
6) Acetylation 
The free amine groups were acetylated twice with 5% acetic anhydride & 6% 
DIPEA in DMF (2x3min), followed by washing with DMF (5x). 
7) Shrinking 
The resin was washed with MeOH (5x) and shrunk with MeOH for 30min. After 
that, it was transferred into a weighed 50ml flask and dried in vacuo. 
8) Cleavage 
The dried resin was cleaved in the flask for 3h with 95% TFA / 2.5% TIS / 2.5% 
H2O (Σ=10ml), filtered into another 50ml flask through the batch reactor used 
for synthesis and rinsed with 2-3ml of TFA. The combined filtrates were evapo-
rated to dryness in HV, using an additional nitrogen trap in order to prevent TFA 
from damaging the pump. 
 
 
coupling
Kaiser test
& capping 
 
 
deprotection 
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9) Workup 
The residue was precipitated with 5ml of ice-cold diethyl ether, centrifuged in a 
bluecap and washed 3-4x with ice cold ether which was discarded afterwards. 
Drying was performed on air flow. 
10) Purification 
All oligomers were purified using semi-preparative RP-HPLC.237 The crude 
product was dissolved in 4ml 0.1% TFA, 2ml of which were injected into the 
loop after syringe filtration. Purification was carried out using a standard gradi-
ent suitable both for analytical and preparative runs with 0.1%TFA in acetoni-
trile and 0.1% TFA in H2O (flow: 8ml/min). 
  
t %MeCN 
0 5 
30 50 
35 95 
40 5 
   
  
11) Analytics 
All samples were dissolved in 0.1% TFA for MALDI-TOF. MALDI spectra 
were measured before and after HPLC purification of the crude product. 
 
Monitoring 
In order to supervise the progress of syntheses, some resin beads were taken out of the 
vessel after the questionable step (omitting deprotection / acetylation, shrinking and 
drying), transferred into a flask and cleaved with for 2h with 95% TFA / 2.5% TIS / 
2.5% H2O (Σ=2ml). The solution was filtered through a 0.22µm syringe filter, and the 
TFA was removed in vacuo. Workup was similar to that of the final crude product, and 
the sample was subjected to MALDI-TOF. 
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8.7 Synthesis of PNA Oligomers – Specific Sequences and Modifi-
cations 
 
The synthesis of N-acetylated PNA oligomers has been described before. 
 
The concept of incorporating ligands to the end and to the center of the sequence was 
designed to be compatible with the standard protocol in terms of peptide coupling. 
All amino acids (Fmoc-Phe-OH, Fmoc-Phe(NO2)-OH 5.2 and Fmoc-Gly-OH as a 
spacer), and the aminohexanoic acid linker (Fmoc-Ahx-OH) were introduced into the 
PNA chain according to the standard method mentioned in the previous chapter and 
thus treated like PNA monomers. Differing procedures will be described in the follow-
ing: 
 
Attachment of Carboxyl Ligands 
 
In order to obtain a central anchoring group for carboxyl-functionalized ligands, 
Phe(NO2) was inserted into the sequence, followed by on-resin reduction and ligand 
coupling. The phenylalanine nitro group was reduced twice overnight with a 0.9M solu-
tion of SnCl2⋅2H2O (406mg / 1.8mmol) in DMF (2ml). 
 
For the attachment of ligands to free amino groups both at the end and in the center of 
the sequence, the following protocol turned out to be optimum: 
 
Tab. 8.1: Ligand coupling (for 22.5µmol of resin) 
 M [g/mol]  
95µmol HATU 380.20 36.12mg 
440µl DMF / 440µl 
1mmol (10eq.) DIPEA 129.24 129.24mg = 174µl 
100µmol Ligand 363.42 36.34mg 
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1) Deprotection 
The resin was deprotected with 20% piperidine in DMF for 2x3min, washed 
with DMF (3x), DCM (3x) and again DMF (3x). 
2) Coupling 
HATU was dissolved in DMF (440µl) together with DIPEA (174µl), added to 
4.4 equivalents (100µmol) of ligand and shaken for 15min. at 640rpm. The cou-
pling was performed twice overnight, and the resin was washed with DMF (5x). 
3) Kaiser test 
In order to assure the coupling being quantitative, a Kaiser test was performed. 
4) Capping 
Free amine groups were capped once with 5% acetic anhydride & 6% DIPEA in 
DMF (3min), followed by washing with DMF (5x). 
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Attachment of Amino Ligands 
 
In order to couple amino groups to the PNA chain, the N-terminus thereof first of all 
had to be converted into a C-terminus. This was achieved by the introduction of a dicar-
boxylic acid linker (Fig. 8.5). 
 
O
O H OMeO-Ada-OH
HATU/DIPEAPNA
PG PNAPG PNAPG
20% Piperidine
DMF
4
O
O
0.5% LiOH
DMF/dioxane
O
PNAPG
4
OH
O
O
PNAPG
4
NH
O
1) HATU/DIPEA
2) phen*-H 3.8
 
Fig. 8.5: Pathway for the attachment of amino ligands to N-terminal PNA 
 
Tab. 8.2: Linker coupling (for 22.5µmol of resin) 
 M [g/mol]  
95µmol HATU 380.20 36.12mg 
440µl DMF / 440µl 
1mmol (10eq.) DIPEA 129.24 129.24mg = 174µl 
100µmol Linker 160.17 16.02mg 
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1) Deprotection 
The resin was deprotected with 20% piperidine in DMF for 2x3min, washed 
with DMF (3x), DCM (3x) and again DMF (3x). 
2) Coupling 
HATU was dissolved in DMF (440µl) together with DIPEA (174µl), added to 
4.4 equivalents (100µmol) of linker and shaken for 15min. at 640rpm. 
The coupling was performed twice overnight, and the resin was washed with 
DMF (5x). 
3) Kaiser test 
In order to assure the coupling being quantitative, a Kaiser test was performed. 
4) Capping 
Free amine groups were capped once with 5% acetic anhydride & 6% DIPEA in 
DMF (3min), followed by washing with DMF (5x). 
 
After the coupling, the methyl ester was cleaved overnight with 0.5% LiOH in 
DMF/dioxane, followed by washing with dioxane and DMF. 
HATU (7.2mg, 19µmol) and DIPEA (25µl, 200µmol) were dissolved in DMF (200µl), 
and the resin-bound carboxylic groups were activated overnight. 
Phen*-H 3.8 (19.52mg, 100µmol) was dissolved in DMF (600µl) and added to the acti-
vated resin. Coupling was performed overnight. The solution changed its colour from 
orange to green-brown. 
Tab. 8.3: Amine Coupling 
 M [g/mol]  
19µmol HATU 380.20 7.2mg 
800µl DMF / 200µl+600µl 
200µmol (11eq.) DIPEA 129.24 25.85mg = 35µl 
100µmol Ligand 195.23 19.52mg 
 
A MALDI spectrum was performed after each step with some cleaved resin beads in 
order to verify the particular reaction. 
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Appendix 
Sequences – Overview 
 
Reaction No. Name Sequence Mcalc Mfound 
NMN-TK-135-02 Ac8K Ac-tgttatcc-Lys 2321.0 2323.0 
NMN-TK-143-02 Ac9K Ac-tgttatccc-Lys 2572.1 2573.2 
NMN-TK-138-02 Ac10K Ac-tgttatccct-Lys 2838.2 2839.7 
NMN-TK-134-03 tpy8K tpy*-tgttatcc-Lys 2624.1 2626.2 
NMN-TK-143-03 tpy9K tpy*-tgttatccc-Lys 2875.2 2876.3 
NMN-TK-138-03 tpy10K tpy*-tgttatccct-Lys 3141.3 3143.5 
NMN-SK-115 bpa’8K bpa*Ahx-tgttatcc-Lys 2707.2 2709.0 
NMN-TK-124-01 Ac4-c-4K Ac-taccctgtt-Lys 2572.1 2573.1 
NMN-TK-140-01 Ac5-c-5K Ac-ttaccctgtta-Lys 3113.3 3115.1 
NMN-TK-157-01 Ac6-c-6K Ac-attaccctgttat-Lys 3655.5 3654.9 
NMN-TK-154-01 Ac4-4K Ac-tacctgtt-Lys 2321.0 3221.7 
NMN-TK-155-01 Ac5-5K Ac-ttacctgtta-Lys 2862.2 2863.1 
NMN-TK-156-01 Ac6-6K Ac-attacctgttat-Lys 3404.4 3404.5 
NMN-TK-136-01 Ac4-GF-4K Ac-tacc-GlyPhe-tgtt-Lys 2525.0 2526.7 
NMN-TK-144-01 Ac5-GF-5K Ac-ttacc-GlyPhe-tgtta-Lys 3066.3 3067.6 
NMN-TK-150-01 Ac6-GF-6K Ac-attacc-GlyPhe-tgttat-Lys 3608.5 3608.3 
NMN-TK-151-01 Acg1-GF-g2K Ac-gggtt-GlyPhe-aaggg-Lys 3221.3 3221.3 
NMN-TK-152-01 Acg3-GF-g4K Ac-ggagg-GlyPhe-ggtgg-Lys 3262.3 3263.0 
NMN-TK-127-11 Ac4-GFtpy-4K Ac-tacc-GlyPhe(tpy*)-tgtt-Lys 2885.2 2886.2 
NMN-TK-137-04 Ac5-GFtpy-5K Ac-ttacc-GlyPhe(tpy*)-tgtta-Lys 3426.4 3428.6 
NMN-TK-158-04 Ac6-GFtpy-6K Ac-attacc-GlyPhe(tpy*)-tgttat-Lys 3967.6 3968.8 
NMN-TK-148-04 Ac4-GFbpa-4K Ac-tacc-GlyPhe(bpa*)-tgtt-Lys 2855.2 2855.1 
NMN-TK-149-04 Ac5-GFbpa-5K Ac-ttacc-GlyPhe(bpa*)-tgtta-Lys 3396.4 3397.8 
 
  
 
DNA-Sequences Purchased from IBA 
 
# 5’                Sequenz                 3’  A G C T M ε c 
68137N TAG GGA TAA CAG GGT AAT 3’6-G-115’ 7 6 1 4 6018 222.70 0.0782
68138N TAG GGA TAA CAG GGT AAT 3’6-G-115’ 7 6 1 4 6018 222.70 0.0834
73329N TAG GGA TAA CAG GGT AAT 3’6-G-115’ 7 6 1 4 6018 222.70 0.0952
76339N TAG GGA TAA CAG GGT AAT 3’6-G-115’ 7 6 1 4 6018 222.70 0.0594
77512N TAG GGA TAA CAG GGT AAT 3’6-G-115’ 7 6 1 4 6018 222.70 0.0672
77513N TAG GGA TAA CAG GGT AAT 3’6-G-115’ 7 6 1 4 6018 222.70 0.0477
77514N TAG GGA TAA CAG GGT AAT 3’6-G-115’ 7 6 1 4 6018 222.70 0.0890
77122N TAG GGA TAA CAG GGT AAT 3’6-G-115’ 7 6 1 4 6018 222.70 0.0590
76340N TAG GGA TAA CA    GGT AAT 3’6-115’ 7 5 1 4 5665 210.50 0.0847
77515N TAG GGA TAA CA    GGT AAT 3’6-115’ 7 5 1 4 5665 210.50 0.0782
77516N TAG GGA TAA CA    GGT AAT 3’6-115’ 7 5 1 4 5665 210.50 0.0834
77131N TAG GGA TAA CA 3’115’ 5 3 1 2 3629 138.10 0.0952
77132N GGT AAT 3’65’ 2 2 0 2 1952 72.40 0.0891
67230N AAC AGG GT 3’85’ 3 3 1 1 2611 101.10 0.0752
68139N TAC CCT GTT 5’4-C-43’ 1 1 3 4 2857 85.10 0.0845
77124N TTA CCC TGT TA 5’5-C-53’ 2 1 3 5 3522 109.10 0.0860
77123N ATT ACC CTG TTA T 5’6-C-63’ 3 1 3 6 4187 133.10 0.0501
77127N TAC CTG TT 5’4-43’ 1 1 2 4 2544 77.50 0.0902
77126N TTA CCT GTT A 5’5-53’ 2 1 2 5 3209 101.50 0.0954
77125N ATT ACC TGT TAT 5’6-63’ 3 1 2 6 3874 125.50 0.0872
77130N TGT TAT CC 5’83’ 1 1 2 4 2544 77.50 0.0969
77129N TGT TAT CCC 5’93’ 1 1 3 4 2857 85.10 0.0966
77128N TGT TAT CCC T 5’103’ 1 1 3 5 3185 93.80 0.0968
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